Functional and genomic analysis of MEF2 transcription factors in neural development by Andzelm, Milena Maria
 
Functional and genomic analysis of MEF2 transcription factors in
neural development
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 17, 2015 1:07:09 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13070059
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAFunctional and genomic analysis of MEF2 transcription factors in neural development 
A dissertation presented 
by 
Milena Maria Andzelm 
 
to 
The Division of Medical Sciences 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of 
Immunology 
 
 
Harvard University 
Cambridge, Massachusetts 
June 2014  
© 2014 Milena Maria Andzelm 
All rights reserved. 
 	 ﾠ
	 ﾠ iii 
Dissertation Advisor: Michael E. Greenberg        Milena Maria Andzelm 
 
Functional and genomic analysis of MEF2 transcription factors in neural development 
Abstract 
Development of the central nervous system requires the precise coordination of intrinsic 
genetic programs to instruct cell fate, synaptic connectivity and function. The MEF2 family of 
transcription  factors  (TFs)  plays  many  essential  roles  in  neural  development;  however,  the 
mechanisms of gene regulation by MEF2 in neurons remain unclear. This dissertation focuses on 
the  molecular  mechanisms  by  which  MEF2  binds  to  the  genome,  activates  enhancers,  and 
regulates gene expression within the developing nervous system. 
We find that one MEF2 family member in particular, MEF2D, is an essential regulator of 
the development and function of retinal photoreceptors, the primary sensory neurons responsible 
for vision. Despite being expressed broadly across many tissues, in the retina MEF2D binds to 
retina-specific  enhancers  and  regulates  photoreceptor-specific  transcripts,  including  critical 
retinal  disease  genes.    Functional  genome-wide  analyses  demonstrate  that  MEF2D  achieves 
tissue-specific binding and action through cooperation with a retina-specific TF, CRX. CRX 
recruits MEF2D away from canonical MEF2 binding sites by promoting MEF2D binding to 
retina-specific enhancers that lack a strong consensus MEF2 binding sequence. MEF2D and 
CRX then synergistically co-activate these enhancers to regulate a cohort of genes critical for 
normal  photoreceptor  development.  These  findings  demonstrate  that  MEF2D,  a  broadly 
expressed TF, contributes to retina-specific gene expression in photoreceptor development by 
binding to and activating tissue-specific enhancers cooperatively with CRX, a tissue-specific co-	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factor.  
A  major  unresolved  feature  of  MEF2D  function  in  the  retina  is  that  the  number  of 
MEF2D binding sites significantly exceeds the number of genes that are dependent on MEF2D 
for  expression.  We  investigated  causes  of  this  discrepancy  in  an  unbiased  manner  by 
characterizing  the  activity  of  MEF2D-bound  enhancers  genome-wide.  We  find  that  many 
MEF2D-bound  enhancers  are  inactive.  Furthermore,  less  than  half  of  active  MEF2D-bound 
enhancers  require  MEF2D  for  activity,  suggesting  that  significant  redundancies  exist  for  TF 
function within enhancers. These findings demonstrate that observed TF binding significantly 
overestimates direct TF regulation of gene expression. Taken together, our results suggest that 
the broadly expressed TF MEF2D achieves tissue specificity through competitive recruitment to 
enhancers by tissue-specific TFs and activates a small subset of enhancers to regulate genes. 	 ﾠ
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Chapter 1 
Introduction 
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Preface 
How a single cell develops into a complex multicellular organism is a remarkable process 
mediated by extensive cell division and differentiation into a diverse array of cell types. The 
specification of unique cell types, their subsequent differentiation, and their acquisition of varied 
functions is fundamentally determined by distinct gene expression programs. These programs of 
gene expression are orchestrated by transcription factors (TFs), which combinatorially regulate 
genes  by  acting  on  associated  DNA  regulatory  elements,  promoters  and  enhancers.  The 
expression of some transcription factors is limited to one or a few cell types, and their presence 
may lead to expression of cell type-specific genes. Many other transcription factors, however, are 
widely expressed, and so how they contribute to cell type-specific gene expression programs is 
less clear. Advances in molecular biology, which allow genome-wide analyses of transcription 
factor function, have provided new insights into tissue-specific mechanisms of gene regulation, 
including the central role of enhancers. How broadly expressed TFs work to selectively regulate 
enhancers and genes in a tissue-specific manner remains a question of great interest, and insights 
into this process should shed light on how cells acquire specific functions and how this might be 
disrupted in human disease.   
The myocyte enhancer factor-2 (MEF2) family of broadly expressed transcription factors 
is made up of four family members in vertebrates, MEF2A, B, C, and D. MEF2 family members 
are  highly  conserved  and  important  for  a  variety  of  functions  across  cell  types,  including 
differentiation and response to extracellular stimuli. In the nervous system, MEF2 factors are 
critical  for  neuronal  survival,  synaptic  plasticity  and  memory  formation;  their  importance  is 
underscored  by  the  discovery  that  mutations  in  MEF2  factors  cause  inherited  neurological 	 ﾠ
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disease (Bienvenu et al., 2013; Novara et al., 2010). Furthermore, the function of MEF2 family 
members in neurons can be regulated by stimuli critical to neuronal development and synaptic 
maturation, for example growth factors or synaptic activity (Flavell et al., 2006). Given the 
importance  of  MEF2  transcription  factors  in  the  nervous  system,  elucidating  how  MEF2 
regulates neuronal-specific gene expression is of great interest. However, insight into MEF2 
transcriptional  mechanisms  in  a  biologically  significant  context  in  the  CNS  has  remained 
challenging,  largely  due  to  the  difficulties  of  studying  transcriptional  mechanisms  in  the 
heterogeneous neuronal populations of the CNS, as well as the overlap in MEF2 family member 
expression patterns throughout the nervous system.  
The  molecular  mechanisms  by  which  MEF2  transcription  factors  regulate  gene 
expression have however been studied in myocytes and lymphocytes. Although these studies 
were generally limited to in vitro paradigms using reporters and MEF2 overexpression, they have 
nonetheless provided insight into how the function of MEF2 might be specified in a given cell 
type. This work found that MEF2 family members both repress and activate target genes through 
interactions with co-factors, which can differ across cell types (Molkentin et al., 1995; Morin et al., 2000). 
MEF2  family  members  regulate  these  co-factor  interactions  as  well  as  their  DNA  binding  affinity  in 
multiple ways, but most commonly through differential posttranslational modifications. Whether these or 
other mechanisms contribute to how MEF2 family members regulate gene expression in neurons is not yet 
well elucidated.  
In this introduction, I first provide an overview of the molecular mechanisms of gene regulation, 
particularly mechanisms by which TFs achieve tissue-specific function (Chapter 1.1). Next, I provide an 
overview of research related to the MEF2 family members, including studies of MEF2 function in muscle 	 ﾠ
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and hematopoietic cells that highlight mechanistic knowledge of how MEF2 family members regulate 
gene expression and achieve tissue-specific function in non-neural systems (Chapters 1.2-1.4). I then review 
the key roles of MEF2 family members in neuronal biology, and the limited mechanistic information 
known for how MEF2 family members regulate gene expression in the nervous system (Chapter 1.5). 
Finally, I will introduce retinal photoreceptors, one neuronal cell type in the CNS that we 
have  found  specifically  expresses  a  single  MEF2  family  member,  MEF2D.  I  review  the 
development of photoreceptors and how they have emerged as an excellent paradigm for studying 
transcriptional mechanisms in neural development (Chapter 1.6). This dissertation focuses on 
applying genome-wide analyses to elucidate the molecular mechanisms of MEF2-mediated gene 
expression  in  the  nervous  system,  using  retinal  photoreceptors  as  our  model  for  neural 
development.  
   	 ﾠ
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1.1 Cell type-specific gene regulation  
   While each cell begins with essentially the same DNA sequence, an extensive array of 
distinct cell types is generated in the development of an organism. Elucidating how cell type-
specific programs of gene expression are established is currently an area of extensive research, 
including in the nervous system. In recent years, distal DNA regulatory elements known as 
enhancers and their interactions with transcriptional promoters as well as other co-regulatory 
regions  have  been  suggested  to  be  major  contributors  to  cell  type  specificity  (Bulger  and 
Groudine, 2011). 
 
Characterization of regulatory elements 
  Transcription  factors  bind  to  regulatory  elements  within  the  genome  to  drive  gene 
expression. These elements include promoters, which are located at the transcriptional start site 
of  genes,  and  enhancers,  which  act  over  a  greater  difference  in  an  orientation-independent 
manner (Banerji et al., 1981; Moreau et al., 1981). These regulatory elements are hubs that allow 
transcription  factors  to  dock  to  the  genome,  to  interact  with  one  another  and  to  recruit 
components of the basal transcriptional complex (Spitz and Furlong, 2012). These regions of 
DNA  are  also  powerful  substrates  for  evolutionary  change  because  changes  in  the  DNA 
sequence can modify the regulation of a gene without compromising its coding sequence (Baker 
et al., 2012). How transcription factors identify and regulate these regions of DNA in neurons is 
only beginning to be understood and is hampered in part by the cellular heterogeneity that makes 
up the CNS.  A better understanding of these regulatory elements would do a great deal to unlock 	 ﾠ
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the gene regulatory logic that drives specific expression programs in neurons. 
The first step toward understanding the role of DNA regulatory elements in the nervous 
system is their identification.  Promoters can be identified by their proximity to target genes.  
Enhancer elements have been harder to identify because they may act at a great distance from 
their target genes (Lettice et al., 2003). However, the task of identifying enhancers on a genome-
wide  scale  has  recently  become  possible  through  the  advances  of  high-throughput  DNA 
sequencing technology coupled to both chromatin immunoprecipitation (ChIP-Seq) and DNAse-
hypersensitivity assays (DNAse-Seq) (Johnson et al., 2007; Mikkelsen et al., 2007; Robertson et 
al., 2007). Enhancer elements can now be exhaustively identified throughout the genome of a 
given  cell  type  or  tissue  using  these  assays  according  to  their  epigenetic  signatures.  
Nucleosomes bordering enhancer elements are enriched for mono-methylation at lysine 4 of 
histone  3  (H3K4me1)  while  promoters  tend  to  have  tri-methylated  H3K4  (H3K4me3) 
(Heintzman et al., 2007). Furthermore, active enhancers and promoters can be distinguished from 
inactive ones by ChIP-Seq for acetylation or methylation at lysine 27 of histone 3, modifications 
that correlate with either active or inactive loci, respectively (Rada-Iglesias et al., 2011). Lastly, 
active  enhancers  and  promoters  may  also  be  distinguished  from  inactive  ones  by  their 
transcription of bi-directional enhancer RNAs (eRNAs) or promoter anti-sense RNAs (pasRs) 
(Kim et al., 2010; Li et al., 2013; Wang et al., 2011). The discovery that eRNAs and H3K27Ac 
are robust markers of enhancer activation has allowed a new level of insight by allowing the 
evaluation of regulatory element activity in the context of the endogenous genome. Together 
these  tools  facilitate  the  identification  of  how  transcription  factors  bind  to  enhancers  and 
promoters, regulate their activity and influence target gene expression. 	 ﾠ
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Competition for TF binding 
One important modulator of TF binding is the existence of competition for TFs in the 
nucleus. In general, there are 10,000 to 50,000 molecules of each TF in a cell,  although some 
can  be  as  high  as  300,000  (Biggin,  2011).  There  is  still  controversy  over  whether  TF 
concentration is limiting with respect to the number of available binding sites (Biggin, 2011), 
however studies suggest that for any single TF, >90% of molecules are bound to DNA. A large 
portion of this binding is suggested to be non-functional and designed to limit the concentration 
of free TF molecules in the nucleus (Kao-Huang et al., 1977; Liu et al., 2007). 
A recent study has explored the interplay between TF number and binding site number at 
promoters.  Brewster  and  colleagues  titrated  the  concentration  of  TFs  in  E.coli  and  varied 
whether the TF binding site was within a chromosome or on multi-copy plasmids (Brewster et 
al., 2014). They found complex dosage responses to TF and plasmid copy numbers suggesting 
the  number  of  binding  sites  for  a  TF  can  have  strong  effects  on  how  a  TF  controls  gene 
expression. This has important implications for previous research done examining TF activity in 
the context of high copy reporters and overexpression of the TF protein. The effect of limiting 
TF expression would certainly be lost in an artificial system of overexpressing TFs. In addition, 
reporter assays with high plasmid copy number would likely not reflect competitive aspects of 
TF binding as well. Therefore, loss of function studies at endogenous loci will be particularly 
important for teasing apart the endogenous function of a TF and the cooperative mechanisms it 
uses to drive gene expression.  
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Molecular mechanisms to specify function of broadly expressed TFs 
There are several ways in which transcription factors may regulate cell type-specific gene 
expression programs in neurons. In the simplest model a lineage specific transcription factor may 
bind to promoters or enhancers and directly regulate a battery of proximal target genes (Hobert, 
2008).  For  example,  the  homeodomain  transcription  factor  Crx  is  highly  enriched  in 
photoreceptors  and  regulates  expression  of  photoreceptor-specific  genes  (Chen  et  al.,  1997; 
Freund et al., 1997; Furukawa et al., 1997). Human mutations in CRX can lead to blindness, 
underscoring the importance of such cell type-specific factors (Swain et al., 1997). Alternatively, 
a transcription factor could be differentially modified in different cell types or in response to 
different  extrinsic  stimuli  in  a  manner  that  affects  target  gene  expression.    This  model  is 
powerful in that allows a single factor to regulate gene programs in more than one way.  A third 
model  of  regulation  requires  that  two  or  more  transcription  factors  act  cooperatively  or 
sequentially  to  activate  gene  expression.  This  type  of  regulation  allows  for  a  diversity  of 
transcriptional outputs.  For example, if two transcription factors have overlapping but distinct 
expression domains then three different modes of regulation are possible; two modes where each 
transcription factor is working alone and a third where they regulate gene expression together.  
This model helps explain how a broadly expressed transcription factor may have very different 
roles in two distinct cell types.  For example, the overlapping patterns of dorsal-ventral and 
rostral-caudal  Hox  gene  expression  in  the  developing  spinal  cord  exemplify  this  type  of 
intersectional  regulation  (reviewed  in  (Dasen  and  Jessell,  2009)).  This  type  of  combinatory 
regulation allows for a great deal of flexibility and precision, and is likely a common mechanism 
for specifying gene expression in a given cell-type.  	 ﾠ
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Diverse molecular mechanisms of TF cooperativity 
To understand how a TF regulates a cell type-specific program of gene expression, it is 
critical to understand where it binds in the genome and how it is recruited to specific DNA 
regulatory elements. One method to identify possible sites of TF binding is by searching for 
known transcription factor binding motifs throughout the genome.  The presence of a consensus 
DNA binding motif alone however is not predictive of transcription factor binding (White et al., 
2013). How therefore does a transcription factor decide where to bind? Chromatin availability is 
one factor that limits binding.  Many transcription factors can only bind their consensus motifs 
within open chromatin.  Such a protein may therefore first require a pioneer factor to sit down 
and remodel the chromatin landscape (Figure 1.1).  Another limiting factor may be the affinity 
of a transcription factor to a given binding motif.  Transcription factors typically bind 6-12bp 
DNA sequences with varying degrees of degeneracy.  This affinity can be increased however 
through  cooperative  binding  at  an  enhancer.  For  example,  multiple  TFs  may  co-activate  an 
enhancer  and  this  may  stabilize  their  binding  through  the  formation  of  a  larger  activating 
complex. For example, TFs may co-recruit HATs and HDACs (Spitz and Furlong, 2012). P300 
and CBP in particular have been suggested to act as bridges between TFs and have been shown 
to have multiple TF interaction domains (Chan and La Thangue, 2001). In these two examples 
the cooperativity between TFs is indirect. However, the cooperativity between TFs may also be 
direct. For example, direct binding between TFs may increase their affinity for DNA, allowing 
them to bind where they would have previously been unable to, such as to lower affinity motifs 
   A
B
Figure 1.1. Indirect mechanisms of TF cooperativity at enhancers. 
(A) Activator protein 1 (AP-1) functions as a pioneer factor for glucocorticoid receptor (GR). In 
the absence of AP-1, GR cannot bind its binding motif as it is in a nucleosome-bound region of 
DNA and inaccessible. AP-1 binding to its proximal binding motif (A) repositions the nucleo-
some, exposing the GR motif (B) and allowing GR to bind (Biddie et al., 2011). 
(B) Co-recruitment of a co-factor may stabilize TF binding. Two TFs may initially bind DNA 
independently and then recruit a HAT such as CBP/p300. CBP/p300 may directly interact with 
both TFs at two distinct domains, and this tripartite complex may stabilize binding of the original 
TFs (Merika et al., 1998). References and images from (Spitz and Furlong, 2012).  
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 or to motifs in less accessible DNA. In all of these scenarios, the consensus binding motifs of 
the cooperating TFs may be clustered together at enhancers. 
Within a given enhancer, several possibilities for binding of many transcription factors 
exist (Figure 1.2). There may be an established motif grammar constant to all sets of a particular 
enhancer type, suggesting that a specific cohort of required transcription factors always binds 
together in a fixed arrangement to provide a consistent protein interface (Spitz and Furlong, 
2012) (Figure 1.2A). Alternatively, a group of transcription factors may function cooperatively 
to activate an enhancer but with more flexibility. Not all TFs in the group may be required at an 
enhancer, and the position of motifs may not be consistent. In this scenario, each TF adds toward 
the activation of an enhancer but a strict arrangement is not required (Figure 1.2B). An example 
of this can be found in a recent study where the binding motifs for CREB, MEF2 and SRF 
cluster  together  in  an  enhancer  regulatory  element  termed  the  synaptic-activity  responsive 
element (SARE), but not necessarily in the same configuration at each enhancer. This set of 
motifs  is  however  found  proximal  to  many  activity-regulated  genes  and  is  hypothesized  to 
mediate a coordinated gene expression response to neuronal activity (Rodriguez-Tornos et al., 
2013). Whether all three TFs are required at each of these SAREs remains to be determined. 
Finally, not all TFs may need to bind to the DNA directly but may interact with other TFs in the 
group. In this case, binding is highly cooperative and the motifs present in the enhancer are 
variable (Figure 1.2C).  
Examples of co-factors facilitating binding have provided examples of TF cooperativity and 
illustrate  the  power  of  genome-wide  analyses  in  assessing  determinants  of  TF  binding  and 
cooperativity. Recent work showed that SMAD proteins have highly cell type-specific binding,Enhancer 1
Enhancer 2
Same at each enhancer 
regulated by these TFs
ABC
Enhancer 1
Enhancer 2
Enhancer 3
Figure 1.2. Models of enhancer activation.
Multiple models have been proposed for how TFs might cooperate to activate enhancers. These 
models include the following: 
 (A) Binding of all TFs in a set is required to form a higher-order protein interface for enhancer 
activation. DNA motif composition and positioning is identical at all enhancers regulated by this 
“enhanceosome” (Merika and Thanos, 2001). 
(B) Motif positioning is flexible. All TFs bind their motifs and cooperatively contribute to 
enhancer activation but their specific location on the DNA relative to each other is not critical.
(C) A consistent group of TFs binds many enhancers but motif composition and positioning is 
variable. Not all TFs need to directly bind DNA, and not all members of the TF group are 
required at each enhancer for activation (Junion et al., 2012). 
References and images adapted from (Spitz and Furlong, 2012).  
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and that this was mediated by pioneer factors which provided tissue specific DNA accessibility 
that  revealed  SMAD  binding  sites  to  specify  SMAD  binding  as  part  of  the  TGFβ  response 
(Mullen  et  al.,  2011).  SMADs  have  a  short,  degenerate  consensus  binding  sequence  and 
therefore likely have a high requirement for DNA accessibility provided by pioneer factors. 
Additionally, recent work has examined the binding dynamics of Sox2 and Oct4 with single 
molecule imaging in ES cells and demonstrated that Sox2 searches the DNA, binds, and then 
assists Oct4 in more directed binding, which leads to a stabilized Sox2-Oct4 complex bound to 
DNA (Chen et al., 2014). Finally, a recent paper demonstrated sequence-independent binding of 
estrogen receptor alpha (ERα) (Gertz et al., 2013). ERα binds to shared sites with high-affinity 
response elements (EREs) or at cell type specific sites without EREs that are more accessible and 
co-bound by other factors. A model was proposed for estrogen receptor alpha at sites without 
high-affinity response elements (EREs), where ERα is tethered to the DNA by protein-protein 
interactions with other TFs (Gertz et al., 2013). Taken together, these examples illustrate how 
TFs can function as co-factors to provide DNA accessibility, facilitate other TF binding, or tether 
other TFs at a regulatory element where they do not have a binding site.  
The  genome-wide  patterns  of  transcription  factor  cooperation  and  TF  function 
specification  are  just  beginning  to  be  revealed  in  the  nervous  system.  In  induced  cultured 
neurons, specification of cranial versus spinal motor neurons was shown to require cooperative 
binding of two different sets of homeodomain factors, Isl1-Phox2a or Isl1-Lhx3. The different 
outcomes in neuronal cell types was found to be mediated by differential binding of Isl1 to the 
genome, due to specific sets of motif co-occurrences which helped specify the different binding 
of  the  two  pairs  of  TFs  (Mazzoni  et  al.,  2013).  However,  these  mechanisms  have  not  been 	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carefully investigated in vivo and further work to elucidate how these mechanisms function in the 
nervous system is required.  
   	 ﾠ
	 ﾠ 15 
 
1.2 Introduction to MEF2 transcription factors 
 
MEF2 family members have critical functions in development and disease 
Vertebrates have 4 MEF2 family members, MEF2A-MEF2D, which are homologous to three 
MEF2 isoforms in Xenopus laevis (MEF2A, MEF2C and MEF2D) as well as single MEF2 proteins in 
Saccharomyces  cerevisiae,  Drosophila  melanogaster  and  Caenorhabditis  elegans.  These  4  family 
members are expressed in distinct though overlapping patterns across cell types (Black and Olson, 1998; 
Potthoff  and  Olson,  2007).  While  MEF2  transcription  factors  were  initially  characterized  in 
muscle, they are widely expressed and are important in cell survival, differentiation and response 
to stimulus in many other tissues (Potthoff and Olson, 2007). For example, MEF2 family members 
are critical for numerous functions in the nervous system as well as important in T cell, bone and neural 
crest development (Arnold et al., 2007; Rashid et al., 2014; Savignac et al., 2007; Verzi et al., 2007), and 
endothelial cell organization and vascular integrity (Lin et al., 1997).  Furthermore, MEF2 family members 
have been implicated in human diseases in multiple organ systems, including neurodevelopmental defects 
(Bienvenu et al., 2013; Novara et al., 2010), coronary artery disease (Bhagavatula et al., 2004; Wang et 
al., 2003) and migraines (Chasman et al., 2014; Freilinger et al., 2012). 
 
Discovery of MEF2 	 ﾠ
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  In 1989, Myocyte enhancer factor 2 (MEF2) was discovered as a factor expressed early after the 
induction of myocyte differentiation and bound to regulatory elements for muscle-specific genes (Gossett et 
al., 1989). In 1991, a separate line of inquiry also led to the discovery of MEF2, in a search for homologues 
of Serum Response Factor (SRF), a transcription factor that was beginning to be characterized at growth 
factor inducible promoters (Pollock and Treisman, 1991). MEF2 was discovered because it shared a domain 
with SRF, the MADS domain. This DNA-binding domain is highly conserved throughout eukaryotes, as 
demonstrated  by  its  namesakes,  several  of  the  earliest  factors  characterized  with  it: Minichromosome 
Maintenance 1 (MCM1), Agamous, Deficiens and SRF (Gramzow and Theissen, 2010). MCM1 is a 
protein  characterized  in  Saccharomyces cerevisiae as  important  for  viability  and  pheromone  response, 
among  other  functions  (Shore  and  Sharrocks,  1995;  Treisman  and  Ammerer,  1992).  Agamous  and 
Deficiens are proteins expressed in the plants Arabidopsis thaliana and Antirrhinum majus, respectively, 
and mediate floral organogenesis and morphogenesis (Gramzow and Theissen, 2010). Finally, SRF was 
initially characterized in human cell lines as being expressed in response to serum and growth factors, and 
was shown to have an important role in directly promoting fos transcription (Norman et al., 1988; Rivera et 
al., 1990). SRF has since been found to have broader functions in stimulus responsive gene expression 
across many cell types (e.g., (Mylona et al., 2011; Ramanan et al., 2005; Xia et al., 1996)}).  
These two approaches that led to the discovery of MEF2 illustrate two of the main features of 
MEF2 TFs that were immediately apparent. First, they are critical in muscle differentiation and stimulus 
response. Secondly, they have highly conserved domains, and members of their family of MADS-box TFs 
had  important  functions  across  phyla.  We  now  know  they  play  similarly  important  roles  in  cell 
differentiation and response to stimuli across many cell types, and these functions are conserved across 
organisms as well (Potthoff and Olson, 2007). 	 ﾠ
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Basic structure of MEF2 TFs 
  The MADS domain comprises the first 57 amino acids of the N terminus of MEF2 TFs, and is a 
minimal DNA binding domain (Figure 1.3) (Black and Olson, 1998). This is followed by a 29 amino acid 
MEF2 domain, which is also highly conserved among MEF2 family members and is responsible for high 
affinity DNA binding and homo and heterodimerization among MEF2 family members (Molkentin et al., 
1996a). The MADS and MEF2 domains mediate high affinity DNA binding to the consensus MEF2 
Response Element (MRE) which is YTAWWWWTAR (Flavell et al., 2008; Potthoff and Olson, 2007). 
This A/T rich sequence is similar to the sequence bound by SRF (CCWWAWWWGG) and previous work 
has shown that this specificity in binding sites is primarily due to three differing amino acids in the MADS 
DNA binding domain (Nurrish and Treisman, 1995).  While the DNA binding domains of MEF2 family 
members are well conserved, the C terminus of MEF2 proteins, which contains transactivation domains, is 
highly divergent between family members. While some areas of homology and parallels in regulation exist, 
often the divergent C termini provide the opportunity for differential post-translational regulation of the 
different MEF2s (see below).  
 
Key mechanisms of MEF2 regulation 
The MADS and MEF2 domains at the N terminus have additional functions beyond DNA binding 
and dimerization. The majority of characterized interactions between MEF2 and other TFs that serve as co-
factors are mediated by regions within the MADS domain (McKinsey et al., 2002). The MADS domain is 
also critical for the interaction of MEF2 with Histone acetyltransferases (HATs) and Histone deacetylases 
(HDACs) (Lu et al., 2000; Sartorelli et al., 1997).    Figure 1.3. Basic structure and conservation of MEF2 family members.
MEF2 family members have highly conserved N-terminal MADS/MEF2 domains and a diver-
gent C-terminus. Image is from (Potthoff and Olson, 2007).
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  As MEF2 interacts with both activating HATs and repressing HDACs, a model of dual functions 
for MEF2 has been proposed (McKinsey et al., 2002). In this model, MEF2 binds DNA and associates 
with class IIa HDACs, which recruit class I HDACs, and this represses gene expression (Figure 1.4). 
Signaling  upon  a  differentiation  stimulus  in  myocytes  or  TCR  engagement  in  thymocytes  leads  to 
dissociation  of  HDACs,  which  allows  MEF2  to  now  bind  p300/CBP  and  activate  gene  expression 
(Haberland et al., 2007; McKinsey et al., 2000; Youn et al., 2000b). HDAC and p300/CBP binding with 
MEF2 is thought to be mutually exclusive and a major mechanism for how MEF2 contributes to 
the repression or activation, respectively, of a regulatory element.  
  There are also numerous mechanisms of regulation of the MEF2 family members at post-
transcriptional and post-translational levels. These modifications occur predominantly through 
phosphorylation  and  dephosphorylation  of  serine/threonine  residues  across  the  body  of  the 
protein (Figure 1.5). For example, phosphorylation of serine 59 in the MADS/MEF2 domains by 
casein  kinase  II  (CKII)  increases  DNA  binding  affinity  in  cultured  cells  (Molkentin  et  al., 
1996b). There are also critical sites of phosphorylation in the transactivation domains of MEF2, 
which  are  often  regulated  in  a  cell  type  specific  manner  and  which  also  modulate  the 
transcriptional  activity  of  MEF2  (McKinsey  et  al.,  2002).  Finally,  alternative  splicing  in  the 
transactivation domains of MEF2 family members changes how the MEF2s are regulated and produces a 
greater diversity of MEF2 functions (Lyons et al., 2012; Sebastian et al., 2013). 
MEF2 transcription factors have been most thoroughly investigated in muscle, hematopoietic, and 
neural lineages (Potthoff and Olson, 2007). Examples of tissue-specific mechanisms of MEF2 regulation 
and function for these best characterized cell types will be discussed further in Chapters 1.3-1.5.   Figure 1.4. Dual functions of MEF2 as both activator and repressor.
In some systems, MEF2 sits on DNA and associates with HDACs to repress gene expression 
under baseline conditions. Various stimuli can activate Ca2+/Calmodulin-dependent protein 
kinase signaling, which phosphorylates the HDACs, promoting their association with 14-3-3 and 
export from the nucleus. MEF2, still bound to the DNA, can now associate with HATs such as 
p300 and become an activator of gene expression instead of a repressor. Image adapted from 
(McKinsey et al., 2002).
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Figure 1.5. Diverse mechanisms of MEF2 regulation.
MEF2 family members are extensively modified throughout the body of the protein to regulate 
their functions. This diagram demonstrates modifications in neurons but many happen in other 
tissues as well, for example CKII  phosphorylation of MEF2 in the MEF2 domain. Modulatory 
events in blue increase MEF2 activity whereas those in red decrease MEF2 activity. Apart from 
phosphorylation of MEF2, other modulations include acetylation (Ac)/sumoylation (Sm) as well 
as degradation. Image adapted from (Rashid et al., 2014).	 ﾠ
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1.3 MEF2 transcription factors in muscle  
MEF2 factors in muscle development  
The MEF2 family members were first characterized as factors able to promote myogenic 
differentiation in vitro (Gossett et al., 1989). In this experimental paradigm, serum withdrawal 
prompted  conversion  of  cultured  fibroblasts  into  developing  myocytes  and  expression  of 
myocytes  genes  such  as  myosin  heavy  chain  (MHC)  (Edmondson  and  Olson,  1989). 
Alternatively,  this  conversion  could  be  initiated  by  the  overexpression  of  the  bHLH  factor 
myocyte enhancer factor 1 (MEF1), now known as MyoD (Buskin and Hauschka, 1989; Davis et 
al.,  1987;  Lassar  et  al.,  1989;  Tapscott  et  al.,  1988).  In  searching  for  additional  myocyte-
promoting factors, MEF2 was discovered as able to potentiate the conversion into myocytes. It 
was also proposed to be able to induce the myogenic lineage alone as MYOD can (Kaushal et al., 
1994),  though  this  was  controversial  and  disputed  by  other  papers  (Molkentin  et  al.,  1995). 
However,  expression  of  a  MEF2  dominant  negative  protein  blocked  myocyte  differentiation 
(Ornatsky  et  al.,  1997),  establishing  that  MEF2  factors  were  critical  for  this  process.  The 
importance  of  MEF2  family  members  in  muscle  has  now  been  demonstrated  across  many 
organisms, including Drosophila melanogaster (Bour et al., 1995; Lilly et al., 1995) Xenopus 
laevis (Della Gaspera et al., 2012; Kolpakova et al., 2013), Mus musculus (Lin et al., 1997), and 
Homo sapiens (Bhagavatula et al., 2004; Wang et al., 2003). 
The first evidence for the importance of MEF2 function in muscle in vivo came from 
Drosophila. MEF2 is expressed in myogenic lineages in Drosophila embryogenesis (Lilly et al., 
1994).  D-mef2  mutant  Drosophila  embryos  demonstrate  abnormal  differentiation  of  all 
myogenic  lineages  (cardiac,  skeletal,  visceral)  (Bour  et  al.,  1995;  Lilly  et  al.,  1995).  These 	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findings were extended to vertebrates with the generation of the first MEF2 knockout mice. 
These confirmed the importance of MEF2 family members in muscle development, most notably 
in the development of cardiac muscle. MEF2C total knockout mice are embryonic lethal due to severe 
defects in early cardiac development (Lin et al., 1997). MEF2A total knockout mice are born but die by 
P7, also due to cardiac defects (Lin et al., 1997; Naya et al., 2002). Previously published MEF2D knockout 
mice appear phenotypically normal but still have cardiac abnormalities, specifically resistance to stress-
induced cardiac remodeling (Kim et al., 2008; Potthoff et al., 2007). Finally, there is evidence for the 
importance of MEF2 in human muscle development as well, as mutations in MEF2A have been linked to 
cardiac disease (Bhagavatula et al., 2004; Wang et al., 2003). 
Molecular mechanisms of MEF2 function in muscle 
In striated muscle, MEF2 family members are transcriptionally activated by MYOD and 
other muscle-specific bHLH family members. They then co-bind with these family members to 
activate the expression of genes critical for muscle differentiation. Over the past twenty years, 
significant  gains  in  understanding  these  molecular  mechanisms  of  MEF2-mediated  gene 
expression have been made through studying the interactions of MEF2 factors and MYOD or 
MYOG in myocyte cell lines, primarily through the use of reporter systems (Black and Olson, 
1998). 
The interaction of MEF2 and the myogenic bHLH factors is mediated by regions in their 
respective DNA-binding domains (Molkentin et al., 1995). Experiments in cultured myocytes 
have suggested that the direct interaction between MEF2 and MYOD is sufficient to allow both 
proteins to regulate gene expression even if only one DNA binding site is present. One of the 
earliest  investigations  of  this  cooperativity  demonstrated  that  myogenic  bHLH  factors  can 	 ﾠ
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activate a Myog promoter reporter with MEF2 factors where there is an MRE but no E-box 
(Edmondson  et  al.,  1992).  Furthermore,  in  a  GAL4  reporter  system,  the  motif  for  bHLH 
heterodimer binding, an E-box, is dispensable as long as MEF2 is able to bind to its MEF2 
response element (MRE), and the converse is true as well (Molkentin et al., 1995). In addition, a 
MEF2C mutant with the single amino acid mutation R24L, which renders it unable to bind DNA 
(Molkentin et al., 1996a) is able to effectively co-activate reporters with MYOD (Molkentin et 
al., 1995). However, when this was investigated in the context of endogenous gene expression, 
both  DNA  binding  motifs  were  required  for  MYOG  and  MEF2  co-activation  of  the  Mrf4 
promoter in myogenesis (Naidu et al., 1995). Thus, whether MEF2 and MYOD both need to bind 
to DNA to effectively co-activate gene expression remains unclear. 
Further research has examined how MYOD and MEF2 may co-activate gene expression 
once bound to the DNA.  Initial studies found that p300/CBP interact with MYOD through its N 
terminal domain to amplify myogenic conversion of fibroblasts (Sartorelli et al., 1997). This N 
terminal activation domain of MYOD is unavailable for p300 binding when just MYOD is bound 
to DNA. It was proposed that cofactor binding might induce a change in conformation that 
would then make this domain of MYOD functional (Davis et al., 1990; Huang et al., 1998). 
MEF2C  was  also  found  to  interact  with  CBP/p300  through  its  MADS  domain,  and  this 
potentiated  MEF2C’s  transcriptional  activating  ability,  though  how  MEF2,  MYOD  and 
p300/CBP may form a complex to regulate transcription was not tested (Sartorelli et al., 1997). 
In  addition,  overexpressing  MYOD  and  p300  alone  was  sufficient  to  induce  synergistic 
activation,  suggesting  that  MEF2  family  members  are  not  necessary  cofactors  for  MYOD 
interactions  with  p300  (Sartorelli  et  al.,  1997).  Taken  together,  these  results  have  suggested 	 ﾠ
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multiple mechanisms of interaction between MEF2 and myogenic bHLH factors for co-binding 
and co-activation. How these happen in vivo remains to be elucidated. 
  Beyond MYOD, MEF2s have been suggested to work with several other cofactors in 
myocytes, including thyroid hormone receptor (De Luca et al., 2003; Lee et al., 1997), SMADs 
(Quinn et al., 2001), and LMD in Drosophila (Cunha et al., 2010). In cardiac muscle, a key co-
factor  for  MEF2  is  the  zinc  finger  protein  GATA4.  Using  similar  strategies  as  those  to 
characterize MEF2 interactions with MYOD, it was shown that GATA4 can recruit MEF2 to 
cardiac target gene promoters to potentiate GATA4’s activity (Morin et al., 2000). Similar to 
MYOD,  GATA4  can  recruit  MEF2  in  an  MRE-independent  manner  (Morin  et  al.,  2000). 
However in contrast to MYOD, in cardiac myocytes MEF2D alone bound to p300 whereas 
GATA4 did not (Slepak et al., 2001). This MEF2D-p300 interaction was sufficient to drive the 
alpha-actin  promoter  in  cardiac  myocytes.  How  these  mechanisms  work  in  an  endogenous 
context remains to be examined. 
The  co-factor  binding  and  transcriptional  activity  of  MEF2  family  members  are  also 
regulated by posttranslational modifications of MEF2, many of which were first identified in 
muscle. For example, MEF2 binding to p300/CBP not only serves to recruit these HATs to the 
DNA, but MEF2 is also directly acetylated in its transactivation domain by p300, which further 
activates MEF2 (Ma et al., 2005).  
Phosphorylation of MEF2 family members also mediates MEF2 function in muscle. For 
example,  Protein  kinase  A  (PKA)  is  known  to  phosphorylate  MEF2D  at  S121/S190,  which 
inhibits  MEF2D  function  and  represses  myogenesis  (Du  et  al.,  2008).  There  is  a  myocyte-
specific, developmentally controlled alternate splice form of MEF2D that does not contain these 	 ﾠ
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two  serines,  rendering  MEF2D  insensitive  to  PKA-mediated  inhibition  and  able  to  promote 
myocyte  differentiation  (Sebastian  et  al.,  2013).  A  recent  study  has  demonstrated  that  these 
differentially  modified  splice  forms  do  not  differ  in  their  binding  of  DNA.  However,  this 
modification does affect the co-factors MEF2D associates with, as in the phosphorylated form, 
MEF2D associates with co-repressors HDAC4/HDAC9, whereas in the later non-phosphorylated 
form, MEF2D associates with the Ashl2 co-activator complex, likely accounting for the switch 
in MEF2D function from inhibitor to promoter of myogenesis (Sebastian et al., 2013). 
Global gene regulation in muscle by MEF2  
The majority of work done to investigate MEF2-mediated global mechanisms of gene 
regulation has been done in the context of Drosophila mesoderm development. MEF2 ChIP-
ChIP throughout Drosophila development demonstrated that MEF2 binds proximally to muscle 
genes throughout embryonic development, and binds near genes misregulated in MEF2 mutant 
embryos (Sandmann et al., 2006). When combined with data for binding of other key myogenic 
factors, it was observed that MEF2 participates in a feed forward loop in Drosophila muscle 
development, where the bHLH factor Twist regulates the expression of Mef2 and then binds to 
the genome in overlapping patterns with MEF2 (Sandmann et al., 2007).  
Studies  of  how  MEF2  globally  mediates  gene  expression  in  vertebrates  are  now 
beginning  to  emerge.  Two  studies  have  characterized  MEF2A  binding  in  the  context  of  the 
cardiac muscle differentiation transcriptional network. These studies demonstrated that MEF2A 
binding overlapped with other transcriptional network components and that regulatory elements 
with multiple TFs present are more likely to be active (He et al., 2011; Schlesinger et al., 2011). 	 ﾠ
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These studies underscore the importance of MEF2 in muscle development and that it 
cooperates with co-factors in muscle differentiation. While MEF2 has been best characterized in 
muscle,  some  of  these  molecular  mechanisms  occur  in  the  hematopoietic  system  as  well, 
suggesting some universal principles in how MEF2 family members function.     	 ﾠ
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1.4 MEF2 transcription factors in the hematopoietic system  
MEF2 in T lymphocytes 
T  cells  have  well  defined  calcium-dependent  responses  to  stimuli  using  mechanisms 
parallel  to  those  used  in  muscle  or  neurons  (Savignac  et  al.,  2007).  Briefly,  when  T  cells 
encounter an MHC-peptide bearing cell with sufficient affinity to their T cell receptor (TCR), 
engagement of the TCR triggers a signaling cascade that involves calcium influx from both the 
ER  as  well  as  external  calcium  via  CRAC  channels.  This  calcium  influx  regulates  the 
transcriptional  activity  of  MEF2  family  members,  which  then  play  an  important  role  in 
regulating several aspects of T cell development and function (Savignac et al., 2007). 
Developing T cells (thymocytes) with a T cell receptor (TCR) that reacts too strongly to 
an  MHC-self  peptide  complex  undergo  apoptosis  in  a  process  known  as  negative  selection. 
Strong TCR engagement in this process triggers calcium influx, which activates MEF2 and lead 
to the expression of nur77, which mediates thymocyte apoptosis (Youn et al., 1999). Prior to 
activation, MEF2 is bound by its co-repressor Cabin1. Calcium influx prompts the binding of 
Cabin1 to calmodulin, which dissociates it from MEF2.  
To further test whether the interaction of Cabin1 with MEF2 is important for thymocyte 
negative selection, a mouse with a mutant form of Cabin1 that could not bind MEF2 was created.  
This mouse however did not have defects in negative selection, which suggested other regulatory 
mechanisms must also be involved (Esau et al., 2001). Calcium influx also activates CamKIV 
and Calcineurin, which can directly phosphorylate and dephosphorylate MEF2, respectively, at 
different  residues  to  activate  it  (Blaeser  et  al.,  2000;  Rashid  et  al.,  2014).  Calcineurin  also 	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dephosphorylates NFATp and allows it to translocate into the nucleus, where it associates with 
MEF2. NFATp and MEF2 then co-recruit p300/CBP to activate the nur77 promoter and promote 
nur77 expression (Blaeser et al., 2000; Youn et al., 2000a; Youn and Liu, 2000; Youn et al., 
1999). In this paradigm, MEF2D is bound directly to the nur77 promoter but NFATp does not 
require its DNA recognition site, and instead was thought to bind directly to MEF2D through its 
MADS domain (Youn et al., 2000a).  
   Beyond negative selection, MEF2 has also been suggested to have a parallel role in 
mature T cells in regulating cytokine expression (Savignac et al., 2007). In this case, the mutant 
mouse where Cabin1 could no longer interact with MEF2 supported these findings, as these mice 
had increased cytokine expression (Esau et al., 2001). Furthermore, MEF2 binding sites were 
found in the promoter of IL-2, and MEF2 was shown to promote calcium-mediated expression of 
Il-2, also together with NFATp (Pan et al., 2004). Further work remains to examine how MEF2D 
works in T cells in vivo.   
 
MEF2C in early lymphopoiesis 
While MEF2D has a role in thymocyte development and T cell activation, MEF2C is 
expressed earlier in lymphoid development, in particular in hematopoietic stem cells, common 
lymphoid progenitors, and common myeloid progenitors (Stehling-Sun et al., 2009). A recent 
study  suggested  that  MEF2C  regulates  a  key  choice  in  hematopoietic  development  between 
lymphoid and myeloid differentiation. Early deletion of Mef2c in hematopoietic development led 
to impaired pan-lymphocyte differentiation (Stehling-Sun et al., 2009). This regulation of earlier 	 ﾠ
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lymphopoiesis by MEF2C may have implications for human disease as well. Translocations 
leading to the upregulation of Mef2c expression have been found in subtypes of acute myeloid 
leukemia and T-cell acute lymphoblastic leukemia (Cante-Barrett et al., 2014). 
Taken together, the data in Chapters 1.3 and 1.4 highlight the critical function of MEF2 
factors in lymphocyte and myocyte biology as well as human disease. They also illustrate the 
diverse  array  of  co-factors  as  well  as  signaling  mechanisms  employed  to  regulate  MEF2 
function. MEF2 transcription factors have also been found to have critical roles in neuronal 
biology  and  human  neurological  disease  and  investigation  into  MEF2  transcription  factor 
function in the nervous system is an area of ongoing intensive research.  
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1.5 MEF2 transcription factors in the nervous system  
MEF2  transcription  factors  play  critical  roles  in  the  nervous  system.  While  several 
examples of MEF2 co-factors exist in non-neural tissues as discussed in Chapters 1.3 and 1.4, 
investigating these kinds of interactions has been limited in the nervous system. MEF2 has been 
suggested to interact with the neurogenic bHLH factor MASH1 (Black et al., 1996; Mao and 
Nadal-Ginard,  1996),  however  demonstrating  a  biological  function  for  this  interaction  has 
remained elusive. Beyond this, co-factors for MEF2 family members in the nervous system have 
not yet been described, likely due to limitations in examining the molecular function of MEF2s 
in  the  nervous  system.  However,  the  critical  role  of  MEF2  transcription  factors  in  neuronal 
biology at multiple levels has been well established.  
 
Role of MEF2 in neuronal differentiation 
  The MEF2 family members are expressed throughout the nervous system in different but 
overlapping patterns. Expression of MEF2 family members often begins once a neuron begins to 
differentiate, suggesting that MEF2 plays a role in this process (Heidenreich and Linseman, 
2004; Ikeshima et al., 1995; Lam and Chawla, 2007; Lyons et al., 1995). MEF2 may also play an 
active role in neural differentiation, as it has been shown to promote the expression of neural 
genes  in  P19  embryonic  carcinoma  cells,  including  the  neurogenic  bHLH  factor  MASH1 
(Skerjanc and Wilton, 2000). Furthermore, MEF2C may have a neurogenic role in murine ES 
cells (Li et al., 2008b), and enhance neuron generation in hESC-derived neural stem progenitor 
cell (Cho et al., 2011). However, perhaps the best evidence that MEF2 factors play a role in 	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neuronal differentiation comes from a study of mice with conditional loss of MEF2C in neuronal 
progenitor cells. These mice had cortical layering defects and deficits in neuronal maturation (Li 
et al., 2008a). However, mice with a similar loss of MEF2C in early neural progenitors were not 
reported as having neuronal maturation defects but rather later developmental synaptic defects 
(Barbosa et al., 2008), and while these synaptic defects could be secondary to more subtle earlier 
defects in neuronal maturation, these results remain unclear. Further investigation of the role that 
MEF2s play in neural differentiation in an endogenous context is required.   
 
MEF2 mediates neuronal survival 
Most initial studies that explored mechanisms of MEF2 regulation in neurons studied the 
role of MEF2 in promoting neuronal survival and preventing apoptosis. MEF2 was first shown to 
be important for the survival of cerebellar granule cells (Mao et al., 1999). Cultured cerebellar 
granule  cells  normally  undergo  apoptosis  when  neuronal  activity  is  withdrawn  (Mao  et  al., 
1999). Expressing a constitutively active form of MEF2 was found to rescue these cells from 
apoptosis; however expressing a dominant negative form accelerated this process (Mao et al., 
1999). This was suggested to be a process based on activation of p38 MAPK that would then 
phosphorylate and activate MEF2C. Further experiments extended these findings to implicate 
other MEF2 family members MEF2A and MEF2D (Gaudilliere et al., 2002; Wang et al., 2009). 
Other stimuli and modifications of MEF2 regulate its role in neuronal survival as well. 
Several kinases have been identified that phosphorylate MEF2 family members and inhibit their 
function,  leading  to  neuronal  apoptosis.  For  example,  GSK3β  phosphorylates  3  residues  in 	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MEF2D that inhibit MEF2D activity, which leads to cerebellar granule cell apoptosis (Wang et 
al., 2009). Activation of Protein kinase A (PKA) by cAMP leads to PKA-mediated inhibitory 
phosphorylation  of  MEF2D  at  S121/S190,  which  results  in  hippocampal  neuron  apoptosis 
(Salma  and  McDermott,  2012).  Finally,  neurotoxic  stimuli  induce  Cdk5-mediated  inhibitory 
phosphorylation  of  MEF2A  and  MEF2D  at  S408  or  S444,  respectively,  which  results  in 
apoptosis of cortical neurons (Gong et al., 2003).  
The importance of MEF2 factors in neuronal survival has also been observed in vivo.  
Mice with expression in the nervous system of MEF2A, MEF2C and MEF2D mutants missing 
DNA binding domains instead of wildtype proteins demonstrated defects in neuronal survival 
(Akhtar et al., 2012). However, mice where only one or two of the MEF2 family members were 
mutated did not have such defects, likely due to the ability of co-expressed MEF2 factors to 
compensate for each other (Akhtar et al., 2012).  
 
MEF2 regulates synapse number  
MEF2 family members have been implicated in later stages of neuronal development as 
well, particularly in modulating synapse number through regulation of synapse formation and/or 
synapse  elimination.  Excitatory  synapses  are  the  primary  form  of  communication  between 
neurons  in  the  CNS,  and  during  development  they  undergo  a  period  of  exuberant  growth 
followed by selective refinement. Simultaneous MEF2A and MEF2D knockdown in rat hippocampal 
neuron culture increases excitatory synapse density. MEF2-VP16, a hyperactivated version of MEF2, can 
lead to a decrease in synapse density (Flavell et al., 2006). Furthermore, MEF2A and MEF2D are activated 	 ﾠ
	 ﾠ 34 
by neuronal depolarization. MEF2A and MEF2D have a homologous serine on their transactivation 
domains,  S408  and  S444,  respectively,  whose  phosphorylation  inhibits  MEF2  activity,  as 
described above. Neuronal activity activates calcineurin, and activity-dependent dephosphorylation 
of MEF2 by calcineurin at S408/444 can activate MEF2A/MEF2D and alter the transcription of hundreds 
of genes. These studies have demonstrated that MEF2A/MEF2D regulate synapse number by controlling 
the expression of a cohort of immediate early genes that mediate the response to activity (e.g. fos, egr1) as 
well as genes with clear synaptic and neurological functions (e.g. homer1, arc, bdnf) (Flavell et al., 2008). 
The observation that MEF2 factors regulate synapse number has been extended beyond in vitro 
cultured  neurons  as  well.   In hippocampal  organotypic  culture,  expressing  an overactive  MEF2-VP16 
decreased excitatory synapses and dendritic spines in CA1 hippocampal neurons, whereas expressing the 
dominant negative MEF2-Engrailed led to an increase in synapses and dendritic spines (Pfeiffer et al., 
2010). Furthermore, these studies have been extended in vivo through the use of conditional knockout mice. 
MEF2C conditional knockout mice have an increase in excitatory synapses onto dentate granule cells in the 
hippocampus, though these mice lose MEF2C early in development so it is difficult to identify the cause as 
direct or indirect due to defects in neuronal health or differentiation (Barbosa et al., 2008). 
 
Role of MEF2 in neural circuit development 
  Most recently, the study of MEF2 factors in neurons has been extended to investigating 
their role in vivo in brain circuitry. This has typically involved manipulating MEF2 activity in 
select brain regions and observing behavioral changes correlated to changes in dendritic spine 
density, which are neuronal structures that correlate with the presence of excitatory synapses. 	 ﾠ
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One of the first examples was a study that demonstrated that chronic cocaine use in mice inhibits 
MEF2A and MEF2D in the nucleus accumbens. This inhibition leads to an increase in dendritic 
spines that may suppress sensitized drug responses. Perturbing this response by overexpressing a 
constitutively active MEF2-VP16 protein represses the increase in dendritic spines and increases 
behavioral sensitization to the drug (Pulipparacharuvil et al., 2008). 
  MEF2 family members have also been implicated in restricting memory formation by 
regulating spine development (Rashid et al., 2014). Through the use of dominant negative or 
constitutively active MEF2 factors as well as loss of function experiments, general principles 
have emerged for how MEF2 plays a role in memory. Memory formation leads to inhibitory 
phosphorylation of MEF2A and MEF2D at S408/S444, which allows for the increases in spine 
formation normally associated with memory formation (Cole et al., 2012). Increasing MEF2 
activity by expressing MEF2-VP16 blocks this increase in spines and consequently new memory 
formation. This pathway has been implicated in memory and spine formation in the anterior 
cingulate  cortex,  hippocampus  and  amygdala  (Cole  et  al.,  2012;  Vetere  et  al.,  2011). 
Furthermore, recent work has suggested that much of this MEF2 dependent spine regulation is 
dependent on MEF2’s regulation of its previously identified target gene arc (Cole et al., 2012; 
Flavell et al., 2008). 
Given the effects on memory demonstrated throughout regions of the brain, it might be expected 
that MEF2 conditional knockout mice would have memory defects as well. However, MEF2A/MEF2D 
brain-specific deletions had no deficits in memory formation (Akhtar et al., 2012). MEF2C brain-specific 
knockout mice had limited defects in fear memory formation, having a deficit in contextual but not cued 
fear  memory  formation  (Barbosa  et  al.,  2008).  The  lack  of  significant  memory  defects  may  reflect 
compensation by remaining MEF2 family members. It might also reflect differences between the acute 	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manipulations employed to disrupt MEF2 in initial studies versus the effects of chronic loss of MEF2 early 
in neuronal development. Finally, it may also reflect complications in interpreting the phenotypes in these 
knockout mice, which still express large truncated MEF2 family members instead of full loss of function 
mutants (Akhtar et al., 2012; Barbosa et al., 2008).  
 
MEF2s in the retina  
Several studies have indirectly implicated MEF2 transcription factors as being possibly 
involved in photoreceptor function and disease. The MRE was found to be slightly enriched in 
regions bound by transcription factors important in photoreceptor biology (Hao et al., 2012). 
Additionally, Mef2c RNA expression levels are decreased in adult knockout mouse models of 
retinal degeneration, including CRX and NRL KO mice (Hsiau et al., 2007; Yoshida et al., 
2004). Mef2c levels are also reduced in Rpe65 knockout mice, another mouse model of retinal 
degeneration, however with the caveat that this photoreceptor abnormality is secondary to a 
defect intrinsic to retinal pigment epithelial cells (Escher et al., 2011). Finally, limited work has 
suggested  MEF2C  is  important  in  the  mature  retina.  One  study  found  that  NRL,  a  key 
photoreceptor  transcription  factor,  could  promote  the  transcription  of  Mef2c  from  a  retina-
specific promoter (Hao et al., 2011). Furthermore, MEF2C was important for the expression of a 
rhodopsin promoter reporter in retinal photoreceptors in vivo. Taken together, these studies have 
suggested that MEF2 factors, particularly MEF2C, may have a role in mature photoreceptors. 
Direct  evidence  of  MEF2  factor  regulation  of  photoreceptor  biology,  however,  has  thus  far 
remained elusive.  	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MEFs in neurological disease  
MEF2 family members have been implicated in several human neurological diseases. The 
most direct association is that haploinsufficiency of MEF2C leads to a neurological disorder 
characterized by epilepsy, mental retardation, absence of speech and other neurodevelopmental 
symptoms, many of which overlap with Rett syndrome (Bienvenu et al., 2013; Novara et al., 
2010; Zweier et al., 2010; Zweier and Rauch, 2012). Other studies have also indirectly linked 
MEF2 to autism and neurodevelopmental disorders. Many neuronal genes that have been found 
to  be  MEF2  target  genes  are  also  possible  disease  genes  associated  with  autism  spectrum 
disorder (Flavell et al., 2008; Morrow et al., 2008), suggesting MEF2 or its targets may play an 
important role in regulating synaptic plasticity and misregulation of MEF2 or any of these target 
genes may lead to neurological disease. Furthermore, MEF2 has been proposed to work with 
FMRP to regulate excitatory synapse and dendritic spine number. FMRP is mutated in patients 
with fragile X syndrome, which is characterized by autism and mental retardation, as well as an 
excess of dendritic spines (Irwin et al., 2001). Mouse neurons missing FMRP do not undergo 
MEF2-mediated synapse restriction as WT neurons do (Pfeiffer et al., 2010). Together, these 
observations suggest that MEF2-mediated mechanisms to reduce spine number may be defective 
in these patients.  
MEF2 has also been suggested to play a role in Parkinson’s disease. In vitro experiments 
in a dopaminergic cell line suggested that inactive MEF2D is normally shuttled from nucleus to 
cytoplasm  for  degradation  by  chaperone-mediated  autophagy,  which  is  disrupted  by  alpha-
synuclein, leading to neuronal death. As alpha-synuclein is elevated in patients with Parkinson’s 
disease, this suggests a possible pathway of dopaminergic cell death in the disease. These results 	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are limited to cell culture experiments, although it was also noted that patients with Parkinson’s 
disease  have  increased  levels  of  MEF2D  in  their  striata,  suggesting  some  aspects  of  this 
mechanism may be related to human disease (Yang et al., 2009).  	 ﾠ
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1.6 Gene regulation in photoreceptor development  
Photoreceptors are the primary sensory neurons of the retina responsible for the initial 
processing of vision. When photons of light enter the eye, they travel through the eye until they 
reach the apical processes of the photoreceptors, known as the outersegments (Figure 1.6A). A 
single  photon  of  light  triggers  the  phototransduction  cascade  within  the  outersegment  by 
isomerizing 11-cis-retinal into all-trans-retinal in visual pigments. This isomerization triggers a 
series of biochemical events that ultimately leads to the conversion of this photon of light into an 
electrical signal via the hyperpolarization of the photoreceptor. This hyperpolarization reduces 
excitatory synaptic activity from the photoreceptor axon terminal to its postsynaptic neurons, 
bipolar and horizontal cells (Luo et al., 2008). These neurons propagate this signal to amacrine 
and retinal ganglion cells, which ultimately transmit this information to the brain  
Photoreceptors vastly outnumber other neuronal cell types in the retina, making up ~ 80% 
of neurons. Rod photoreceptors make up 97% of all photoreceptors, with the remaining 3% being 
cones (Jeon et al., 1998; Young, 1985). The retina is characterized by a stereotypical and well-
defined anatomy (Figure 1.6B), and photoreceptors are tightly packed together, with nuclei in 
the outer nuclear layer (ONL) and synaptic contacts in the outer plexiform layer (OPL).  
 
Retinal Photoreceptor Development  
While there are ultimately ~55 distinct cell types in the mammalian retina, there are six 
broad categories of retinal neuron types: photoreceptors-rods and cones, bipolar cells, horizontal    AB
Figure 1.6. Structure of the retina and retinal photoreceptors. 
(A) Overall structure of the retina. Light enters from the ganglion cell layer side and traverses the 
neural retina until arriving at the photoreceptor layer, where it activates the phototransduction 
system in either rod (R) or cone (C) photoreceptors. Rods and cones transmit this signal to hori-
zontal cells (H) and bipolar cells (B)  and then these signals are integrated with amacrine cells 
(A) until finally the signal reaches ganglion cells (G), which transmit the information to the 
brain. Also depicted are Muller glia which help support the neurons of the retina.  
(B) Magnified structure of rod (on left) and cone (on right) photoreceptors demonstrates their 
unique morphology. The apical processes of photoreceptors are stacked membranous disks 
known as outer segments (OS) that contact the retinal pigment epithelium (RPE) for a continu-
ous recycling process. The inner segment (IS) has metabolic machinery; the cell bodies (CB) 
contain  the  nuclei  and  are  located  in  the  retinal  outer  nuclear  layer.  Images  adapted  from 
(Swaroop et al., 2010). 
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cells, amacrine cells and retinal ganglion cells (Masland, 2001). These different categories of 
neurons  have  some  distinct  features,  which  include  their  localization  in  the  retina,  their 
morphologies, and their birth order in the development of the retina. All retinal neurons as well 
as Mueller glia originate from a common retinal progenitor cell. The developmental time point at 
which  they  are  born,  combined  with  intrinsic  and  extrinsic  cues  helps  determine  their  fate 
(Cepko et al., 1996). For example, cone photoreceptors are among the earliest cells born in 
retinal development in mice, and are born from embryonic day 10 (E10) to E18, peaking at ~ 
E14 (Carter-Dawson and LaVail, 1979), whereas rod photoreceptors are born over a broader 
time period between E13 and postnatal day 7 (P7), peaking at P0-P1 (Carter-Dawson and LaVail, 
1979)(Figure 1.7).  
After each neuron type is specified from retinal progenitor cells, these newborn neurons 
differentiate into the unique morphologies necessary for the distinct functions of that particular 
cell type. At about P6, photoreceptors begin to make synapses with their postsynaptic neurons as 
well as elaborate their outersegments (Olney, 1968). Outersegment growth in mice continues 
rapidly  until  P21  and  by  ~P28  the  mouse  retina  is  mature  (Olney,  1968).  Early  in  this 
development,  multiple  important  photoreceptor  specific  genes  begin  to  be  expressed,  for 
example rhodopsin which begins to be expressed at about P2 (Swaroop et al., 2010). Precise 
control of gene expression from photoreceptor birth through maturation is critical for normal 
photoreceptor development.  
   42
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Differentiation 
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Figure 1.7. Timeline of retinal development.
(A) Overview of retinal development. Neuronal cell birth begins embryonically and continues 
until it begins to taper off in the first postnatal week. Synaptogenesis and differentiation begin 
to increase in the first postnatal week, especially for photoreceptors. Retinal light responses 
emerge prior to eye opening, which is generally at P12-P14. 
(B) Timing of photoreceptor birth in mice. Cone photoreceptors are born early, prior to mouse 
birth. Rods have a wider time range of birth but peak perinatally. In the first week after birth, 
rod photoreceptor cell birth decreases and photoreceptor maturation begins, including forma-
tion of OS and expression of key phototransduction molecules such as the opsins. Image 
adapted from (Swaroop et al., 2010).	 ﾠ
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Transcriptional networks that regulate photoreceptor development 
The  regulatory  networks  that  mediate  retinal  neuron  development  have  been  most 
extensively  studied  in  the  case  of  photoreceptors.  One  of  the  first  transcriptional  regulators 
demonstrated to be critical for photoreceptor fate determination and further differentiation of 
photoreceptors is the homeobox factor Otx2. Mice missing Otx2 have a defect in producing 
photoreceptors, whereas misexpressing Otx2 leads to a cell fate bias toward rods versus other 
retinal neurons (Nishida et al., 2003). Blimp1 and bHLH factors have also been implicated in 
photoreceptor cell fate determination and bHLH factors have been shown to be important in rod 
survival as well as in other critical functions in retinal development (Brzezinski et al., 2010; 
Hatakeyama et al., 2001; Katoh et al., 2010; Morrow et al., 1999).   
Once  photoreceptor  cell  fate  is  specified,  another  transcriptional  network  becomes 
important  in  promoting  photoreceptor  differentiation  and  specific  gene  expression.  Crx  is  a 
homeobox factor closely related to Otx2 that is expressed very early after photoreceptor cell fate 
is determined (Chen et al., 1997; Furukawa et al., 1997). Otx2 and CRX are expressed in both 
rods and cones and play critical roles in gene expression in both cell types, including promoting 
the  expression  of  downstream  TFs.  TFs  specific  to  cone  photoreceptors  include  Thyroid 
hormone receptor beta, specific to green cones in mice (Ng et al., 2001), as well as Nr2b3/RXRγ, 
which  is  critical  for  blue  cones  (Roberts  et  al.,  2005).  Nrl  expression  is  required  for  rod 
differentiation  and  NRL  induces  the  expression  of  Nr2e3,  which  reinforces  the  rod 
differentiation phenotype primarily by repressing cone genes (Chen et al., 2005; Mears et al., 
2001).  	 ﾠ
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The  TFs  NRL,  CRX  and  NR2E3  are  particularly  important  for  establishing  the 
photoreceptor transcriptional network (Hsiau et al., 2007), and loss of any of these 3 proteins 
severely disrupts photoreceptor development and leads to human retinal disease (Bessant et al., 
1999; Coppieters et al., 2007; Gerber et al., 2000; Haider et al., 2000; Nishiguchi et al., 2004; 
Swain et al., 1997). This underscores the necessity of proper gene regulation and activation of 
regulatory elements for normal photoreceptor development. 
The molecular mechanisms by which NRL, CRX and NR2E3 cooperate to activate gene 
expression are now beginning to be elucidated. CRX and NRL co-bind genome-wide and NRL, 
CRX and NR2E3 activate key photoreceptor regulatory elements as seen by increases in histone 
acetylation and DNA looping (Corbo et al., 2010; Hao et al., 2012; Rao et al., 2011). CRX has 
also been found to bind the histone acetyltransferase (HAT) P300, suggesting that these factors 
recruit co-activators to promote photoreceptor gene expression (Peng and Chen, 2007; Yanagi et 
al., 2000). 
Cis-regulatory logic of photoreceptor differentiation as a model for neural development 
Mouse retinal development is an excellent system for systems biology research of gene 
regulatory networks, primarily due to the extensive research on retinal cell fate determination 
and cell differentiation of retinal neurons (Zhang et al., 2011). Furthermore, the retina is easily 
accessible for genetic manipulation using for example DNA electroporations or viral infections 
(Cepko et al., 1998; Matsuda and Cepko, 2004), particularly when compared to the rest of the 
CNS.  Another  significant  difficulty  in  studying  gene  regulation  in  the  CNS  arises  from  its 
diversity of cell types and heterogeneity of neurons throughout the brain. A key advantage of rod 
photoreceptors is that they make up about 80% of neurons and 75% of all retinal cells (Jeon et 	 ﾠ
	 ﾠ 45 
al.,  1998;  Young,  1985).  This  facilitates  analyses  focused  on  this  single  neuronal  cell  type 
without necessitating complex processing of tissues that might distort the endogenous biological 
mechanisms being studied.  
The  cis-regulatory  logic  controlling  photoreceptor  development  has  been  particularly 
well studied and serves as an excellent example of how a cell type specific program of gene 
expression  is  coordinated  in  the  nervous  system  (Hsiau  et  al.,  2007;  Swaroop  et  al.,  2010). 
Transcription factors important for photoreceptor development as well as their target genes have 
also been found to be mutated in human disease, suggesting that a better understanding of the 
gene  regulatory  networks  underlying  the  biology  of  photoreceptor  development  will  provide 
critical  insight  for  future  medical  therapies  (Swaroop  et  al.,  2010).  Taken  together,  these 
advantages  suggest  that  photoreceptors  are  an  excellent  model  for  studying  in  vivo  gene 
regulation in the CNS. 
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1.7 Summary of the dissertation  
The highly conserved MEF2 family of transcription factors plays important roles in many 
aspects  of  neuronal  development  and  function.  However,  the  mechanisms  by  which  MEF2 
comes to regulate neuronal-specific genes is poorly understood, and no co-factors for MEF2 in 
the nervous system have been reliably identified. At the outset of this dissertation we sought to 
elucidate the molecular mechanisms by which MEF2 regulates gene expression in the nervous 
system.  
In Chapter 2, we discover that MEF2D is the unique MEF2 family member expressed in 
developing retinal photoreceptors, and generate MEF2D knockout mice to evaluate the role of 
MEF2D in these neurons. We find that MEF2D is important for normal retinal photoreceptor 
development and that MEF2D knockout mice are blind. Retinal photoreceptor development is an 
excellent model for exploring gene regulatory networks in the CNS, and so we chose to use this 
model to study MEF2-mediated gene expression. Using genome-wide analyses, we found that 
MEF2D  directly  regulates  a  cohort  of  photoreceptor-specific  and  retinal  disease-associated 
genes. MEF2D co-regulates these genes with the retina-specific co-factor CRX, and these factors 
have similar defects in photoreceptor development as well. The mechanism of co-regulation is 
two-fold. First, CRX recruits MEF2D to retina-specific enhancers that have a weak MRE, at the 
expense of other MEF2D binding sites that have a strong MRE. Next, CRX and MEF2D co-
activate regulatory elements to co-regulate target genes. These analyses demonstrated that the 
broadly expressed TF MEF2D acquires tissue-specific functions in the nervous system by co-
binding and co-activation of tissue-specific enhancers with the tissue-specific TF CRX.  	 ﾠ
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In Chapter 3, we use the behavior of MEF2D in developing photoreceptors as a system to 
investigate a fundamental feature of transcriptional biology: that transcription factors bind the 
genome extensively, but regulate a relatively small number of target genes. This has often been 
observed in genome-wide studies but has yet to be carefully examined. To investigate the causes 
of  this  discrepancy,  we  evaluate  in  an  unbiased  manner  the  activity  of  all  MEF2D-bound 
enhancers as determined by levels of H3K27 acetylation and eRNA production. We determine 
that the majority of our MEF2D-bound enhancers are inactive, and so not directly regulating 
gene expression at the time we evaluate changes in gene expression. Of those that are active, 
about half are not dependent on MEF2D for that activity, suggesting significant redundancy 
among bound TFs exists within an enhancer. This demonstrates that TF binding significantly 
overestimates how many TF-bound regulatory elements are directly engaged in regulating gene 
expression,  and  suggests  that  functional  analyses  of  enhancer  activity  are  essential  for 
delineating the specific function of a TF in regulating gene expression.  
Taken  together,  the  work  in  this  dissertation  describes  a  novel  role  for  MEF2D  in 
regulation of photoreceptor development, and provides an in depth analysis of the mechanisms 
MEF2D uses to perform this function, including how it acquires a highly tissue-specific role. We 
show that MEF2D selectively activates a cohort of its bound enhancers and cooperates with the 
tissue-specific factor CRX for both regulatory element binding and activation. This provides a 
model of how MEF2D functions in neuronal development and how it might function in other cell 
types in vivo as well.  	 ﾠ
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Chapter 2 
MEF2 regulates retinal photoreceptor development through 
synergistic binding and selective activation of tissue-specific 
enhancers 
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2.1  Abstract 
Development of the central nervous system requires the precise coordination of intrinsic 
genetic programs to instruct cell fate, synaptic connectivity and function. The MEF2 family of 
transcription  factors  plays  many  essential  roles  in  neuronal  development,  however  the 
mechanism by which this broadly expressed TF contributes to the great diversity of cell types in 
the brain remains unclear. We find that one MEF2 family member in particular, MEF2D, is an 
essential regulator of retinal photoreceptor development and function. Despite being expressed 
broadly  across  many  tissues,  in  the  retina  MEF2D  binds  to  retina-specific  enhancers  and 
regulates photoreceptor-specific transcripts including critical retinal disease genes.  Functional 
genome-wide  analyses  demonstrate  that  MEF2D  achieves  tissue-specific  binding  and  action 
through cooperation with a retina-specific transcription factor, CRX. CRX recruits MEF2D away 
from canonical MEF2 binding sites by promoting MEF2D binding to retina-specific enhancers 
that lack a strong consensus MEF2 binding sequence. Once bound to retinal specific enhancers, 
MEF2D and CRX work together to regulate a cohort of genes critical for normal photoreceptor 
development. These findings demonstrate that MEF2D, a broadly expressed transcription factor, 
contributes to retina-specific gene expression in photoreceptor development by binding to and 
selectively  activating  tissue-specific  enhancers  cooperatively  with  CRX,  a  tissue-specific  co-
factor.  Thus,  broadly  expressed  transcription  factors  may  achieve  tissue  specificity  through 
competitive  recruitment  to  enhancers  by  tissue-specific  transcription  factors  and  selective 
activation of these enhancers to regulate tissue-specific target genes. 
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2.2  Background and Significance 
A remarkable feature of the development of complex multicellular organisms is that this 
extraordinary process is controlled by a relatively limited number of transcription factors (TFs). 
TFs determine the exquisite patterns of gene expression that define the tissues and cell types of 
an organism. The diversity of TF function is especially evident in the brain, where a vast array of 
different cell types gives rise to our ability to extract information from the external environment 
and respond appropriately.  While a number of TFs with tissue-specific expression have been 
identified, most TFs somehow function in a wide range of cell types, yet in a given cell type can 
contribute to cell type specific gene expression. The best evidence that broadly expressed TFs 
contribute to cell type specific functions is that mutations in broadly expressed TFs often result 
in tissue-specific disease phenotypes (Amiel et al., 2007; Amir et al., 1999; Novara et al., 2010). 
Nevertheless, it is not yet well understood how the function of widely expressed TFs is tailored 
to achieve cell type specificity. Elucidating the mechanisms that specify the function of a broadly 
expressed TF within a given tissue is critical for understanding how genes are differentially 
regulated to achieve the diversity of cell types throughout the organism.  
  The highly conserved MEF2 family of transcription factors (MEF2A-D) is expressed in 
virtually all cells of multi-cellular organisms yet plays specific and critical roles in development 
of the brain, muscle, bone and hematopoietic lineages (reviewed in (Potthoff and Olson, 2007)). 
In  the  mammalian  nervous  system  MEF2s  regulate  neural-progenitor  differentiation, 
neurotrophin  and  activity-dependent  neuronal  survival,  the  activity-dependent  restriction  of 
excitatory  synapse  number  as  well  as  synaptic  plasticity  and  behavior  (Akhtar  et  al.,  2012; 
Barbosa et al., 2008; Chen et al., 2012; Cole et al., 2012; Flavell et al., 2006; Li et al., 2008a; 	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Pulipparacharuvil et al., 2008; Shalizi et al., 2006) In humans, mutations in MEF2C can lead to 
severe intellectual disability, epilepsy and an absence of speech. (Bienvenu et al., 2013; Novara 
et  al.,  2010)  Despite  their  clear  importance  in  the  nervous  system  and  many  other  tissues, 
relatively little is known about how these globally expressed TFs regulate distinct steps in the 
development of the nervous system and a wide range of other tissues. 
  The effect of MEF2 on gene expression in a given cell type is determined at least in part 
by where MEF2 binds across the genome. MEF2 family members are known to recognize and 
bind  to  a  common  consensus  DNA  motif  (YTAWWWTAR)  termed  the  MEF2  responsive 
element (MRE) (Flavell et al., 2008; Potthoff and Olson, 2007). In vitro experiments indicate 
that DNA sequences that conform to this consensus site bind MEF2 with high affinity, while 
sequences that differ from the consensus MRE bind MEF2 with lower affinity (Pollock and 
Treisman, 1991). These findings have led to the suggestion that MEF2 binding in a cell might be 
inferred  from  the  presence  of  good  consensus  MREs  within  the  promoters  of  genes  whose 
expression is altered when MEF2 function is inhibited. 
One clue as to how MEF2 family members achieve their tissue specific functions has 
been  provided  by  characterization  of  MEF2  target  genes  in  distinct  tissues.  This  has  been 
accomplished using chromatin immunoprecipitation assays to identify genomic regions that bind 
MEF2, and gene disruption experiments to determine if the expression of MEF2-bound genes is 
altered by the inhibition of MEF2 function. Using these approaches in neurons, MEF2 has been 
shown to control the transcription of synaptic regulatory proteins such as Arc and Syngap1, and 
in myocytes and hematopoietic cells to regulate Myog and Il2 respectively (Andres et al., 1995; 
Flavell et al., 2008; Pan et al., 2004; Potthoff and Olson, 2007; Sebastian et al., 2013).  While to 
date no experiments have directly compared MEF2 target genes across different tissues, this 	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work suggests that MEF2 functions at least in part by regulating distinct target genes in different 
cell types.  However, it is not known if MEF2 achieves cell type specificity by differential 
binding  to  promoters  or  by  binding  to  the  same  regulatory  elements  across  tissues  but 
differentially activating target genes in these distinct cell types.  
The  recent  identification  of  enhancers  as  important  mediators  of  tissue-specific  gene 
expression (Spitz and Furlong, 2012) raises the possibility that MEF2 achieves at least some of 
its tissue-specific function by binding to and regulating tissue-specific enhancers.  Alternatively, 
MEF2 could bind to the same enhancers in all tissues, but function at just a subset of these sites 
in a specific tissue. Significant innovations in high-throughput sequencing technology now make 
it possible to identify sites of TF binding genome-wide and to assess the activity of each bound 
region (Creyghton et al., 2010; Johnson et al., 2007; Kim et al., 2010; Rada-Iglesias et al., 2011), 
however these approaches have not yet been used to determine whether or how MEF2 selectively 
regulates enhancers or promoters in a tissue-specific manner.  
Once bound to an MRE that is present in an enhancer or target gene promoter, MEF2 is 
believed to either repress or activate nearby target genes, largely through interactions with co-
factors such as histone deacetylases and acetylases (Potthoff and Olson, 2007). In addition, it has 
been suggested that in myocytes MEF2 family members work together with muscle specific 
bHLH factors to regulate gene expression. Several models for the possible functions of this 
interaction  have  been  proposed,  ranging  from  cooperative  binding  to  cooperative  activation 
(Black and Olson, 1998; Molkentin et al., 1995). However, whether MEF2’s interaction with co-
factors actually contributes to MEF2-dependent gene expression in vivo, and if MEF2s employ 
similar mechanisms to regulate gene expression in the central nervous system (CNS) have not 
been examined.   	 ﾠ
	 ﾠ 53 
To determine how a widely expressed TF such as MEF2 regulates tissue specific gene 
expression during key steps in CNS development, we identified a cell type in the CNS, the 
photoreceptor  cells  of  the  mouse  retina,  where  a  single  MEF2  family  member,  MEF2D,  is 
predominantly  expressed.  A  newly  generated  loss-of-function  allele  for  MEF2D  revealed  a 
critical role for MEF2D in mouse retinal photoreceptor development and in the regulation of cell 
type-specific gene expression, including genes that are mutated in human retinal diseases. In vivo 
genomic and phenotypic analyses demonstrated that MEF2D regulates cell type-specific gene 
expression  in  photoreceptors  by  binding  tissue-specific  enhancers  together  with  the  retina-
specific  TF  CRX.  Analysis  of  MEF2D  binding  and  enhancer  activation  in  Crx  KO  retinae 
revealed that CRX shapes MEF2D function by recruiting MEF2D to tissue specific enhancers 
that based on their sequence would have been expected to bind MEF2 only weakly, and once 
bound, co-activating a subset of the MEF2D-CRX bound elements. These findings suggest that 
broadly expressed TFs acquire their tissue-specific functions through competitive recruitment to 
enhancers by tissue-specific TFs and selective activation of these enhancers to regulate tissue-
specific target genes.  
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2.3  Results 
Mef2d is required cell-autonomously for photoreceptor development and function 
To address how the broadly expressed MEF2 transcription factor family achieves tissue-
specific function in the CNS, we focused our studies on a single family member, Mef2d, that is 
widely expressed and has been implicated in critical aspects of neural development (Flavell et 
al., 2006; Flavell et al., 2008). We first sought to identify a region of the CNS where MEF2D is 
the  predominant  family  member  expressed  and  therefore  is  not  likely  to  be  functionally 
redundant with other MEF2 family members. We reasoned that such a region could serve as an 
experimental  system  for  understanding  the  context-dependent  role  of  MEF2D  in  neuronal 
development.  An investigation of MEF2 expression in the cortex, hippocampus and cerebellum 
revealed that the major cell types of these regions co-express MEF2 family members (data not 
shown).  We therefore turned to the retina, whose well-characterized and spatially separated cell 
types might allow us to identify a cell type that exclusively expresses MEF2D. We found that 
both MEF2A and MEF2D are expressed in the developing retina. In contrast MEF2C is only 
expressed after retinal development is complete (Figure 2.1A). While both MEF2A and D are 
co-expressed in many types of retinal neurons such as horizontal, bipolar, amacrine and retinal 
ganglion  cells  (Figure  2.1B),  MEF2D  is  the  dominant  MEF2  family  member  expressed  in 
maturing  photoreceptor  cells  in  the  outer  nuclear  layer  (ONL)  (Figure  2.1B).  Retinal 
photoreceptor cells are a specialized class of primary sensory neurons that detect the incidence of 
photons  upon  the  retina  and  transduce  this  event  into  a  neural  signal  for  processing  by 
downstream regions of the visual system. Given the importance of MEF2 family members in 
neuronal development we hypothesized that MEF2D may play a critical role in the development	 ﾠ
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Figure 2.1. Expression of MEF2 family members in the retina 
(A) Western blot of MEF2 family member expression in mouse retina over development.  
(B) Immunofluorescence (IF) of P25 WT retina for MEF2A (red) and MEF2D (green), DAPI 
(blue). 
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Figure 2.1. (Continued) Expression of MEF2 family members in the retina 
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of photoreceptor cells and that this role may yield important insights into the cell-type specific 
functions of MEF2 factors. 
   To explore the role of MEF2D in photoreceptors we generated a Mef2d knockout allele in 
which the first five protein-coding exons of Mef2d, including the entirety of the highly conserved 
MADS and MEF2 DNA-binding and dimerization domains, were removed (Figure 2.2).  This 
allele differs from a previously generated mutant allele of Mef2d, in which only the second 
coding exon of Mef2d was removed (Kim et al., 2008). This previously generated allele results in 
a highly expressed truncated protein product with a partial DNA binding domain.  The presence 
of this residual protein product could potentially complicate the interpretation of phenotypes in 
these mice.  This potential problem is eliminated in the new line of conditional Mef2d knock out 
mice, termed Mef2d
Δ2-6 (Figure 2.2). These mice were used for all subsequent analyses and are 
referred to below as Mef2d KO mice. 
Mef2d  KO  mice  are  born  in  Mendelian  ratios  and  are  fertile  but  exhibit  a  slightly 
decreased body weight compared to WT littermates (p=1.35e-6; Figure 2.2H). While MEF2D is 
expressed throughout the CNS, the brains of Mef2D KO mice appear normal, most likely due to 
compensation by other MEF2 family members.  By contrast, the retinae of Mef2d KO mice 
display a significant defect in the maturation of rod and cone photoreceptors.  At postnatal day 
11 (p11) Mef2d KO retinae are grossly normal and contain all major cell types. However, by 
p21, Mef2d KO photoreceptor cells differ strikingly from WT photoreceptors in that they lack 
the  outer  segment  structures  that  are  necessary  for  vision  (Figure  2.3).  Photoreceptor  outer 
segments are an apical organelle of stacked membranous discs in which phototransduction    	 ﾠ
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Figure 2.2. Generation and validation of new Mef2d knockout and conditional mice 
 (A) Schematic of the Mef2d gene targeting strategy. Top, WT allele schematic, aligned with 
the corresponding part of the targeting construct. The Mef2d allele was targeted by flanking 
exons 2 through 6 of the Mef2d genomic locus with loxP sequences (red triangles). Exons 2 and 
3 include the highly conserved MEF2 and MADS domains critical for DNA-binding and MEF2 
dimerization. A neomycin positive selection cassette (N) was inserted with a 3
rd loxP site at the 
3’  end  of  the  targeted  region  and  Diphtheria  toxin  A  (DTA)  served  as  a  negative  selection 
marker. Targeted ES cells were selected by resistance to G418 (and survival, and therefore lack, 
of DTA) and analyzed by Southern analysis. Purple and blue boxes represent relative positions 
external to the targeted region of 5’ and 3’ southern probes, respectively, and southern digest 
sites are denoted in corresponding colors as (T) and (AI) again for 5’ and 3’ southern analysis of 
ES cells. Distances between endogenous Tth111I or ApaI restriction sites for southern analysis in 
either the WT locus or targeted allele are illustrated. Successfully targeted ES cells were then 
injected  into  pseudopregnant  females,  and  subsequent  progeny  were  assessed  for  successful 
germline transmission of the targeted allele. Mice carrying the targeted allele were crossed to the 
EIIA-Cre deleter line to generate Mef2d KO mice, where the entire region between the most 5’ 
and 3’ loxP sites was deleted, and Mef2d
fl/fl conditional mice, where only the neomycin cassette 
was removed by Cre but two loxP sites remained in a now otherwise WT locus.  Green and 
yellow arrows denote relative positions of PCR genotyping primers.  
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Figure 2.2. (Continued) Generation and validation of new Mef2d knockout and conditional 
mice 
 
(B) Southern analysis of ES cells. Southern blot analysis of Tth111I (top) or ApaI (bottom)-
digested genomic DNA from targeted ES cells using 5’ or 3’ probes (purple and blue boxes in 
Figure  2.2A,  respectively)  indicates  correct  targeting  of  the  Mef2d  genomic  locus.  Expected 
genomic DNA fragment lengths are illustrated in Figure 2.2A above. Southern analysis shown 
was performed prior to Cre-mediated removal of the neomycin cassette. 
(C) Southern analysis of targeted mice. Southern blot performed as described above using 
ApaI-digested  genomic  DNA  from  mouse  liver  and  the  same  3’  probe.  Genomic  fragment 
lengths indicate correct targeting of the Mef2d genomic locus. Southern analysis shown was 
performed prior to Cre-mediated removal of the neomycin cassette.  
(D)  PCRs  used  for  routine  genotyping  of  Mef2d  floxed  mice.  Genotyping  of  the  Mef2d 
conditional  allele.  Genotyping  was  performed  by  PCR  using  primer  pairs  5’F  (5′-
gggttcagtccccagtgtaa-3′)  and  5’R  (5′-  ccccctagtcagagcttgtg-3′)  as  well  as  3’F  (5′-
tgagggtaaccatgtgcttg-3′) and 3’R (5′- aaggcctggagagaaggtgt-3′), which span the 5’ and 3’ loxP 
sites introduced in introns I and VI, respectively.  
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Figure 2.2. (Continued) Generation and validation of new Mef2d knockout and conditional 
mice 
 
(E) PCRs used for routine genotyping of Mef2d knockout mice. Genotyping of the Mef2d null 
allele. Genotyping was performed by PCR using primers as described above in the following 
pairs: 5’F and 5’R, or 5’F and 3’R, to test for the presence of a WT or null allele, respectively. 
5’F and 3’R are significantly far away on the WT allele and so a productive PCR reaction is only 
observed with a null allele. 
(F) Absence of full-length MEF2D protein in Mef2d KO mice. Western blot of MEF2D in  
whole  brain  lysates  in  Mef2d  KO  mice  and  littermates  heterozygous  or  WT  for  Mef2d.  An 
antibody  that  recognizes  part  of  the  protein  C-terminal  to  the  exons  deleted  in  the  Mef2d 
targeting strategy demonstrates complete loss of the full-length protein in the KO mice. A small 
truncated product appears in Mef2d KO lysates with very low levels of expression (asterisk).  
(G) Effective removal of conditional Mef2d allele. Western blot of MEF2D in whole brain 
lysates of a Mef2d
fl/fl mouse with nestin-cre and a littermate Mef2d
fl/fl mouse with no Cre. Actin 
was used as a loading control.  
(H) Mef2d KO mice have reduced body weight. Mef2d KO mice were weighed at p11 along 
with a paired WT littermate. N=24 pairs. Graph demonstrates mean +/- SEM. *p=1.35e-6.  B
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Figure 2.3. Mef2d KO mice have defects in retinal photoreceptor development 
(A) Time course of toluidine blue-stained 1µm cross-sections of MEF2D KO and WT littermate 
retinas. 
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occurs and where the cascade of neuronal signaling that underlies the visual response to light 
begins.    The  development  of  these  structures  normally  occurs  between  p11  and  p28,  which 
corresponds  to  the  functional  maturation  of  photoreceptors.  The  failure  of  outer  segment 
development  in  Mef2d  KO  retinae  should  lead  to  a  deficit  in  photoreceptor  function.  
Correspondingly,  in  vivo  electroretinograms  (ERGs)  performed  at  p21  revealed  that  visual 
responses are almost completely absent in Mef2d KO mice compared to WT littermates in both 
dark  and  light-adapted  conditions  (Figure  2.4).  This  indicates  that  both  rod  and  cone 
photoreceptors are non-functional in Mef2d KO mice, and that the failure of rods and cones to 
elaborate outer segments in the absence of MEF2D renders Mef2d KO mice blind.  Very few 
apoptotic  cells  are  present  in  Mef2d  KO  retinae  at  p21,  however  the  failure  of  Mef2d  KO 
photoreceptors to develop normally eventually leads to a slow retinal degeneration (Figure 2.3).  
Taken together these findings indicate that MEF2D is required for photoreceptor development, 
long-term survival and vision.  
Since MEF2D is expressed in retinal photoreceptors, the developmental failure of photoreceptors 
to form outer segments in Mef2d KO retinae seems likely to be due to a cell-intrinsic requirement 
for  Mef2d.    However,  to  rule  out  the  possibility  that  a  MEF2D-dependent  alteration  in  the 
extracellular  environment  during  photoreceptor  development  is  responsible  for  the  deficits 
observed (Thompson et al., 2000), we selectively removed Mef2d from individual developing 
photoreceptors by sparsely introducing Cre recombinase into Mef2d
fl/fl photoreceptors using in 
vivo electroporation. We found that at p21, photoreceptors in which the expression of MEF2D is 
disrupted  have  highly  abnormal  outer  segments  when  compared  to  photoreceptors  still 
expressing MEF2D (Figure 2.5). The abnormal morphology was also recapitulated in    	 ﾠ
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Figure 2.4. Mef2d KO mice are functionally blind 
(A) Representative electroretinograms (ERGs) from a P21 MEF2D KO mouse and WT littermate 
in both dark-adapted (DA) and light-adapted (LA) conditions.  
(B) Quantification of A and B wave amplitudes from individual mice for ERGs shown in (A). 
N=3 each MEF2D WT and KO littermates. ND= not detected.  50 msec
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Figure 2.5. Mef2d is required cell autonomously for photoreceptor development 
(A) Representative image of MEF2D immunofluorescence of photoreceptor nuclei in ONL of 
P21 retina electroporated at P0 for sparse expression of CRE recombinase and GFP in a Mef2d
fl/fl 
mouse.  Asterisks  indicate  example  GFP+  cells  expected  to  be  expressing  CRE  and  to  have 
removed MEF2D.  
(B)  Schematic  of  quantification  of  disruption  of  OS  in  sparse  electroporations.    ABCA4 
immunostaining identified outer segments (OS) and the area between ABCA4 and DAPI staining 
was considered inner segments (IS). Mean GFP intensity in the OS was normalized to mean GFP 
intensity in the IS. 
(C)  Representative  immunofluorescence  images  of  morphology  of  P21  retinal  photoreceptor 
cells electroporated at P0 for sparse expression of Cre recombinase and GFP in either Mef2d
fl/fl or 
Mef2d
fl/+ mice.   
(D)  Quantification  of  OS  from  GFP-positive  photoreceptors  as  shown  in  (C).  Mean  GFP 
intensity in the ABCA4-positive region (OS GFP) was normalized to mean GFP intensity in the 
inner segments (IS GFP) as a control for electroporation density (Mef2d
fl/+, N=6; Mef2d
fl/fl, N=3 
retinas). Error bars represent S.E.M.  
(E)  Representative  image  of  MEF2D  IHC  of  photoreceptor  nuclei  in  ONL  of  P21  retina 
electroporated  at  P0  with  GFP  and  MEF2D  shRNA  in  an  otherwise  WT  mouse.  Asterisks 
indicate example GFP+ cells expected to be expressing MEF2D shRNA. 
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Figure  2.5.  (Continued)  Mef2d  is  required  cell  autonomously  for  photoreceptor 
development 
 
(F) Left, representative images of IHC of photoreceptors of P21 WT retinas electroporated at P0 
for sparse expression with pCAG-GFP and either a scrambled shRNA control (scrm shRNA), or 
MEF2D shRNA. Right, Quantification of OS disruption from GFP-positive photoreceptors as 
shown at left.  Error bars represent S.E.M.   
(G) Left, representative images of IHC of photoreceptors of P21 WT retinas electroporated at P0 
for sparse expression with pCAG-GFP and either MEF2D shRNA or MEF2D shRNA with an 
shRNA-resistant form of MEF2D (MEF2D RiR). Right, Quantification of OS disruption from 
GFP-positive photoreceptors as shown at left.  Error bars represent S.E.M.   
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photoreceptors where MEF2D shRNA was selectively introduced in an otherwise WT retina. 
Finally, the disruption of photoreceptor development was reversed when the MEF2D shRNA 
was co-expressed with an shRNA-resistant form of MEF2D (Figure 2.5).  Taken together these 
findings suggest that MEF2D functions cell-intrinsically to promote photoreceptor development, 
and that in the absence of MEF2D, photoreceptors fail to mature and ultimately die.  
 
MEF2D regulates critical cell-type specific targets and disease genes in the retina 
  Given that MEF2D is a TF it is likely that the gene targets of MEF2D regulate aspects of 
photoreceptor  development  and  function.  One  possibility  is  that  MEF2D  regulates 
photoreceptor-specific  target  genes  that  encode  proteins  necessary  for  photoreceptor 
development.  Alternatively,  because  MEF2  family  members  are  expressed  in  a  multitude  of 
different tissues, it could be that MEF2D controls photoreceptor differentiation by regulating a 
core  set  of  target  genes  that  are  shared  across  cell  types.  To  distinguish  between  these 
possibilities and to identify candidate target genes of MEF2D we performed high-throughput 
RNA sequencing (RNA-seq) of total RNA from WT and Mef2d KO retinae at p11. At p11, 
MEF2D  is  strongly  expressed  but  WT  and  Mef2d  KO  retinae  are  morphologically 
indistinguishable.  Thus, differences in gene expression between WT and Mef2d KO retinae at 
p11 should be primarily due to the disruption of MEF2D-dependent transcriptional programs 
rather than due to cell attrition or the secondary effects of disrupted retinal development.  
  We find that the expression of most genes is unchanged when WT and Mef2d KO p11 
retinae are compared (Spearman’s correlation coefficient r= 0.988355) (Figure 2.6).  However, a    	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Figure  2.6.  MEF2D  regulates  critical  cell-type  specific  targets  and  disease  genes  in  the 
retina 
(A) RNA-seq average exon density for individual genes in P11 WT and MEF2D KO retinae are 
displayed  in  gray  (n=2  per  genotype).  Genes  were  considered  upregulated  (green  dots)  or 
downregulated (red dots) if average KO exon density was 2x or more reduced with respect to 
average WT exon density. The black line indicates unity.  
(B) qPCR validation of RNA-seq results for example MEF2D target genes; n=3 for each data 
point. Error bars represent S.E.M.  
(C,D) IHC of P11 MEF2D KO and WT littermate retinae for MEF2D target genes (C) GUCA1B 
AND (D) ARR3.  
(E) Western blot for ARR3 expression in P11 MEF2D KO and WT littermate retinas.  
 (F) Examples of MEF2D target genes relevant to photoreceptor cell biology. Genes implicated 
in retinal disease are in blue.  Figure 2.6. (Continued) Mef2d regulates critical cell type-specific targets and 
disease genes in the retina
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Figure 2.6. (Continued) Mef2d regulates critical cell-type specific targets and 
disease genes in the retina
C D
F
75	 ﾠ
	 ﾠ 76 
Table 2.1. Significantly misregulated genes in MEF2D KO versus WT retinae  
Gene  GeneID  RefSeqs  Avg WT 
exon density 
Avg KO 
exon density 
KO/WT exon 
density 
Ahrr  11624  NM_009644.2  0.202  0.030  0.146 
Apobec2  11811  NM_009694.2  3.617  0.474  0.131 
Arg2  11847  NM_009705.1  2.299  1.042  0.453 
Atp10a  11982  NM_009728.1  0.122  0.042  0.342 
Pcdh15  11994  NM_023115.2  4.611  0.606  0.131 
Zfp36l2  12193  NM_001001806.2  1.960  0.558  0.285 
Cacna1s  12292  NM_001081023.1  0.137  0.023  0.168 
Cdc25c  12532  NM_009860.2  0.153  0.052  0.338 
Cdr2  12585  NM_007672.1  8.160  3.417  0.419 
Cr2  12902  NM_007758.2  0.053  0.203  3.830 
Cst7  13011  NM_009977.2  0.040  0.126  3.152 
Drd4  13491  NM_007878.2  10.252  3.078  0.300 
Egr1  13653  NM_007913.5  0.177  0.581  3.293 
Gngt1  14699  NM_010314.2  236.598  115.056  0.486 
Lrp2  14725  NM_001081088.1  0.955  0.295  0.309 
Gpr56  14766  NM_018882.2  0.103  0.211  2.047 
Guca1a  14913  NM_008189.2  11.870  5.147  0.434 
Hk2  15277  NM_013820.2  1.424  0.190  0.133 
Igj  16069  NM_152839.1  1.036  0.026  0.025 
Cd74  16149  NM_001042605.1|NM_01054
5.3 
0.046  0.238  5.234 
Jag1  16449  NM_013822.3  4.285  1.855  0.433 
Mesp1  17292  NM_008588.1  0.215  0.585  2.729 
Mod1  17436  NM_008615.1  3.134  1.456  0.465 
Myom1  17929  NM_010867.1  0.308  0.113  0.368 
Nppb  18158  NM_008726.3  0.047  0.116  2.495 
Pax7  18509  NM_011039.2  0.085  0.298  3.496 
Pcolce  18542  NM_008788.2  0.206  0.457  2.219 
Prkcm  18760  NM_008858.2  2.843  1.342  0.472 
Pla2r1  18779  NM_008867.1  6.804  0.267  0.039 
Ppp1r1b  19049  NM_144828.1  0.184  0.416  2.266 
Prss12  19142  NM_008939.1  0.070  0.193  2.767 
Prtn3  19152  NM_011178.2  0.108  0.053  0.492 
Pygm  19309  NM_011224.1  2.681  0.854  0.319 
Rps3a  20091  NM_016959.3  23.658  0.356  0.015 
Sag  20215  NM_009118.2  516.187  205.101  0.397 
Six1  20471  NM_009189.2  0.038  0.193  5.013 
Slc31a2  20530  NM_025286.2  3.711  0.791  0.213 
Slc6a2  20538  NM_009209.2  0.113  0.010  0.088 
Tnfaip3  21929  NM_009397.2  4.588  1.654  0.361 
Tnfsf12  21944  NM_011614.1  3.048  1.316  0.432 
Tnnt1  21955  NM_011618.1  1.142  0.501  0.439 
Tph1  21990  NM_009414.2  0.318  0.710  2.234 
Vtn  22370  NM_011707.1  23.612  4.136  0.175 
Clca3  23844  NM_017474.1  0.615  0.262  0.426 
Slc27a2  26458  NM_011978.2  0.250  0.570  2.283 
Rnu32  27209  NR_000002.8  0.659  1.337  2.027 
Mapk12  29857  NM_013871.2  0.378  0.139  0.367 
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Table 2.1. (Continued) Significantly misregulated genes in MEF2D KO versus WT retinae  
Gene  GeneID  RefSeqs  Avg WT 
exon density 
Avg KO 
exon density 
KO/WT exon 
density 
Chst3  53374  NM_016803.2  0.328  0.158  0.482 
Col5a3  53867  NM_016919.2  0.421  1.101  2.617 
Srpk3  56504  NM_019684.1  0.167  0.019  0.114 
Ankrd2  56642  NM_020033.1  0.392  0.884  2.252 
Rabgef1  56715  NM_019983.2  9.874  3.114  0.315 
Rgs20  58175  NM_021374.3  0.673  0.100  0.148 
Rab37  58222  NM_021411.3  0.146  0.401  2.742 
Fcamr  64435  NM_144960.1  0.236  0.018  0.076 
1110032A04Rik  66183  NM_133675.1  0.322  0.713  2.212 
2310007A19Rik  66353  NM_025506.2  3.096  1.185  0.383 
Pcp4l1  66425  XM_484933.5  5.257  2.561  0.487 
Asrgl1  66514  NM_025610.3  6.175  2.413  0.391 
Grtp1  66790  NM_025768.2  5.386  1.986  0.369 
D16Ertd472e  67102  NM_025967.2  2.817  1.097  0.389 
Ube2t  67196  NM_026024.2  0.219  0.679  3.101 
2810055F11Rik  67217  NM_026038.2  0.618  1.255  2.031 
Lass4  67260  NM_026058.3  11.140  4.316  0.387 
Hapln3  67666  NM_178255.3  0.287  0.133  0.462 
Wfdc2  67701  NM_026323.2  0.069  0.171  2.478 
Tmem86a  67893  NM_026436.2  2.501  5.102  2.040 
Rpl34  68436  NM_001005859.2|NM_02672
4.1 
12.895  0.582  0.045 
1110012N22Rik  68515  XM_126634.6  0.372  0.132  0.355 
Uckl1  68556  NM_026765.3  10.491  4.285  0.408 
1110020G09Rik  68646  NM_001040395.2  26.976  11.732  0.435 
Fndc1  68655  NM_001081416.1  0.168  0.081  0.482 
Mybphl  68753  NM_026831.1  0.125  0.021  0.169 
2610034M16Rik  69239  NM_027001.1  5.578  0.008  0.001 
Tnfsf13  69583  NM_023517.2  6.526  2.420  0.371 
2610528A11Rik  70045  XM_980662.1  0.078  0.177  2.270 
Dpf3  70127  NM_058212.1  6.821  2.902  0.425 
2510049J12Rik  70291  XM_132808.3  0.376  0.765  2.033 
Lrfn2  70530  NM_027452.2  0.859  0.325  0.378 
Glb1l3  70893  XM_983469.1  0.121  0.015  0.127 
4921537P18Rik  70952  NM_026256.2  0.114  0.027  0.234 
5430419D17Rik  71395  NM_175166.3  0.450  0.002  0.003 
Bbs7  71492  NM_027810.2  27.336  13.118  0.480 
Ppm1j  71887  NM_027982.2  0.999  0.363  0.363 
Slc39a4  72027  NM_028064.2  0.080  0.256  3.187 
Tnfrsf13c  72049  NM_028075.2  0.090  0.493  5.472 
Rrp1b  72462  NM_028244.1  6.624  2.801  0.423 
2810030E01Rik  72668  NM_028317.1  4.211  1.616  0.384 
Rbm20  73713  XM_001002314.2  1.077  2.236  2.076 
Psd  73728  NM_028627.2  4.247  1.566  0.369 
Arsg  74008  NM_028710.2  1.353  0.601  0.444 
2310042D19Rik  74183  NM_172417.2  0.079  0.184  2.323 
1700092M07Rik  74307  XM_897786.2  0.088  0.226  2.566 
4833403I15Rik  74574  XM_988298.1  0.030  0.141  4.712 
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Table 2.1. (Continued) Significantly misregulated genes in MEF2D KO versus WT retinae   
Gene  GeneID  RefSeqs  Avg WT 
exon density 
Avg KO 
exon density 
KO/WT exon 
density 
Rab3il1  74760  NM_144538.2  0.671  1.605  2.390 
Calml4  75600  NM_138304.2  0.769  3.222  4.188 
Dock8  76088  NM_028785.3  0.200  0.463  2.311 
Gpsm2  76123  NM_029522.1  5.163  2.560  0.496 
Slc38a3  76257  NM_023805.2  12.139  4.815  0.397 
D230044M03Ri
k 
76743  XM_354583.3  0.399  1.346  3.374 
C030048H21Rik  77481  XM_975397.2  0.590  1.183  2.005 
A930004D18Rik  77940  XR_035303.1  0.624  0.283  0.454 
A930023M06Ri
k 
77958  XM_001478569.1  0.456  0.072  0.158 
D730039F16Rik  77996  NM_030021.2  0.644  1.395  2.168 
Pde6h  78600  NM_023898.4  20.224  2.878  0.142 
Cstad  78617  NM_030137.2  0.308  0.154  0.498 
Il23a  83430  NM_031252.2  0.066  0.172  2.613 
Lin28  83557  NM_145833.1  0.151  0.474  3.136 
Kcnn1  84036  NM_032397.1  1.714  3.866  2.256 
Igsf9  93842  NM_033608.2  1.196  0.426  0.356 
Ehd4  98878  NM_133838.3  2.555  0.855  0.335 
Stard7  99138  NM_139308.1  12.281  5.639  0.459 
Olfml3  99543  NM_133859.2  0.973  0.297  0.305 
AW011738  100382  XM_001478065.1  0.458  1.023  2.234 
Cd276  102657  NM_133983.3  1.044  0.306  0.293 
Sncb  104069  NM_033610.2  8.279  3.870  0.467 
Nxph4  104080  NM_183297.2  0.301  0.631  2.097 
Slc16a6  104681  NM_001029842.1|NM_13403
8.2 
7.231  1.344  0.186 
Guca1b  107477  NM_146079.1  6.373  0.260  0.041 
Hist1h1t  107970  NM_010377.2  0.074  0.164  2.205 
Chrna5  110835  NM_176844.3  1.370  0.599  0.437 
Emid2  140709  NM_024474.2  0.602  2.598  4.317 
P2ry14  140795  NM_001008497.1|NM_13320
0.3 
0.204  0.080  0.394 
Arr3  170735  NM_133205.2  7.210  0.023  0.003 
Glmn  170823  NM_133248.1  11.118  3.420  0.308 
Accn3  171209  NM_183000.1  0.729  1.554  2.131 
Cnksr1  194231  NM_001081047.1  0.472  0.179  0.379 
4831426I19Rik  212073  NM_001042699.1|NM_17250
0.2 
0.313  1.207  3.856 
6330514A18Rik  216166  NM_183152.2  3.498  8.922  2.550 
Atad4  217138  NM_146026.1  0.038  0.148  3.854 
Tmc6  217353  NM_145439.1|NM_181321.3  0.127  0.290  2.290 
BC048943  217874  XM_127170.7|XM_902085.2  29.618  13.858  0.468 
BC027072  225004  NM_146082.3  11.219  4.303  0.383 
5430407P10Rik  227545  NM_144883.3  1.759  4.459  2.534 
1700019L03Rik  227736  NM_025619.1  0.141  0.067  0.474 
Bpil3  228796  NM_199303.1  0.200  0.021  0.105 
Adamtsl4  229595  NM_144899.2  0.089  0.209  2.339 
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Table 2.1. (Continued) Significantly misregulated genes in MEF2D KO versus WT retinae  
Gene  GeneID  RefSeqs  Avg WT 
exon density 
Avg KO 
exon density 
KO/WT exon 
density 
Ddefl1  230837  NM_001008232.1  0.548  1.143  2.084 
Xylt1  233781  NM_175645.3  1.034  0.484  0.468 
Dnahc9  237806  XM_110968.7  0.652  0.275  0.421 
Fscn2  238021  NM_172802.2  5.271  0.516  0.098 
Kcnv2  240595  NM_183179.1  36.929  16.085  0.436 
Kcng1  241794  NM_001081134.1  0.052  0.130  2.491 
BC029684  242707  XM_205950.7  1.474  3.066  2.081 
Padi6  242726  NM_153106.2  0.047  0.194  4.142 
Srd5a2l2  243078  NM_153801.2  0.291  0.034  0.117 
Hspb6  243912  NM_001012401.2  1.459  0.238  0.163 
Wdr17  244484  NM_028220.2  25.765  7.561  0.293 
BC038479  244757  NM_153803.1  5.651  1.541  0.273 
Kcne2  246133  NM_134110.2  6.383  2.810  0.440 
Sntg2  268534  NM_172951.2  0.746  0.084  0.112 
Scube3  268935  NM_001004366.1  1.054  2.814  2.670 
Hist2h2ac  319176  NM_175662.1  15.087  4.005  0.265 
Lrtm1  319476  NM_176920.3  5.236  2.281  0.436 
Tmem26  327766  NM_177794.2  0.850  0.240  0.283 
9130227L01Rik  329159  XM_488894.3  0.067  0.152  2.268 
Pla2g4e  329502  NM_177845.4  0.136  0.066  0.488 
Catsper4  329954  NM_177866.3  0.245  0.065  0.263 
Adamts3  330119  NM_001081401.1  2.106  0.409  0.194 
Ccdc63  330188  NM_183307.2  0.205  0.094  0.461 
Gal3st4  330217  NM_001033416.2  0.469  1.962  4.181 
Mapk15  332110  NM_177922.2  0.097  0.355  3.642 
Col27a1  373864  NM_025685.3  0.126  0.451  3.583 
EG381438  381438  NM_198657.2  0.338  0.001  0.003 
Gm1698  382003  NM_001033467.1  0.199  0.025  0.127 
Adcy1  432530  NM_009622.1  8.049  2.454  0.305 
LOC434166  434166  XM_001478477.1  2.646  1.258  0.476 
1700120B06Rik  436062  NM_001033980.1  0.089  0.298  3.330 
EG545987  545987  XM_899834.2  0.845  1.952  2.311 
LOC546006  546006  XM_620573.4  0.341  0.002  0.005 
EG546164  546164  XM_620794.4  0.201  0.072  0.360 
OTTMUSG0000
0006683 
550619  NM_001017362.2  0.193  0.602  3.123 
Tnfsf12-tnfsf13  619441  NM_001034097.1|NM_00103
4098.1 
4.582  1.779  0.388 
EG624121  624121  XR_035463.1  0.249  0.589  2.367 
EG639545  639545  XM_974340.2  0.101  0.419  4.163 
EG667728  667728  XR_035232.1  0.086  23.528  274.058 
LOC100039504  100039504  XM_001473019.1  0.347  0.745  2.147 
LOC100039605  100039605  XM_001473183.1  1.445  0.602  0.416 
LOC100040711  100040711  XM_001474867.1  0.114  0.044  0.384 
LOC100042271  100042271  XM_001477849.1  0.357  0.867  2.430 
LOC100042588  100042588  XM_001478609.1  0.266  0.008  0.032 
LOC100043173  100043173  XM_001479673.1  0.137  0.002  0.017 
LOC100043305  100043305  XM_001480125.1  0.004  0.352  80.805 
LOC100043412  100043412  XM_001479664.1  1.592  0.191  0.120 
LOC100043600  100043600  XM_001480969.1  0.193  0.073  0.379 	 ﾠ
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subset of 185 genes are strongly misregulated in Mef2d KO retinae (Figure 2.6, Table 2.1). This 
set of misregulated genes is significantly enriched for retina-specific genes (p=5e-9) using the 
DAVID web tool (Dennis et al., 2003; Huang da et al., 2009a, b). Furthermore, gene ontology 
(GO)  analysis  found  that  these  misregulated  genes  are  most  enriched  for  genes  involved  in 
processes such as visual perception and sensory perception of a light stimulus. This analysis 
suggests that MEF2D promotes photoreceptor development by regulating a network of genes 
essential for photoreceptor function rather than a common set of core target genes shared across 
cell types and tissues.  
  The  most  highly  misregulated  candidate  MEF2D  target  genes  have  critical  roles  in 
photoreceptor  function  (Figure  2.6).  For  example,  Sag,  Gngt1,  Arr3,  Pde6h,  Guca1a  and 
Guca1b are key components of the phototransduction cascade. Misregulation of these transcripts 
in combination would be expected to severely disrupt phototransduction and is likely to be the 
primary cause of the abnormal photoresponses in Mef2d KO mice.  Indeed human mutations in 
Sag, Pde6h, Guca1a and Guca1b are all associated with visual disorders (Downes et al., 2001; 
Fuchs et al., 1995; Kohl et al., 2012; Nakazawa et al., 1998; Payne et al., 1998; Piri et al., 2005; 
Sato et al., 2005). Other photoreceptor-specific target genes which are not directly part of the 
phototransduction cascade may contribute to the structural defects in outer segment formation 
observed  in  Mef2d  KO  retinae.  For  example,  Fscn2,  a  photoreceptor  specific  actin-bundling 
protein, is mutated in human forms of retinitis pigmentosa and has been demonstrated to be 
necessary for outer segment elongation (Wada et al., 2003; Wada et al., 2001; Yokokura et al., 
2005).  Similarly,  Pcdh15,  a  cadherin  superfamily  member,  has  been  implicated  in  vesicular 
trafficking between the inner and outer segments and is mutated in a form of Usher Syndrome 
(USH1F) characterized by visual impairment and hearing loss (Cosgrove and Zallocchi, 2014; 	 ﾠ
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Daiger et al., 2013). In contrast, MEF2 targets that have been identified in other neuronal cell 
types such as Nur77, Arc and Syngap1 (Flavell et al., 2008) are not strongly expressed in the 
developing retina under normal conditions. These analyses suggest that the primary function of 
MEF2D  in  the  retina  is  to  regulate  the  expression  of  genes  that  are  critical  for  specific 
photoreceptor functions rather than genes with common functions across cell types. 
 
MEF2D binds tissue-specific enhancers with the retina-specific co-factor CRX 
  We next sought to understand the mechanism by which MEF2D achieves photoreceptor 
specific  regulation  of  its  targets.    Elucidating  this  mechanism  is  of  interest  because  many 
MEF2D targets are essential for photoreceptor function and are mutated in human diseases of the 
retina. The simplest and most prevalent model of MEF2 function is that MEF2 binds to MEF2 
consensus binding sites (MREs) in the promoters or enhancers of its target genes and thereby 
controls their expression (Edmondson et al., 1992; Sandmann et al., 2006; Yee and Rigby, 1993). 
Given the photoreceptor-specific expression of many MEF2D target genes, in this model the 
binding of MEF2D would be expected at MREs that are accessible in photoreceptors but not 
other neuronal cell types. The ability of MEF2D to recognize and bind to these photoreceptor 
specific MREs would somehow be specified during CNS development, for example through 
changes in DNA accessibility or through interaction with tissue-specific co-factors. A second 
possibility is that MEF2D binds to a common set of MREs accessible in all tissues and that these 
bound elements are selectively activated in a tissue-specific manner.  To begin to distinguish 
between these possibilities we analyzed MEF2D binding across the retinal genome by ChIP-Seq 
and compared MEF2D binding in the retina to that observed in cortex and muscle.  	 ﾠ
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  To  determine  the  sites  of  MEF2D  binding  in  the  retina  with  high  confidence  we 
performed  two  bioreplicates  of  MEF2D  ChIP-Seq  using  p11  wild  type  retinae,  and  also 
performed MEF2D ChIP-Seq in Mef2d KO retinae as a control for specificity. Because ~80% of 
cells  in  the  mouse  retina  are  photoreceptors,  it  is  likely  that  the  vast  majority  of  identified 
MEF2D binding sites represent MEF2D binding in photoreceptors instead of other retinal cell 
types  (Jeon  et  al.,  1998).  Each  MEF2D  ChIP-Seq  replicate  alone  yielded  ~12,000  unique 
MEF2D-binding sites with an overlap of ~4,000 reproducible binding sites between the two 
replicates, suggesting that a high degree of biological or technical noise is inherent to these 
experiments. The number of high-confidence MEF2D binding sites was further decreased to 
2403 when we considered only those peaks that are specifically reduced in the Mef2d
 knockout 
(Figure  2.7A,B).  As  an  independent  check  for  specificity,  we  determined  that  the  MEF2 
response element (MRE) is the top significantly enriched motif under the MEF2D peaks in the 
genome using a hypergeometric test (p=1e-1255; 1261/2403 peaks) (Figure 2.7C) (Heinz et al., 
2010). Strikingly, 2403 is a large number of MEF2D binding sites compared to 185 highly 
misregulated target genes, suggesting that only a small number of the MEF2D bound sites are 
likely to be essential for normal gene expression. We next asked whether these MEF2D binding 
sites were proximal to target genes. MEF2D was found to bind to 18 promoter regions and 75 
enhancers near genes that are highly misregulated in Mef2d KO retinae including many genes 
that are photoreceptor-specific and associated with retinal diseases (Figure 2.7D; Table 2.2). 
Thus,  MEF2D  appears  to  regulate  many  of  its  photoreceptor-specific  targets  by  binding  to 
proximal  regulatory  elements,  suggesting  this  binding  may  be  unique  to  the  retina  and  help 
define the function of MEF2D in regulating retinal gene expression.  
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 Figure 2.7. MEF2D binds broadly throughout the retinal genome 
(A) Guca1b genomic locus with MEF2D ChIP-seq data from both WT and KO retinae; arrow 
denotes  Guca1b  transcriptional  start  site  (TSS).  Horizontal  rows  display  the  numbers  of 
normalized ChIP-Seq reads across the locus, for both Input and MEF2D antibody. A light gray 
vertical bar highlights the identified MEF2D peak. Mammalian conservation is also displayed. 
(B) Binding profile of MEF2D ChIP-seq signal at MEF2D peaks in P11 retinae. 2 WT and 1 
MEF2D KO experiment are shown. Each MEF2D peak is represented as a single line centered 
on the peak summit. Intensity of color correlates with ChIP-seq peak size. MEF2D peaks are 
ordered according to peak size. 
(C) Top, Position weighted matrix (PWM) of top motif enriched in MEF2D-bound genomic 
regions  in  retina  obtained  with  de  novo  motif  discovery  using  Homer.  Bottom,  top  ranking 
JASPAR matrix corresponding to most enriched PWM. Matrix was identified in JASPAR as 
MEF2. 
(D) Distribution of MEF2D ChIP-Seq peaks with respect to MEF2D target genes (n=71 with a 
proximal MEF2D peak). Each line represents a gene locus. MEF2D peaks (purple triangles) are 
shown with respect to the gene TSS (black line) and gene body (gray bar). TSS’s were aligned 
and peaks were ordered according to their proximity to the TSS. 
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Table 2.2. Direct MEF2D target genes and associated MEF2D-bound regulatory elements  
Chr  Summit 
Location 
Distan
ce to 
closest 
TSS 
Closest 
Gene to 
Peak 
GeneID  RefSeqs  Avg 
WT 
exon 
density 
Avg 
KO 
exon 
density 
KO/WT 
exon 
dens. 
CRX 
co-
bound 
chr1  4960826  -48634  Rgs20  58175  NM_021374.3  0.673  0.100  0.148  YES 
chr1  55945098  72655  913022
7L01Ri
k 
329159  XM_488894.3  0.067  0.152  2.268  NO 
chr1  55945661  72092  913022
7L01Ri
k 
329159  XM_488894.3  0.067  0.152  2.268  YES 
chr1  89700137  118  Sag  20215  NM_009118.2  516.187  205.10
1 
0.397  YES 
chr1  89774674  -74419  Sag  20215  NM_009118.2  516.187  205.10
1 
0.397  NO 
chr1  132695454  2025  Fcamr  64435  NM_144960.1  0.236  0.018  0.076  NO 
chr1  137986723  -37245  Cacna1s  12292  NM_001081023.1  0.137  0.023  0.168  NO 
chr1  173131342  4176  Pcp4l1  66425  XM_484933.5  5.257  2.561  0.487  NO 
chr10  18673126  -62047  Tnfaip3  21929  NM_009397.2  4.588  1.654  0.361  NO 
chr10  18673550  -61623  Tnfaip3  21929  NM_009397.2  4.588  1.654  0.361  YES 
chr10  18861494  12632
1 
Tnfaip3  21929  NM_009397.2  4.588  1.654  0.361  YES 
chr10  68164696  21820  Tmem2
6 
327766  NM_177794.2  0.850  0.240  0.283  NO 
chr10  73163753  12087
8 
Pcdh15  11994  NM_023115.2  4.611  0.606  0.131  YES 
chr10  73325126  -40495  Pcdh15  11994  NM_023115.2  4.611  0.606  0.131  YES 
chr11  6956206  7286  Adcy1  432530  NM_009622.1  8.049  2.454  0.305  YES 
chr11  69507194  -2062  Tnfsf12  21944  NM_011614.1  3.048  1.316  0.432  YES 
chr11  120227626  -4778  Fscn2  238021  NM_172802.2  5.271  0.516  0.098  YES 
chr11  120509487  -164  111001
2N22Ri
k 
68515  XM_126634.6  0.372  0.132  0.355  NO 
chr12  31054807  -3386  Sntg2  268534  NM_172951.2  0.746  0.084  0.112  YES 
chr12  51715529  -34556  Prkcm  18760  NM_008858.2  2.843  1.342  0.472  YES 
chr12  113215518  -4010  BC0489
43 
217874  XM_127170.7|X
M_902085.2 
29.618  13.858  0.468  NO 
chr12  113219396  -132  BC0489
43 
217874  XM_127170.7|X
M_902085.2 
29.618  13.858  0.468  NO 
chr13  54861823  -5978  Sncb  104069  NM_033610.2  8.279  3.870  0.467  YES 
chr13  74358316  -71441  Ahrr  11624  NM_009644.2  0.202  0.030  0.146  YES 
chr15  9018188  -16758  111002
0G09Ri
k 
68646  NM_001040395.2  26.976  11.732  0.435  YES 
chr15  9022022  -20592  111002
0G09Ri
k 
68646  NM_001040395.2  26.976  11.732  0.435  YES 
chr15  102488755  -1197  LOC10
004360
0 
100043
600 
XM_001480969.1  0.193  0.073  0.379  NO 
chr16  78574823  -2069  D16Ert
d472e 
67102  NM_025967.2  2.817  1.097  0.389  YES 	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Table 2.2. (Continued) Direct MEF2D target genes and associated MEF2D-bound 
regulatory elements  
Chr  Summit 
Location 
Distan
ce to 
closest 
TSS 
Closest 
Gene to 
Peak 
GeneID  RefSeqs  Avg 
WT 
exon 
density 
Avg 
KO 
exon 
density 
KO/WT 
exon 
dens. 
CRX 
co-
bound 
chr16  92295723  -3089  Kcne2  246133  NM_134110.2  6.383  2.810  0.440  YES 
chr17  7827041  -
17079
8 
Fndc1  68655  NM_001081416.1  0.168  0.081  0.482  YES 
chr17  32189809  -16702  Rrp1b  72462  NM_028244.1  6.624  2.801  0.423  YES 
chr17  47519110  3232  Guca1b  107477  NM_146079.1  6.373  0.260  0.041  YES 
chr17  47536237  -1296  Guca1a  14913  NM_008189.2  11.870  5.147  0.434  YES 
chr17  48569850  -2203  Apobec
2 
11811  NM_009694.2  3.617  0.474  0.131  NO 
chr17  48838040  23366
4 
Lrfn2  70530  NM_027452.2  0.859  0.325  0.378  YES 
chr17  59130930  132  261003
4M16Ri
k 
69239  NM_027001.1  5.578  0.008  0.001  YES 
chr17  72102375  150  BC0270
72 
225004  NM_146082.3  11.219  4.303  0.383  YES 
chr17  84505867  -81420  Zfp36l2  12193  NM_001001806.2  1.960  0.558  0.285  YES 
chr17  84556701  -30586  Zfp36l2  12193  NM_001001806.2  1.960  0.558  0.285  YES 
chr19  6384312  117  Pygm  19309  NM_011224.1  2.681  0.854  0.319  NO 
chr19  9244543  34487  Asrgl1  66514  NM_025610.3  6.175  2.413  0.391  YES 
chr19  27351339  14524  LOC10
004258
8 
100042
588 
XM_001478609.1  0.266  0.008  0.032  YES 
chr19  27396961  148  Kcnv2  240595  NM_183179.1  36.929  16.085  0.436  YES 
chr19  46397242  -4404  Psd  73728  NM_028627.2  4.247  1.566  0.369  YES 
chr2  17959449  85  A93000
4D18Ri
k 
77940  XR_035303.1  0.624  0.283  0.454  YES 
chr2  30450437  127  Cstad  78617  NM_030137.2  0.308  0.154  0.498  NO 
chr2  30508276  -57712  Cstad  78617  NM_030137.2  0.308  0.154  0.498  NO 
chr2  30514109  -63545  Cstad  78617  NM_030137.2  0.308  0.154  0.498  NO 
chr2  60389890  -1428  Pla2r1  18779  NM_008867.1  6.804  0.267  0.039  YES 
chr2  69280084  -
14404
0 
Lrp2  14725  NM_001081088.1  0.955  0.295  0.309  YES 
chr2  69422315  -1809  Lrp2  14725  NM_001081088.1  0.955  0.295  0.309  YES 
chr2  119924608  -55703  Ehd4  98878  NM_133838.3  2.555  0.855  0.335  YES 
chr2  127096882  -907  Stard7  99138  NM_139308.1  12.281  5.639  0.459  NO 
chr2  127100727  -4752  Stard7  99138  NM_139308.1  12.281  5.639  0.459  YES 
chr2  136919208  -22859  Jag1  16449  NM_013822.3  4.285  1.855  0.433  YES 
chr2  181313708  -2970  Uckl1  68556  NM_026765.3  10.491  4.285  0.408  YES 
chr3  108166843  986  Mybphl  68753  NM_026831.1  0.125  0.021  0.169  YES 
chr4  61950500  -3021  Slc31a2  20530  NM_025286.2  3.711  0.791  0.213  YES 
chr4  62891121  -14675  Col27a1  373864  NM_025685.3  0.126  0.451  3.583  NO 
chr4  133775111  -8172  Catsper
4 
329954  NM_177866.3  0.245  0.065  0.263  YES 
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Table 2.2. (Continued) Direct MEF2D target genes and associated MEF2D-bound 
regulatory elements  
Chr  Summit 
Location 
Distan
ce to 
closest 
TSS 
Closest 
Gene to 
Peak 
GeneID  RefSeqs  Avg 
WT 
exon 
density 
Avg 
KO 
exon 
density 
KO/WT 
exon 
dens. 
CRX 
co-
bound 
chr5  90273665  -38766  Adamts
3 
330119  NM_001081401.1  2.106  0.409  0.194  YES 
chr5  90301852  -10579  Adamts
3 
330119  NM_001081401.1  2.106  0.409  0.194  YES 
chr5  108003857  -22737  Glmn  170823  NM_133248.1  11.118  3.420  0.308  YES 
chr5  108018804  -7790  Glmn  170823  NM_133248.1  11.118  3.420  0.308  YES 
chr5  130672259  -9209  Rabgef1  56715  NM_019983.2  9.874  3.114  0.315  YES 
chr6  3943960  52  Gngt1  14699  NM_010314.2  236.598  115.05
6 
0.486  YES 
chr6  82722022  -2431  Hk2  15277  NM_013820.2  1.424  0.190  0.133  YES 
chr6  136929110  -26066  Pde6h  78600  NM_023898.4  20.224  2.878  0.142  NO 
chr7  31338226  95  Hspb6  243912  NM_001012401.2  1.459  0.238  0.163  YES 
chr7  66043947  -
13024
5 
Atp10a  11982  NM_009728.1  0.122  0.042  0.342  NO 
chr7  124589155  -64662  Xylt1  233781  NM_175645.3  1.034  0.484  0.468  YES 
chr7  124594924  -70431  Xylt1  233781  NM_175645.3  1.034  0.484  0.468  YES 
chr7  128103838  -21960  Cdr2  12585  NM_007672.1  8.160  3.417  0.419  YES 
chr7  128105256  -20542  Cdr2  12585  NM_007672.1  8.160  3.417  0.419  YES 
chr8  4512335  -18831  Lass4  67260  NM_026058.3  11.140  4.316  0.387  YES 
chr8  4514133  -20629  Lass4  67260  NM_026058.3  11.140  4.316  0.387  NO 
chr8  13181321  -19303  Grtp1  66790  NM_025768.2  5.386  1.986  0.369  YES 
chr8  13200780  156  Grtp1  66790  NM_025768.2  5.386  1.986  0.369  NO 
chr8  13226390  25766  Grtp1  66790  NM_025768.2  5.386  1.986  0.369  YES 
chr8  55804091  60  Wdr17  244484  NM_028220.2  25.765  7.561  0.293  YES 
chr8  95518521  -33392  Slc6a2  20538  NM_009209.2  0.113  0.010  0.088  NO 
chr8  97526145  -17642  Gpr56  14766  NM_018882.2  0.103  0.211  2.047  NO 
chr8  122850933  14956
4 
170012
0B06Ri
k 
436062  NM_001033980.1  0.089  0.298  3.330  YES 
chr9  26600449  -13553  BC0384
79 
244757  NM_153803.1  5.651  1.541  0.273  YES 
chr9  26613638  -364  BC0384
79 
244757  NM_153803.1  5.651  1.541  0.273  NO 
chr9  58404017  1177  Cd276  102657  NM_133983.3  1.044  0.306  0.293  YES 
chr9  86562592  -27238  Mod1  17436  NM_008615.1  3.134  1.456  0.465  YES 
chr9  86595423  5593  Mod1  17436  NM_008615.1  3.134  1.456  0.465  YES 
chr9  107559721  -9984  Slc38a3  76257  NM_023805.2  12.139  4.815  0.397  YES 
chr9  115367584  19858  EG5461
64 
546164  XM_620794.4  0.201  0.072  0.360  NO 
chrX  71019690  71  Srpk3  56504  NM_019684.1  0.167  0.019  0.114  NO 
chrX  97797141  3754  Arr3  170735  NM_133205.2  7.210  0.023  0.003  NO 
chrX  97800771  124  Arr3  170735  NM_133205.2  7.210  0.023  0.003  NO 
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To explore the possibility that MEF2 regulates cell-type specific gene transcription by binding 
the genome in a cell-type specific manner, we compared MEF2D binding in the retina to MEF2D 
binding  in  two  distinct  cell  types  where  MEF2  factors  have  been  shown  to  be  functionally 
important,  cortical  neurons  and  myocytes.  We  performed  ChIP-Seq  for  MEF2D  in  DIV7 
cultured  cortical  neurons  and  analyzed  MEF2D  ChIP-Seq  data  in  C2C12  myocytes  from  a 
previously published dataset (Sebastian et al., 2013). A comparison of MEF2D binding in each 
of  the  three  tissues  showed  that  MEF2D  binding  to  the  enhancers  and  promoters  that  are 
necessary  for  retinal  gene  expression  is  highly  tissue-specific  (~82%,  76/93)  (Figure  2.8A). 
Furthermore,  the  majority  of  MEF2D  binding  genome-wide  in  each  tissue  is  tissue-specific 
(Figure 2.8B,C). This finding suggests that tissue-specific binding of MEF2D is an important 
mechanism governing the specific function of MEF2D in the retina. 
  We next investigated the mechanism by which MEF2D achieves tissue-specific binding 
to promoters and enhancers in the retina.  Several previous studies have suggested that MEF2 
family members can interact with tissue specific TFs and that this interaction imparts specificity 
to MEF2 binding.  However, the functional importance of these TF interactions has not been 
examined in an in vivo genome-wide context (Black et al., 1996; Molkentin et al., 1995). We 
hypothesized that MEF2D interacts with a retinal-specific TF that recruits MEF2D to tissue-
specific  regulatory  sites.    To  begin  to  identify  such  co-factors  in  an  unbiased  manner,  we 
searched the MEF2D binding sites for common DNA sequence features using a de novo DNA 
motif search program (Heinz et al., 2010). This analysis revealed that after the MRE, the most 
abundant motif sequence present within retina-specific MEF2D-bound regions is the sequence 
TAATCNBNTT (p=1e-85) ((Figure 2.8D). This sequence motif matches the binding site for the 
CRX homeodomain factor (p=3.59e-6). In contrast, no single recognizable motif was    	 ﾠ
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 Figure 2.8. MEF2D binds tissue-specific enhancers 
(A) Fraction of MEF2D functional regulatory elements that are specifically bound in retina or are 
also sites of MEF2D binding in DIV7 cultured cortical neurons or myotubes. 
(B) Overlap of all MEF2D-bound genomic regions from ChIP-seq performed in retina and DIV7 
cultured cortical neurons, as well as mapped regions from published MEF2D ChIP-Seq data for 
myotubes.  
(C) MEF2D ChIP-Seq tracks at the Esrrb locus (top) or Nr4a1 locus (bottom) to demonstrate 
retina-specific  or  shared  MEF2D  binding,  respectively.  MEF2D  ChIP-Seq  reads  from  three 
different tissues are shown.   
(D, E) PWMs of enriched motifs in (D) retina-specific peaks or (E) myotube-specific peaks. 
Below each is a high-ranking JASPAR matrix corresponding to the PWM. 
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Figure 2.8. (Continued) MEF2D binds tissue-specific enhancers 
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Figure 2.8. (Continued) MEF2D binds tissue-specific enhancers 
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significantly enriched at MEF2D binding sites in cortical neurons, apart from the MRE, likely 
due to the extreme heterogeneity of these cells. However, when we performed a de novo motif 
search of MEF2D-bound regions identified in myocytes the most prevalent sequence, besides the 
MRE, was CAGCTGTT (p=1e-397), which is the consensus site for binding myogenic basic 
helix-loop-helix (bHLH) proteins, such as MYOD (p=7.41e-6; (Figure 2.8E) (Molkentin et al., 
1995).  These  findings  raise  the  possibility  that  the  specificity  of  MEF2  binding  in  different 
tissues (e.g. photoreceptors versus muscle) is determined by the presence of the binding site for a 
tissue specific TF adjacent to the MEF2 binding site. In particular, the enrichment of the CRX 
consensus motif at retina-specific MEF2D-binding sites suggests that in photoreceptors CRX 
influences  the  binding  of  MEF2D  to  the  promoters  and  enhancers  of  photoreceptor  specific 
genes. 
 
CRX mediates a genome-wide competition for MEF2D binding to retina-specific sites 
CRX  is  a  retina-specific  transcription  factor  that  is  mutated  in  human  congenital 
blindness. Much like MEF2D, CRX is necessary for photoreceptor outer segment development 
and  photoreceptor  function  (Chen  et  al.,  1997;  Freund  et  al.,  1997;  Furukawa  et  al.,  1997; 
Furukawa et al., 1999; Swain et al., 1997). The enrichment of the CRX motif at MEF2D-bound 
sites suggested that CRX protein might be co-bound to these regulatory elements. However, 
recent work has demonstrated that CRX binds only a small fraction of its consensus motifs in the 
genome indicating that the presence of the CRX binding motif is not sufficient to conclude that 
CRX is bound to a given MEF2 binding site (White et al., 2013). We therefore analyzed CRX 
ChIP-Seq data (Corbo et al., 2010) to determine if CRX protein binds to MEF2D-bound sites in    	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Figure  2.9.  CRX  mediates  a  genome-wide  competition  for  MEF2D  binding  to  retina-
specific sites 
(A) Top, MEF2D and CRX ChIP-seq data tracks at the Pla2r1 genomic locus. Arrow denotes 
transcriptional start site (TSS). A light gray vertical bar highlights the identified MEF2D peak. 
(B) Distribution of MEF2D ChIP-Seq peaks with respect to MEF2D target genes as described in 
Figure 2.7D. Places of MEF2D and CRX co-binding (blue triangles) as well as places where 
MEF2D binds without CRX (purple triangles) are shown for MEF2D target genes. 
(C)  MEF2D  ChIP-Seq  signal  in  WT  versus  CRX  KO  retinae  at  individual  MEF2D-bound 
regions. Read density was calculated for the 400bp window around the summit of each MEF2D-
bound region. Data from CRX KO retinae was compared to the data from 3 different WT retinae 
experiments. Peaks highlighted are at least 2x reduced (red) or 2x increased (green) in CRX KO 
retinae as compared to the average ChIP-Seq read value of the 3 WT samples To be considered 
changed, CRX KO versus the 3 WT values for MEF2D ChIP-seq density had to have p<0.01 
significance. Black line indicates unity. 
(D) Aggregate plots of MEF2D ChIP-Seq signal in CRX WT and KO retinae for 5.6kb region 
centered on summits of the different categories of MEF2D-bound regions. 
(E) Gngt1 (right) and Stard7 (left) genomic loci with MEF2D ChIP-Seq tracks from CRX WT 
(representative 1 of 3 bioreplicates) and CRX KO retinae. 
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Figure 2.9. (Continued) CRX mediates a genome-wide competition for MEF2D binding to 
retina-specific sites 
 
(F) Aggregate plots of DNA binding motif occurrence for the MEF2 motif in a 2kb window 
centered on summits of MEF2D-bound regions. Motif enrichments at MEF2D peaks that are 
increased, unchanged, or decreased in CRX KO retinae are shown. 
(G) Cumulative distribution of MRE strength (p-value describing similarity to canonical MRE) 
for all MREs with p<1e-3 found in 200bp regions centered on MEF2D peak summits. Peak sets 
include those where MEF2D peak size goes up greater than 2X (green), does not change (black), 
or goes down greater than 2X in CRX KO retinae (red).  Figure 2.9. (Continued) CRX mediates a genome-wide competition for MEF2D 
binding to retina-specific sites
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the  retina.    Strikingly,  we  found  that  in  the  retina  ~70%  of  functional  MEF2D  regulatory 
elements are co-bound by CRX (Figure 2.9A,B; Table 2.2). This finding suggests that MEF2D 
may  functionally  interact  with  CRX  to  achieve  tissue-specific  binding  to  the  promoters  and 
enhancers of photoreceptor genes. 
  To test if CRX is required for retina-specific MEF2D binding we performed MEF2D 
ChIP-Seq in Crx KO retinae and compared the pattern of MEF2D binding to that of WT retinae. 
By ChIP-Seq we found that MEF2D binding is reduced >2x in Crx KO retinae at 339 MEF2D 
binding sites including many MEF2D regulatory elements near MEF2D target genes (Figure 
2.9C,D).  For example, retina-specific MEF2D binding is particularly dependent on CRX near 
the MEF2D target genes Gngt1, a key component of the phototransduction cascade, and Stard7, 
which has been shown to be critical for photoreceptor development (Hao et al., 2012) (Figure 
2.9E).  Mef2d  is  not  however  a  transcriptional  target  of  CRX  and  therefore  this  decrease  in 
MEF2D ChIP-Seq signal is not due to decreased expression of MEF2D in Crx KO retinae (Hsiau 
et al., 2007). A possible explanation for why only a subset of MEF2D binding sites requires 
CRX is that MEF2D may only require CRX to stabilize binding at regulatory elements with 
weak  MREs.  In  support  of  this  idea,  we  find  that  the  consensus  MEF2D  binding  site  is 
substantially de-enriched in regions where MEF2D binding is CRX-dependent ((Figure 2.9F). 
Surprisingly, we also found that MEF2D binding is actually significantly increased >2x in Crx 
KO retinae at 224 MEF2D-binding sites genome-wide (Figure 2.9C,D).  Notably, these regions 
are enriched for strong consensus MREs relative to MEF2D binding sites where the level of 
MEF2D binding decreases in the absence of CRX (KS test, p= 4.76e-5) ((Figure 2.9F,G). Taken 
together,  these  data  strongly  suggest  that  MEF2D  is  recruited  to  a  subset  of  retina-specific 
binding  sites  by  cooperation  with  CRX,  a  retina-specific  transcription  factor,  and  that  CRX 	 ﾠ
	 ﾠ 98 
competes MEF2D away from other available binding sites. This genome-wide competition for 
MEF2D binding exists between sites with strong consensus MREs and sites that have weak 
MREs but are co-bound by CRX.  This appears to be an important mechanism for conferring 
tissue-specific binding of MEF2D so that it may regulate photoreceptor-specific target genes. 
 
MEF2D regulates retinal gene expression by selective activation of enhancers 
As described above, tissue-specific MEF2D binding in the retina likely plays a critical 
role  in  specifying  the  function  of  MEF2D  in  photoreceptors.  However,  fewer  than  4%  of 
MEF2D-bound sites are located near target genes, suggesting that additional mechanisms exist to 
specify the function of MEF2D at tissue-specific regulatory sites. This broad binding of MEF2D 
but selective regulation of target genes is consistent with previous genome-wide analyses that 
demonstrate that only a small fraction of transcription factor occupancy relates to the expression 
of neighboring genes (Spitz and Furlong, 2012). We hypothesized that additional mechanisms 
are necessary to determine the action of MEF2D in photoreceptors beyond the regulation of 
binding,  and  that  MEF2D  may  exclusively  regulate  expression  of  its  target  genes  through 
selective activation of enhancers. 
To  test  if  MEF2D-bound  regulatory  sites  are  differentially  active,  we  analyzed  two 
features of enhancer activity, acetylation of histone 3 at lysine 27 (H3K27ac) and transcription of 
bidirectional enhancer RNAs (eRNAs), at MEF2D-bound enhancers proximal to target genes and 
compared these enhancers to a control set of MEF2D-bound sites that are not associated with 
changes in nearby gene expression.  H3K27ac and eRNAs are hallmarks of enhancers that are    	 ﾠ
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Figure 2.10. MEF2D regulates retinal gene expression by selective activation of enhancers 
(A) Top, aggregate plots of H3K27Ac ChIP-Seq signal in MEF2D WT (black) or MEF2D KO 
(red) retinae. Plots are centered on summits of MEF2D-bound regions that are either proximal to 
MEF2D target genes (Target enhancers, left), or summits of MEF2D-bound regions proximal to 
genes that do not change in MEF2D KO retinae (Control enhancers, right). Bottom, aggregate 
plots of MEF2D ChIP signal for same regions, demonstrating normalization of data analysis to 
MEF2D peak size. 
(B) H3K27Ac ChIP-seq read density (left) and eRNA read density (right) calculated +/- 1 kb 
from the center of the WT MEF2D peak for 5 MEF2D-dependent enhancers. 
(C) MEF2D-bound enhancer regions (same as in (B)) were cloned into a luciferase reporter 
construct  with  a  minimal  promoter  and  electroporated  into  retinal  explants  at  P0.  DIV11 
luciferase  activity  was  measured  from  native  reporter  constructs  (WT)  together  with  control 
(scrm) or MEF2D shRNAs. * p<0.05  ** p<0.005 
(D) WT reporter construct luciferase activity was compared to MEF2 responsive element (MRE) 
-mutated  enhancers  (MRE  Mut).  Signal  normalized  to  renilla  luciferase  control.  Error  bars 
represent S.E.M., n=12-18 retinae per experimental condition. * p<0.05  ** p<0.005. Figure 2.10. (Continued) MEF2D regulates retinal gene expression by selective 
activation of enhancers
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actively engaged in gene expression (Creyghton et al., 2010; Kim et al., 2010; Li et al., 2013; 
Rada-Iglesias et al., 2011; Wang et al., 2011). We found that MEF2D-bound enhancers near 
target  genes  were  more  active  than  other  MEF2D  binding  sites  (p=0.0002)  (Figure  2.10A). 
Furthermore,  the  levels  of  H3K27ac  were  significantly  decreased  in  MEF2D  KO  retinae  as 
compared to WT retinae at enhancers proximal to MEF2D target genes, suggesting that MEF2D 
plays a key role in the activation of these enhancers to regulate nearby gene expression (Figure 
2.10A,B). To support these results we isolated a subset of MEF2D-bound enhancers near target 
genes  and  tested  their  ability  to  regulate  reporter  gene  expression  in  the  intact  retina  in  a 
MEF2D-dependent manner (Figure 2.10C,D).  All 5 tested enhancers were sufficient to drive 
reporter gene expression in photoreceptors (data not shown; Figure 2.10C). Additionally, the 
activity of 4/5 of these reporters was significantly reduced in the presence of MEF2D shRNA or 
when the MRE was mutated, demonstrating that direct MEF2D binding to these elements is 
required to drive gene expression (Figure 2.10C,D). Together these results show that MEF2D 
regulates target gene expression by selectively activating only a subset of the sites to which it is 
bound. This reveals an additional level of control in how MEF2D regulates gene expression in 
photoreceptors,  and  helps  explain  why  the  number  of  MEF2D-bound  enhancers  greatly 
outnumbers the number of MEF2D target genes. 
 
CRX determines the selective activation of MEF2D-bound retinal enhancers  
To determine the mechanism of selective MEF2D enhancer activation we considered the 
possibility that CRX could serve as a co-activator at MEF2D-bound enhancers, at sites where 
CRX is required for MEF2D binding but also at sites where MEF2D binding is independent of 	 ﾠ
	 ﾠ 102 
CRX. To test this hypothesis, we first asked if CRX binding correlated with enhancer activity at 
MEF2D-bound sites. Genome-wide, the subset of MEF2D-bound enhancers co-bound by CRX 
was significantly more active than the subset of MEF2D-bound elements where CRX does not 
bind,  even  when  the  amount  of  MEF2D  binding  was  similar  (Figure  2.11A).  This  strongly 
suggested that the presence of CRX together with MEF2D might be required for the maximal 
activation of MEF2D-bound enhancers.  
To determine if CRX co-binding was required for activation of MEF2D-bound regulatory 
elements, we performed RNA-Seq in WT and Crx KO retinae at p11 and quantified the levels of 
eRNAs at MEF2D-bound enhancers (Figure 2.11B, C).  In  addition,  we  performed  ChIP  for 
H3K27Ac at select CRX-bound enhancers in WT and Crx KO retinae to confirm that eRNAs 
and H3K27Ac correlated in reflecting loss of activity (Figure 2.11D). As expected we found that 
CRX was required for the majority of eRNA expression at active sites where MEF2D binding is 
dependent  upon  CRX  (Figure  2.11E).    CRX  was  also  required  for  eRNA  expression  at  an 
additional 38% of MEF2D-bound enhancers that are active in WT retinae, but do not require 
CRX for binding.  These sites included enhancers of clinically relevant MEF2D target genes 
such  as  Pcdh15,  Guca1a  and  Guca1b.  These  results  indicate  that  CRX  is  required  for  the 
selective activation of MEF2D-bound regulatory elements not only by recruiting MEF2D, but 
also by directly activating these promoters and enhancers. 
 
MEF2D  and  CRX  coordinate  gene  expression  through  enhancer  co-binding  and  co-
activation   	 ﾠ
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 Figure 2.11. CRX determines the selective activation of MEF2D-bound enhancers 
(A) Three sets of aggregate plots centered on summits of MEF2D-bound regions that are either 
co-bound by CRX (left) or do not have a CRX peak (right). Top, aggregate plots of H3K27Ac 
ChIP-Seq signal in MEF2D WT retinae. Middle, aggregate plots of MEF2D ChIP signal (purple) 
or CRX ChIP signal (blue), demonstrating differential peak size of CRX and normalization of 
data analysis to MEF2D peak size. Bottom, aggregate plots of RNA-seq reads (coding reads 
removed) for forward (dark blue) and reverse (light blue) strands in Mef2d WT retinae. 
(B) MEF2D and CRX ChIP-Seq tracks at Tnfaip3 example genomic locus. RNA-seq data from 
CRX WT (dark blue) and KO (yellow) retinae is also shown. Arrow denotes transcriptional start 
site (TSS). A light gray vertical bar highlights the identified MEF2D peak.  
(C) eRNA read density calculated from RNA-Seq in CRX WT and KO retinae +/- 1 kb from the 
center of all MEF2D-bound enhancers where RNA-seq reads met minimum criteria for eRNAs 
(see methods). N=2 retinae per genotype. Gray line indicates unity.  
(D) Right, eRNA read density for 2 CRX-bound enhancers, 1 co-bound by MEF2D (fscn2) and 
one not (rho), in CRX WT and KO retinae. Left, H3K27Ac ChIP-qPCR results from CRX WT 
and KO retinae for same 2 CRX-bound enhancers. Error bars represent S.E.M. 
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Figure  2.11.  (Continued)  CRX  determines  the  selective  activation  of  MEF2D-bound 
enhancers 
 
(E) Aggregate plots are shown centered on MEF2D enhancers whose MEF2D binding levels are 
unchanged or decreased in CRX KO retinae.  Top, aggregate plots of RNA-seq reads (coding 
reads removed) for forward (dark blue) and reverse (light blue) strands in Crx WT retinae as well 
as  forward  (red)  and  reverse  (pink)  strands  in  Crx  KO  retinae.  Bottom,  aggregate  plots  of 
MEF2D ChIP-Seq signal in CRX WT and KO retinae for same groups of enhancers.  
 
 Figure 2.11. (Continued) CRX determines the selective activation of MEF2D-
bound enhancers
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Ultimately, the interactions of TFs at enhancers and promoters are read out through target gene 
expression. Given the interactions of MEF2D and CRX at critical retinal enhancers it is expected 
that  MEF2D  and  CRX  would  share  specific  target  genes.  Furthermore,  the  shared  loss  of 
function phenotype for these two factors predicts that target genes shared between these TFs 
would be critical for photoreceptor development and function. To identify shared MEF2D and 
CRX target genes we compared the previously described RNA-Seq results from WT, Mef2d KO 
and Crx KO retinae at p11 and found that ~51% of MEF2D direct target genes are also highly 
regulated by CRX (36/71 genes) (Figure 2.12A,B). These shared target genes included Sag, 
Guca1a, Guca1b and Fscn2, genes that together are essential for photoreceptor development and 
function.  We found that ~92% of shared target genes have MEF2D and CRX co-bound at 
nearby enhancers or promoters, demonstrating that CRX and MEF2D are largely working at the 
same regulatory elements to direct expression of these genes. Of these regulatory sites, ~31% 
require CRX for MEF2D binding and activation (Figure 2.12C). The majority of remaining sites 
do not have significant changes in MEF2D binding but lose activity in the Crx KO (Figure 
2.12D). Taken together, these data suggest two mechanistically distinct consequences of the 
interaction  of  MEF2D  with  CRX  (Figure  2.13).    First,  CRX  recruits  MEF2D  away  from 
consensus binding sites toward retina-specific enhancers and stabilizes MEF2D binding at those 
enhancers  where  the  MRE  is  particularly  weak.    Second,  CRX  contributes  to  activation  of 
MEF2D-bound enhancers as determined by increased H3K27Ac levels and eRNA production. It 
is through these mechanisms that MEF2D achieves tissue-specific function in the development 
of the mouse retina.  Disruption of these mechanisms leads to misregulated expression of critical 
cell type-specific genetic programs and abnormal photoreceptor development. 	 ﾠ
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Figure 2.12. MEF2D and CRX coordinate gene expression through enhancer co-binding 
and co-activation 
(A) Average gene expression levels as quantified by exon density of MEF2D direct target genes 
in either MEF2D WT compared to MEF2D KO retinae (left) or in CRX WT retinae compared to 
CRX KO retinae (right).  N=2 mice per condition. Black line indicates unity. Red lines indicate a 
two-fold change from unity. 
(B) MEF2D and CRX ChIP-Seq tracks at Tnfaip3 example genomic locus. RNA-seq data from 
CRX WT (dark blue) and KO (yellow) retinae as well as MEF2D WT (black) and KO (red) 
retinae is also shown. Arrow denotes transcriptional start site (TSS). A light gray vertical bar 
highlights the identified MEF2D peak.  
(C)  MEF2D  ChIP-Seq  signal  in  WT  versus  CRX  KO  retinae  at  MEF2D-bound  regulatory 
regions  that  are  near  MEF2D-CRX  co-regulated  genes.  Gray  line  indicates  unity.  Red  lines 
indicate cutoffs for a two-fold change. 
(D) eRNA read densities at MEF2D-bound enhancers near MEF2D-CRX co-regulated genes. 
N=2 mice/genotype. eRNA Read densities are shown for (left) MEF2D WT versus MEF2D KO 
retinae  and  (right)  CRX  WT  versus  CRX  KO  retinae.  Gray  line  indicates  unity.  Red  lines 
indicate cutoffs for a two-fold change. Figure 2.12. (Continued) MEF2D and CRX coordinate gene expression through 
enhancer co-binding and co-activation 
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Figure 2.13. Model of MEF2D-CRX co-regulation of photoreceptor target genes   
(A) Schematic demonstrating that MEF2D and CRX co-bound regulatory elements are more 
active, and that CRX and MEF2D co-bind near shared target genes (examples on right). As in 
Figure 2.6F, diagram on right demonstrates example genes that are common targets of MEF2D 
and CRX and important in photoreceptor cell biology. Genes implicated in retinal disease are in 
blue.  
(B)  Model  of  contributions  of  MEF2D  and  CRX  to  cooperative  regulation  of  enhancers  or 
promoters in the retinal genome. As shown in (A), CRX-MEF2D co-binding correlates with 
higher enhancer activity. Left, from top to bottom: in the absence of MEF2D,  some, but not all 
MEF2D-CRX co-bound regulatory regions lose marks of activity such as acetyl and eRNAs. A 
smaller fraction of sites bound without CRX are active in WT retinae, and also a smaller fraction 
lose marks of activity in Mef2d KO retinae. It is not yet known if CRX binding is ever dependent 
on MEF2D. Right, from top to bottom: in the absence of CRX, a subset of CRX-MEF2D co-
bound regulatory elements lose both MEF2D binding as well as marks of activity. Some sites 
remain bound but lose activity, and a relatively small subset of sites normally co-bound with 
CRX and MEF2D retain both MEF2D binding and activation in Crx KO retinae. Finally some 
sites with MREs where MEF2D is generally bound without CRX in WT retinae see an increase 
in MEF2D binding, and how this affects activity has not yet been elucidated. Figure 2.13. (Continued) Model of MEF2D-CRX co-regulation of photoreceptor 
target genes  
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2.4 Discussion 
MEF2 TFs have many well-established roles in the development and function of the 
nervous system and have been implicated in neurological disorders including Alzheimer’s and 
Parkinson’s  disease,  autism  and  intellectual  disability  (Rashid  et  al.,  2014).  Despite  their 
importance  in  neuronal  biology  the  mechanisms  of  how  MEF2  regulates  neuronal  gene 
expression  are  still  poorly  understood.  The  development  of  genome-wide  methods  for  the 
analysis of gene expression, TF binding and enhancer activity allows new insights to be gained 
by revisiting longstanding questions of gene regulation.  However, using these techniques to 
dissect TF function in the CNS has remained difficult given the heterogeneity of cell types. 
Evaluating MEF2 function in the CNS has proven still more challenging, as multiple MEF2 
factors often overlap in expression and function. Previous efforts therefore have been limited to 
studying  MEF2  regulation  of  neuronal  gene  expression  through  reporter  assays  and  in  vitro 
analyses (Black et al., 1996; Flavell et al., 2008).  
Here,  we  identify  retinal  photoreceptors  as  a  neuronal  cell  type  in  the  CNS  that 
predominantly expresses a single MEF2 family member, MEF2D, during development and that 
requires  MEF2D  cell-autonomously  for  functional  differentiation  in  vivo  (Figures  2.1-2.5).  
MEF2 TFs have been previously proposed to play a role in photoreceptors (Escher et al., 2011; 
Hao et al., 2011), but attempts to identify this role have been unsuccessful because they focused 
on  MEF2C,  which  is  not  expressed  until  retinal  development  is  complete,  when  it  is  likely 
redundant (Figure 2.1). Instead our analyses demonstrate that MEF2D plays a unique role in 
retinal development by binding to and activating photoreceptor specific enhancers and thereby 
regulating  critical  photoreceptor-specific  genes  including  genes  mutated  in  human  forms  of 	 ﾠ
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retinal  disease.  Within  the  CNS,  retinal  photoreceptors  are  notable  because  they  are  a 
homogeneous and functionally well-characterized cell type that makes up the vast majority of 
cells (~80%) in the retina. This made it possible to perform genomic and epigenetic analyses in 
vivo  to  functionally  dissect  the  mechanisms  of  how  MEF2D  regulates  photoreceptor 
development,  illustrating  that  photoreceptors  are  an  effective  model  for  genomic  studies  of 
transcriptional regulation in the CNS. 
Although  broadly  expressed  across  many  tissues,  we  find  that  MEF2D  regulates  key 
photoreceptor-specific  and  retinal  disease  genes  by  binding  to  and  activating  retina-specific 
enhancers synergistically with the retina-specific homeodomain TF CRX and that interaction 
with CRX is critical for the tissue-specific function of MEF2D.  Our experiments demonstrate 
that the function of MEF2D-CRX interactions is two-fold.  First, CRX recruits MEF2D to certain 
photoreceptor-specific enhancers that lack a consensus MRE (Figure 2.9).  This suggests that 
CRX actively stabilizes MEF2D binding rather than functioning solely as a pioneer factor by 
opening up chromatin to reveal MREs.  Second, CRX interacts with MEF2D to co-activate 
MEF2D-bound enhancers as determined by increased H3K27Ac levels and eRNA production 
where MEF2D and CRX co-bind. These functional interactions may be significant for other cell 
types, as CRX is closely related to two other homeobox factors OTX1 and OTX2 that have 
critical roles in development of the CNS as well as in many non-neuronal cell types (Boncinelli 
et al., 1994; Boyl et al., 2001). Discovery of these dual mechanisms of interaction demonstrates 
how a broadly expressed TF such as MEF2D achieves tissue-specific functions in the retina by 
working with a tissue-specific co-factor to regulate photoreceptor development and function. 	 ﾠ
	 ﾠ 114 
These  observations  provide  in  vivo  and  genome-wide  validation  of  early  studies  of 
MEF2-cofactor  interactions,  while  bringing  novel  insight  into  the  functional  nature  and 
biological consequences of these interactions in the nervous system. In vitro, MEF2 has been 
shown to interact with myogenic bHLH heterodimers during myocyte differentiation (Molkentin 
et al., 1995). In this system, MEF2 and bHLH heterodimers can activate heterologous reporters 
in  the  absence  of  an  MRE  as  long  as  the  bHLH  recognition  element  (E-box)  is  present, 
suggesting that MEF2 can be recruited to these reporters in a sequence independent manner 
(Molkentin et al., 1995) In contrast, others have demonstrated that each factor must bind to its 
recognition element for reporter activation (Naidu et al., 1995). Parallel roles for MEF2-bHLH 
cooperativity  have  been  proposed  in  neurons  however  a  functional  understanding  of  these 
interactions has remained elusive (Black et al., 1996; Mao and Nadal-Ginard, 1996).  Together 
these experiments suggest multiple models of MEF2-bHLH interactions.  However, given the 
heterologous  nature  of  these  reporter  studies,  it  is  unclear  how  each  of  these  mechanisms 
contributes to endogenous gene expression.  Our results demonstrate that in the nervous system, 
MEF2 interacts with a homeodomain-containing TF, CRX, with two distinct consequences at 
endogenous  sites  at  the  level  of  cooperative  binding  and  enhancer  activation  to  co-regulate 
photoreceptor gene expression and development in vivo.  
While  MEF2D  binding  is  lost  in  CRX  KO  retinae  at  many  sites  without  consensus 
MREs, we unexpectedly observed a significant increase in MEF2D binding in the CRX KO at 
distinct sites that are enriched for consensus MREs (Figure 2.9). This finding is noteworthy as it 
demonstrates that CRX mediates a genome-wide competition for MEF2D binding between these 
two populations of enhancers. Previous work has demonstrated a competition between functional 
DNA binding sites and non-functional binding sites located in satellite regions and repetitive 	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DNA, which are thought to limit free TF concentration in the nucleus (Liu et al., 2007). Our 
results  suggest  that  CRX  biases  the  genome-wide  competition  for  MEF2D  binding  toward 
regulatory sites that are relevant to photoreceptor gene expression.  However sites where MEF2D 
binding increases in CRX KO retinae are not merely sponges for TF binding, but may in fact 
have  critical  biological  roles  as  they  are  highly  conserved  (data  not  shown).  Furthermore, 
MEF2D-bound regions that are shared across tissues are overrepresented among the sites of 
MEF2D binding that go up in CRX KO retinae, suggesting that these sites may be active in other 
tissues, when paired with other co-factors, or that these sites may be active in many tissue types 
in a stimulus-dependent manner. In support of this hypothesis, GREAT analysis of enhancers 
where  MEF2D  binding  increases  in  CRX  KO  retinae  reveals  that  nearby  genes  are  most 
significantly  associated  with  generic  biological  processes  such  as  “response  to  endogenous 
stimulus” or “response to insulin stimulus” (McLean et al., 2010). Conversely, GREAT analysis 
of MEF2D peaks whose binding is CRX-dependent demonstrates that these peaks are proximal 
to  genes  associated  with  disease  ontologies  of  retinitis  pigmentosa  and  retinal  degeneration, 
providing evidence for a more tissue-specific role for this cohort of regulatory regions. This 
suggests that MEF2 transcription factors might employ two different mechanisms to regulate 
distinct gene expression programs within the same cell. The first mechanism, shared among 
tissues, regulates broadly expressed genes through binding to regulatory sites with consensus 
MREs, and may function in a stimulus dependent manner. In competition, the second mechanism 
regulates  tissue-specific  gene  expression  with  a  tissue-specific  co-factor,  and  is  critical  for 
programs of differentiation. How both mechanisms might function simultaneously, and whether 
these mechanisms determine dual functions of MEF2 across different cell types, remains to be 
explored. 	 ﾠ
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Once bound to the genome, we find that additional mechanisms must regulate the action 
of  MEF2  function  because  only  a  small  subset  of  MEF2D  binding  sites  are  required  for 
expression of nearby genes. We found that selective activation of a subset of MEF2D-bound 
enhancers  plays  a  significant  role  in  determining  which  genes  require  MEF2D  for  their 
expression, and that CRX contributes to this selective activation (Figures 2.10,2.11). In non-
neural tissues, MEF2 co-factors have been suggested to help recruit co-activators such as histone 
acetyltransferases (HATs) (Sartorelli et al., 1997; Youn et al., 2000a). As CRX binds the HAT 
P300 (Yanagi et al., 2000), this raises the possibility that MEF2D and CRX cooperatively recruit 
HATs. Such a tripartite complex may also stabilize MEF2D binding, in which case a single 
mechanism  would  account  for  the  contribution  of  CRX  to  MEF2D  binding  and  selective 
activation of MEF2D-bound regulatory elements.  
These findings join a significant body of work done to elucidate the network of TFs that 
are  critical  for  photoreceptor  development  (Swaroop  et  al.,  2010).  The  cooperative  gene 
regulation by MEF2D and CRX, a key member of this network, suggests that MEF2D also plays 
an important role. MEF2D is a notable addition to this transcriptional network because while 
previously identified critical members such as CRX, NRL and NR2E3 are highly tissue specific, 
MEF2D is broadly expressed and likely achieves photoreceptor specificity only as part of this 
network. Furthermore, MEF2 family members have been characterized as stimulus-responsive 
TFs, and developing photoreceptors respond to several different stimuli, for example taurine, 
dopamine, and light among others (Cohen et al., 1992; Nir et al., 2002; Young and Cepko, 2004). 
We propose that MEF2D could contribute a stimulus-dependent component to the transcriptional 
regulation of photoreceptor development, though this remains to be explored.  	 ﾠ
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Finally, the present study suggests that MEF2D has the potential to be a key player in 
human retinal disease or may be an as of yet unrecognized retinal disease gene itself. MEF2D 
co-regulates critical retinal disease genes with CRX, which itself is mutated in several retinal 
diseases characterized by photoreceptor degeneration (Sohocki et al., 1998). Importantly, the 
identification  of  active  photoreceptor  enhancers  allows  us  to  identify  critical  MEF2D-bound 
functional regulatory elements, which can be as much as 100kb away from the transcriptional 
start site of retinal disease genes. This is significant as these regulatory elements may correspond 
to sites of genetic variation in humans and may ultimately be found to harbor disease-causing 
mutations. For example, SNPs in these regulatory elements that affect the binding of MEF2D or 
CRX might disrupt enhancer activity and nearby gene expression, leading to retinal disease.  
Such  situations  would  join  a  growing  cohort  of  enhanceropathies  that  contribute  to  human 
disease (Smith and Shilatifard, 2014). Thus these genome-wide analyses provide a rich resource 
for considering how non-coding regulatory regions function in normal development of the retina 
and potentially in human disease.   	 ﾠ
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2.5 Experimental Procedures 
Generation of MEF2D knockout mice and in vivo phenotype analysis  
The targeting construct used for homologous recombination (Figure 2.2) in ES cells was 
cloned  using  nested  PCR  amplification  from  mouse  sv129  genomic  DNA  into  a  vector 
containing a floxed neomycin-resistance positive selection cassette (NEO) and a diphtheria toxin 
A negative-selection cassette (DTA). The final targeting construct inserted 1 loxP site into intron 
I and 2 loxP sites flanking a NEO cassette into intron VI. Care was taken to place loxP sites and 
the NEO cassette in non-conserved regions of the intron.  The region between loxP sites flanked 
a 5.1kb region of the Mef2d locus that spanned exons 2-6. This included the first five coding 
exons  of  MEF2D  including  the  translational  start  site  and  the  conserved  MADS  and  MEF2 
domains, which include the critical DNA and protein binding residues of MEF2D. The arms used 
flanking the targeted region were 4.1kb 5’ and 2kb 3’ to the targeted regions.    
All targeting constructs were confirmed by direct sequencing in their entirety prior to use 
in gene targeting. The constructs were linearized and electroporated into J1 ES cells. Genomic 
DNA isolated from G418-resistant ES cell clones was screened by Southern blot. 5’ and 3’ 
probes external to the genomic fragment contained within the targeting vector were used. For the 
5’ southern, ES cell DNA was digested with Tth111I and positive targeting was indicated by a 
2.4 kb decrease in the digested fragment due to a new Tth111I digest site in the NEO cassette. 
The  3’  side  was  analyzed  by  digesting  ES  cell  DNA  with  ApaI  and  positive  targeting  was 
indicated by a 1.6 kb increase in the size of the digested product as compared to wild-type ES 
cell genomic DNA representing the presence of the NEO cassette in the Mef2d endogenous 
locus. ES cell clones positive for correct targeting of the Mef2d locus by Southern screening 	 ﾠ
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were karyotyped and those with karyotypes > 95% were used to generate mice.  
Two confirmed MEF2D targeted ES cell clones were injected into C57BL/6 blastocysts 
and subsequently implanted into pseudopregnant females. The resulting chimeric offspring were 
mated  with  C57BL/6  mice,  and  the  agouti  offspring  were  screened  by  PCR  genotyping  to 
confirm germline transmission of the mutant allele. Targeted mice were then crossed to E2A-
CRE  expressing  mice  (stock  number  003724;  The  Jackson  Laboratory)  and  offspring  were 
analyzed for expression of the Cre allele and the state of the targeted MEF2D allele using PCR 
genotyping. Mice that expressed Cre and had either excised the neomycin cassette or the full 
targeted region were bred to wildtype C57BL/6 mice and offspring that no longer expressed Cre 
and had transmission of either the floxed allele or the null allele without neomycin were used to 
establish mouse lines.  
Mice were analyzed for gross phenotypes by preservation in Bouin’s Solution (Sigma) 
and histology using hematoxylin and eosin staining of tissues throughout the mouse. Results 
were reviewed with a pathologist.  
 
Animal husbandry and colony management 
For routine experimentation, animals were genotyped using a PCR-based strategy. CRX 
knockout  mice  were  obtained  from  The  Jackson  Laboratories  (stock  number  007064)  and 
genotyped according to their protocols. Animals harboring the Mef2d null allele were genotyped 
with a forward primer upstream of Mef2d exon 2 and a reverse primer either 155bp downstream 
(for  the  WT  allele)  or  a  reverse  primer  just  downstream  of  exon  6  (for  the  null  allele). 	 ﾠ
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Conditional knockout animals were genotyped for the presence of the loxP site, which shifts the 
size of the PCR product. See Figure S1 for PCR product sizes and primer sequences. The use of 
animals was approved by the Animal Care and Use Committee of Harvard Medical School. All 
experiments described here were performed using animals derived from a sv129/C57BL/6 hybrid 
genetic background, with the mutation backcrossed in the C57BL/6 background (Charles River 
Laboratories) between 3 and 8 generations. 
 
Semi-Thin microscopy of retinas  
Retinae  were  dissected  and  eyecups  were  fixed  with  2%  formaldehyde  and  2.5% 
glutaraldehyde in 0.15 M Sorenson’s phosphate buffer (pH 7.4), followed by 1% OsO4, 1.5% 
potassium ferrocyanide, and stained en bloc with 1% uranyl acetate. 0.5-1 µM thick sections of 
the  eyecup  were  stained  with  toluidine  blue  and  examined  with  a  Nikon  Eclipse  E600 
microscope.  
 
Electroretinograms  
Mice were dark-adapted overnight and anesthetized with sodium pentobarbital injected 
intraperitoneally prior to testing. Pupils of each animal were topically dilated with phenylephrine 
hydrochloride  and  cyclopentolate  hydrochloride,  and  mice  were  then  placed  on  a  heated 
platform. Rod dominated responses were elicited in the dark with 10-µs flashes of white light 
(1.37 x 10
5 cd/m
2) presented at intervals of 1 minute in a Ganzfeld dome. Light-adapted, cone 	 ﾠ
	 ﾠ 121 
responses were elicited in the presence of a 41 cd/m
2 rod-desensitizing white background with 
the same flashes (1.37 x 10
5 cd/m
2) presented at intervals of 1 Hz. ERGs were monitored with a 
silver wire loop electrode in contact with the cornea topically anesthetized with proparacaine 
hydrochloride  and  wetted  with  Goniosol,  with  a  cotton  wick  electrode  in  the  mouth  as  the 
reference; an electrically-shielded chamber served as ground.  
All responses were differentially amplified at a gain of 1,000 (-3db at 2 Hz and 300 Hz; 
AM502, Tektronix Instruments, Beaverton, OR), digitized at 16-bit resolution with an adjustable 
peak-to-peak input amplitude (PCI-6251, National Instruments, Austin, TX), and displayed on a 
personal  computer  using  custom  software  (Labview,  version  8.2,  National  Instruments). 
Independently for each eye, cone responses were conditioned by a 60 Hz notch filter and an 
adjustable artifact-reject window, summed (n=4-20), and then fitted to a cubic spline function 
with variable stiffness to improve signal:noise without affecting their temporal characteristics; in 
this way we could resolve cone b-wave responses as small as 2 µV.  
 
Immunoblotting  
  Dissected retinae were homogenized in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
1% Triton-X-100, 0.5% sodium Deoxycholate, 0.1% SDS, 5 mM EDTA, 10 mM NaF, 1 mM 
sodium orthovanadate, complete protease inhibitor cocktail tablet (Roche)) and protein levels 
were measured using the Bradford method (BioRad). 15µg of each protein sample was used. 
Conventional  western  blotting  used  enhanced  chemiluminescence  and  HRP-conjugated 
secondary antibodies. Commercial antibodies used include anti-ARR3 (1:5000, EMD Millipore 	 ﾠ
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AB15282) anti-MEF2D (mouse 1:1000, BD Biosciences), anti-MEF2C (rabbit 1:1000, Abcam 
ab64644) and anti-GAPDH (rabbit 1:5000, Sigma). A MEF2A antibody was raised in rabbit 
against amino acids 272-484 of human MEF2A (1:1000). 
 
Immunohistochemistry 
For  immunostaining  experiments  retinas  or  eyecups  were  cryopreserved  and  20µm 
sections were generated on a Leica CM1950 cryostat and mounted on slides. Sections were 
incubated in block solution (10% goat serum and 0.25% Triton X-100 in 1XPBS) for 1 hour and 
then incubated with primary antibodies in block solution for 2 hours at room temperature or 4° C 
overnight. Alexa dye-conjugated secondary antibodies were used at 1:500 dilutions in block 
solution  (Life  Technologies).  Primary  antibodies  were  anti-ARR3  (rabbit,  1:5000,  EMD 
Millipore  AB15282),  anti-MEF2D  (mouse  1:1000,  BD  Biosciences  610775),  anti-MEF2A 
(rabbit  1:1000,  generated  in  the  Greenberg  lab  as  described  above)  and  anti-GFP  (chicken 
1:1000, Aves Labs GFP-1020). The anti-GUCA1B antibody (rabbit, 1:2500) was a kind gift 
from Dr. A. Dizhoor (Salus University).  Slides were mounted using Prolong Gold AntiFade 
reagent with 4′,6-diamidino-2-phenylindole (DAPI) (Life Technologies).    
 
Images were acquired on a Zeiss LSM5 Pascal confocal microscope at 1024x1024 pixel 
resolution or using a Zeiss Axio Imager microscope with a 63x objective with the use of an 
apotome.  	 ﾠ
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Quantification of outer segment disruption  
Immunohistochemistry was performed as described above. Primary antibodies used were 
anti-ABCA4 (mouse, 1:1000, Novus Biologicals NBP1-30032) and anti-GFP (chicken, 1:1000, 
Aves  labs  GFP-1020).  For  quantification,  images  were  acquired  using  a  Zeiss  Axio  Imager 
microscope  with  a  63x  objective  with  the  use  of  an  apotome.    Microscope  settings  were 
optimized for each image with settings selected such that no pixels were beyond the range of the 
detector.  For each neuron, a Z-stack of 10 sections with a step size of 1µm was collected, and a 
maximal intensity projection was created and used for analysis.  Retinae were analyzed blind to 
genotype or experimental condition.  ImageJ was used for processing. Initial defining of areas for 
analysis was done blind to GFP-image, using ABCA4 and DAPI layers only. Regions of interest 
(ROI) were obtained for both outer segments (OS, ABCA4-positive) or inner segments as the 
control for electroporation efficiency and signal intensity (IS, between ABCA4+ and DAPI+ 
areas). Mean pixel intensity was quantified for GFP in the OS and IS ROI and an index of 
photoreceptor apical process growth was defined as mean GFP in OS/ mean GFP in IS. Mean 
values for an experimental condition were determined from at least 3 retinae imaged from at 
least 2 different sections. Mean index data from each retina was used to analyze significance by 
Student’s T-test.  
 
Plasmids 	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Previously characterized MEF2D shRNA and mutant shRNAs cloned into the pLL3.7 
vector  (Addgene  Plasmid  11795)  were  used  (Flavell  et  al.,  2006;  Lin  et  al.,  2008).  Mouse 
MEF2D cDNA was made resistant to MEF2D-specific shRNA by mutating the sequence 5’- 
AGCTCTCTGGTC-3’;  to  5’-AGCTCACTAGTC-3’  (mutations  in  bold)  using  site-directed 
mutagenesis (Agilent Technologies) The cDNA was then cloned into the pFUIGW vector (Zhou 
et al., 2006).  
 
In vivo retinal electroporations  
Adapted  from  (Cherry  et  al.,  2011;  Matsuda  and  Cepko,  2008)  with  the  following 
modifications: approximately 0.75µl DNA for electroporation were injected into the subretinal 
space of p0 mice using a Nanoject II and pulled glass needles (Drummond Scientific, Broomall, 
PA).  
 
Cortical neuron cell culture and Potassium Chloride-mediated depolarization of cultured 
neurons 
To obtain cortical neurons, mouse cortices were dissected from E16.5 C57BL/6 mouse 
embryos in dissection medium (DM) (10mM MgCL2, 10mM HEPES, 1mM kynurenic acid in 
1X  Hank’s  Balanced  Salt  Solution,  pH  7.2)  and  then  dissociated  for  10  minutes  in  DM 
containing  20U/ml  papain  (Worthington  Biochemicals)  and  0.32  mg/ml  L-cysteine  (Sigma). 
Enzymatic dissociation was terminated by washing dissociated cells three times for two minutes 	 ﾠ
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each  in  DM  containing  1%  ovomucoid  (Worthington  Biochemicals)  and  1%  bovine  serum 
albumin (Life Technologies). Cells were then triturated using a glass Pasteur pipette to fully 
dissociate cells. After dissociation, neurons were kept on ice until plating. Dissociated neurons 
were plated and maintained in Neurobasal medium with B27 supplement (Life Technologies), 1 
mM L- glutamine, and 100 U/mL penicillin/streptomycin for 7 days. For ChIP-Seq experiments, 
neurons were plated at an approximate density of 4x10^7 in 15 cm culture dishes pre-coated with 
a solution of 20 µg/ml poly-D-lysine (Sigma) and 4 µg/ml mouse laminin (Life Technologies) in 
water.  For KCl-mediated depolarization of neurons, neuronal cultures were pre-treated with 
1µM  tetrodotoxin  (TTX,  Fisher)  and  100µM  DL-2-amino-5-phosphopentanoic  acid  (D-APV, 
Tocris  Bioscience)  overnight  to  reduce  endogenous  neuronal  activity  prior  to  stimulation 
(“silencing”). Neurons were membrane depolarized with 55 mM extracellular KCl by addition of 
prewarmed depolarization buffer (170 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES 
pH7.5) to a final concentration of 31% in the neuronal culture medium in the plate. Neurons 
collected  for  ChIP  were  either  only  silenced  or  silenced  with  2  hours  of  membrane 
depolarization.  
 
Chromatin Immunoprecipitation 
ChIP antibodies used were anti-MEF2D (Flavell et al., 2008), anti-H3K27Ac (Abcam 
AB4729). MEF2D ChIP from mouse cortical cultures was performed as described in (Kim et al., 
2010).   MEF2D ChIP from mouse retinae was performed as previously described for brain 
tissue (Hong et al., 2008) with the following modifications:  p11 mouse retinae were dissected in 
ice-cold HBSS prior to homogenization and crosslinking.  4µg of MEF2D antibody was pre-	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bound  to  15µl  of  Protein  A  dynabeads  (Life  Technologies)  per  IP  from  approximately  100 
million  retinal  cells.  Histone  ChIP  was  performed  as  described  above  with  the  following 
modifications: 10 mM sodium butyrate was added to all solutions until post-IP washes with the 
exception of cross-linking buffer.  Chromatin was fragmented for histone ChIP by MNase (New 
England Biolabs) digestion for 8 minutes at 37C to generate mononucleosomes. 0.25µg of anti-
H3K27Ac was used per IP from 10 million retinal cells. After reverse crosslinking all samples 
were purified using phenol/chloroform/isoamyl alcohol followed by column clean up (Qiagen, 
QIAquick PCR Purification Kit). 
 
ChIP-qPCR 
  Quantitative PCR analysis of ChIP samples was carried out using the StepOnePlus qPCR 
system and Power SYBR Green mix (Life Technologies, Beverly, MA).  Fraction of input values 
were calculated by comparing the average threshold cycle of the ChIP DNA to a standard curve 
generated  using  serial  dilutions  of  input  DNA.    Fold  enrichment  for  each  genomic  region 
evaluated was calculated as its fraction of input divided by the average fraction of input value 
calculated for standard background regions at least 2 kb away. Amplicon primers were designed 
using Primer3Plus (Untergasser et al., 2007). Primer sequences available upon request. 
 
ChIP-Seq Sequencing, Data Processing and Peak Characterization 
ChIP samples were submitted to the Beijing Genomic Institute (BGI) for 50 base pair 	 ﾠ
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single end sequencing on the Illumina Hiseq 2000 platform. For each sample, over 20 million 
clean reads were obtained.  
  Sequencing data was obtained from BGI in gzipped fastq file format. Sequencing reads 
were then aligned to the July 2007 assembly of the mouse genome (NCBI 37, mm9) using the 
Burrows- Wheeler Aligner (BWA) with settings -q 0  -t 4  -n 5  -k 2  -l 32  -e -1  -o 0. The 
resulting bwa files were then converted to sam files and uniquely mapped reads were extracted 
from the sam files. Sam files of the uniquely mapped reads were then converted to bam files and 
bed files. SAMTools and BEDTools-2.16.2 were used for the above conversions. Chromosome 
names were changed using a custom perl script. Bed files were then used for peak calling using 
Model-based  Analysis  of  ChIP-Seq  (MACS)  1.4.0  (Zhang  et  al.,  2008)  with  the  following 
parameters:  default  parameters  (p=1e-5)  except  -bw  200,  and  for  histone  marks,  default 
parameters (p=1e-5) except --nomodel --shiftsize 73. To visualize ChIP- Seq data on the UCSC 
genome browser, reads in ChIP-Seq bed files were extended to 200 bp for transcription factors or 
146 bp for histone marks using a custom perl script. BEDTools was then used to convert this file 
to bedgraph, at which point each file was normalized to 10 million total reads, then converted to 
bigwig track format and displayed as the number of input normalized ChIP-Seq reads. 
MEF2D  peaks  were  considered  high  confidence  peaks  if  they  appeared  in  2  WT 
bioreplicates and the MEF2D ChIP-Seq read density in the peak was >=2.5X the read density in 
a MEF2D KO ChIP-Seq. Bioreplicate 1 had 13749 peaks called by MACS over input chromatin. 
Bioreplicate 2 had 11979 peaks. 3664 peaks appeared in both replicates, and 2403 of these peaks 
were down >=2.5x in the MEF2D KO as compared to its wildtype littermate, Bioreplicate 2. We 
used this set of reproducible and specific MEF2D peaks for subsequent analysis. 	 ﾠ
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MEF2D  peaks  were  classified  based  on  their  location  relative  to  genes  in  the  NCBI 
Reference Sequence Database (RefSeq). MEF2D peaks were classified as being proximal if they 
were within 1kb of an annotated transcriptional start site (TSS). MEF2D peaks were classified as 
being distal if they were greater than 1kb from an annotated transcriptional start site (TSS). 
Distal MEF2D peaks were further classified as intragenic if they occurred within a RefSeq gene 
(but not within 1kb of the TSS), or as extragenic if they did not occurred within a RefSeq gene 
(and were greater than 1kb away from a TSS). For chromatin modifications (e.g. H3K27ac), the 
number of input-normalized ChIP-Seq reads within a two kb window centered on each binding 
site  was  taken  to  be  the  ChIP-Seq  signal  at  the  binding  site.  For  transcription  factors  (e.g. 
MEF2D), the number of input-normalized ChIP-Seq reads within a 400 bp window centered on 
each binding site was taken to be the ChIP-Seq signal at the binding site. The number of reads 
was calculated using HOMER (annotatepeaks.pl; (Heinz et al., 2010)) except in the case of the 
initial MEF2D peak ChIP-Seq analysis between MEF2D WT and KO, where read density was 
calculated using a custom perl script for comparison. 
Raw read data, lists of called peaks, as well as raw data for peak enrichment analysis are 
available upon request. 
 
Previously published ChIP-Seq data sets 
In addition to ChIP-Sequencing data we generated, we used previously published data for 
MEF2D  isoform  α1  and  MEF2Dα1-blocked  control  ChIP-seq  in  myocytes  (GSE43223) 
(Sebastian et al., 2013). In addition, we used ChIP-Seq data for two bioreplicates of CRX as well 	 ﾠ
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as an IgG control (GSE20012) (Corbo et al., 2010). Sequencing data was mapped and peaks 
were called as described above.  
 
ChIP-Seq analysis (peak overlap, data plots and motif enrichment) 
For determining overlap of called peaks, intersectbed from BEDTools-2.16.2 was used 
with default settings except the –u option was used to get a list of each unique original feature 
that overlapped from one of the two compared groups instead of overlap regions or other outputs. 
1 bp was sufficient to determine overlap. 
HOMER 4.1 (Heinz et al., 2010) was used for the majority of the analysis of ChIP-Seq 
data. The mm9 genome was used for mapping and fasta file generation. ChIP tag directories 
were created using bed files of unextended reads and Homer MakeTagdirectory with fragment 
length specified as 200 for sonicated samples (transcription factors and H3K27Ac in cortical 
culture), 146 for MNase digested samples (histone marks in retina).  
For  further  analysis  the  following  commands  were  used  with  the  generated  tag 
directories. Settings used were default unless specified otherwise.  
Counts of reads, or “Tag counts” were generated using annotatePeaks.pl with default 
options and a size of 400 bp centered on the peak summit for DHS and transcription factors, or a 
size of 2000 bp centered on the peak summit for histone marks.  
Fixed  line  plots  were  generated  in  R  using  data  generated  from  Homer  4.1  using 
annotatePeaks.pl, with the following options: -size 2000 -len 200 -noann -nogene -ghist -hist 20.  	 ﾠ
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Aggregate plots were generated using annotatePeaks.pl with options –d -size 6000 -hist 
20 for ChIP-seq data. Options for motif aggregate plots were –m -hist 20 -size 400. 
De novo and known Motif Enrichment was performed using findMotifsGenome.pl with 
options -len 6,8,10,12 -S 15 –h. Regions used for Motif calculations were either 400bp (in the 
case of Figure 2.7C) or 200bp (for all other motif enrichments). Unless otherwise specified, 
background for motif enrichment for each peak was an equally sized genomic window at the 
edge of the peak, provided the background region did not overlap with another peak in the 
relevant dataset.  
PWMs from top de novo motifs found were then put into TOMTOM from the MEME 
suite (Bailey et al., 2009) and evaluated for their similarity to motifs in the JASPAR Vertebrates 
and UniPROBE Mouse databases using a Pearson’s correlation coefficient. 
For a finer analysis of motif strength based on its similarity to a given PWM, FIMO from 
the MEME suite was used to identify motifs and their p-values based on provided PWMs and a 
p-value >=1e-4.  Sequence FASTA files for input into FIMO were generated using Homer 4.1 
homertools extract –fa. 200bp regions centered on the peak summit were used.  
MEF2D-bound enhancers were classified into different categories based on the behavior 
of the eRNA read density (quantification described below) and quantified H3K27ac signal at 
each enhancer. Enhancers were classified as having H3K27ac if they had >10 normalized reads 
(tag count, per Homer) in a 2 kb window centered on the MEF2D peak summit. Enhancers with 
H3K27ac were classified as having a MEF2D-dependent decrease in H3K27ac if they exhibited 
a two fold or greater decrease in H3K27ac signal in MEF2D KO retinae.  	 ﾠ
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MEF2D-bound  promoters  were  analyzed  for  H3K27ac  signal  presence  and  MEF2D-
dependence as described above for enhancers but eRNAs were not assessed.  
RNA isolation, reverse transcription & qPCR 
  Total RNA was extracted with Trizol reagent (Life Technologies) followed by column 
purification using the RNeasy Micro kit (Qiagen) with on column DNAse digest.  RNA quality 
was assessed on a 2100 Bioanalyzer (Agilent).  RNA was reverse transcribed with the High 
Capacity  cDNA  Reverse  Transcription  kit  (Life  Technologies).  Real-time  quantitative  PCR 
analysis was carried out using the StepOnePlus qPCR system and Power SYBR Green mix (Life 
Technologies).  Reactions were run in duplicates or triplicates and Tuba1 levels were used as an 
endogenous control for normalization.  Real-time PCR primers were selected from an existing 
database (Origene). Primer sequences available upon request. 
 
RNA-Seq sequencing, data processing and eRNA quantification 
RNA-Seq was performed to a depth of at least ~8x10
7 clean reads per sample. Mapping 
of RNA-Seq reads and subsequent analysis of read-densities across all UCSC annotated genes 
was performed as described (Kim et al., 2010). Exon read density was calculated based on # of 
reads normalized to 10 million/exon length.  
Misregulated genes were defined using the following criteria: To be considered, genes 
needed to be expressed at a read density level of >0.1 in either both WT datasets, or both KO 	 ﾠ
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datasets. Genes were considered misregulated if KO/WT was >2 or <0.5, and the log p-value of 
the KO versus WT datasets was <0.05.   
To evaluate which biological processes might be enriched in our misregulated genes, we 
used the DAVID Functional Annotation web tool (http://david.abcc.ncifcrf.gov), limiting our 
analysis to DAVID’s GO biological process FAT category. DAVID was also used to determine 
tissue enrichment of the gene sets (Dennis et al., 2003; Huang da et al., 2009a, b).  
To define eRNAs, a 2kb window centered on the summit of each enhancer was defined. 
For extragenic enhancers, only those enhancers with a summit>2kb away from the end or TSS of 
a gene were considered. For intragenic enhancers, only those enhancers with a summit >1.2kb 
downstream of the TSS and >2kb away from the end of the gene or TSS of another gene were 
considered. Additionally, for intragenic enhancers the sense strand and its RNA-seq reads was 
removed from consideration. In order to be considered eRNAs, 3 reads were required within the 
2kb window between the 2 WT samples combined.  In addition, a z score of >= 1.645 was 
required for read# downstream of the peak summit versus upstream. This excluded enhancers 
with reads that were not sufficiently asymmetric on a given strand with respect to the enhancer 
summit, as eRNAs have been characterized as being located primarily downstream of enhancer 
peaks on each strand. For extragenic enhancers, a z score of >=1.645, indicating bias of RNA-
seq reads downstream of the enhancer summit, was required on both strands. For intragenic 
enhancers, a z score of >=1.645 was required on only the anti-sense strand and sense reads were 
ignored. For enhancers that met these criteria, eRNA read density was then calculated in the 1kb 
region  downstream  of  the  enhancer  summit  only,  which  represented  2  1kb  windows  for 
extragenic enhancers and 1 1kb window for intragenic enhancers. These eRNA read densities 	 ﾠ
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were  averaged  using  a  geometric  mean  within  a  genotype  (n=2  retinae  per  condition)  and 
changes were compared.  
For eRNA aggregate plots, HOMER 4.1 was used. Reads that were on the transcribed 
sense strand within genes were removed from the analysis using a custom script. As described 
for ChIP-Seq, a tag directory was generated using MakeTagDirectory.pl with a fragment length 
of 90 and Aggregate plots were generated using annotatepeaks.pl and options –d -size 6000 -hist 
20.  
 
Reporter cloning 
Luciferase reporters were generated by amplifying MEF2D-bound promoter or enhancer 
sequences  from  genomic  DNA  isolated  from  C57Bl6/J  mouse  tissue  and  cloning  promoter 
regions into the pGL4.10 vector (Promega) using SacI and XhoI sites and enhancer regions into 
the pGL4.23 vector using BamHI and SalI sites.  
 
Primers used in cloning reporters 
MEF2D bound region  Reporter Cloning Primer Sequence 
2610034M16Rik promoter  for:  atgctagagctcAGCAAATATTAAAATAGACACC 
  rev:  atgctactcgagTCATTTTGGCACAGGTTTC 
Wdr17 promoter  for:  atgctagagctcGCTACAAATGAAGTTATATGGC 	 ﾠ
	 ﾠ 134 
  rev:  atgctactcgagGAATTGGTTTCTTGCTTTTC 
Pcdh15 upstream enhancer  for:  atgctaggatccTGTTGAATTTTAACTAAAG 
  rev:  atgctagtcgacCAAACTGTTAAGAAATGTCA 
Pcdh15 intronic enhancer  for:  atgctaggatccTGCTTCTACGTTTTAAGCCA 
  rev:  atgctagtcgacTTACCAGACATTTGCCTCAA 
Fscn2 intronic enhancer  for:  atgctaggatccAGTTTGTTGGAGGGAGCCCAA 
  rev:  atgctagtcgacCAACAAGGAAGCTGCTCGCA 
Guca1b upstream enhancer  for:  atgctaggatccGGAGCACAGAACATACATGG 
  rev:  atgctagtcgacTTCCTAGCCTGTGTGAGGGT 
Pla2R1 intronic enhancer  for:  atgctaggatccATTTCAGGCTTGTCTACAAT 
  rev:  atgctagtcgacCTTTATCCTCACCAAGGCTA 
Stard7 intronic enhancer  for:  atgctaggatccGGAGCTTTGGTTAGGTGAAG 
  rev:  atgctagtcgacCAATACAAATGATGGAGGAG 
 
Retinal explant luciferase reporter assays   
Explant electroporation protocol adapted from (Matsuda and Cepko, 2008).  Promoter or 
enhancer luciferase reporters were electroporated into dissected retinae at p0 with a reporter 
constitutively  expressing  Renilla  luciferase  was  co-electroporated  as  a  control.  Retinae  were 
cultured for 7 days and then washed briefly in ice cold 1x PBS and homogenized in 500µl 
passive lysis buffer with trituration.  Homogenate was snap frozen to promote cell lysis and 
subsequently thawed for analysis of luciferase activity using the Dual-Glo® Luciferase Assay 
System (Promega). Firefly luciferase activity was normalized to renilla luciferase activity.    	 ﾠ
	 ﾠ 135 
Chapter 3 
 
Features of widespread MEF2D binding and differential function at 
enhancers  
   	 ﾠ
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3.1  Abstract 
 
In the previous chapter we found that MEF2D is important for normal photoreceptor 
development by regulating a cohort of genes critical for photoreceptor function, many of which 
are  mutated  in  retinal  disease.  MEF2D  bound  broadly  but  preferentially  activated  bound 
regulatory elements proximal to these target genes. However, the majority of MEF2D binding 
throughout  the  retinal  genome  was  not  proximal  to  MEF2D  target  genes.  The  function  of 
MEF2D at these other binding sites and how this binding contributes to gene expression remains 
unknown.  The  discrepancy  between  widespread  TF  binding  and  limited  changes  in  gene 
expression has been previously observed in many other genome-wide studies, however a direct 
analysis of reasons for this discrepancy has not yet been performed. To examine the source of 
this discrepancy we evaluated in an unbiased manner the activity of MEF2D-bound enhancers 
genome-wide. We identified several classes of MEF2D-bound enhancers. Many MEF2D-bound 
enhancers  were  inactive,  and  of  the  active  MEF2D-bound  enhancers,  only  a  subset  was 
dependent on MEF2D for activity. Genes near MEF2D-dependent enhancers were more likely to 
be  misregulated  in  the  absence  of  MEF2D,  however  in  many  cases  genes  near  MEF2D-
dependent enhancers were either only slightly misregulated or not misregulated at all, suggesting 
that while selective activation does contribute to specifying the direct target genes of MEF2D, 
mechanisms beyond enhancer activation must ultimately define which MEF2D enhancers truly 
regulate gene expression.  
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3.2  Background & Significance 
Transcriptional regulation of programs of gene expression provides the foundation for 
cellular differentiation and function. Elucidating the mechanisms by which transcription factors 
(TFs) bind DNA and regulate target genes is a longstanding interest in molecular biology and 
significant work over the past decades has demonstrated many examples of TF binding to an 
individual gene promoter or nearby enhancer resulting in direct regulation of the gene bound by 
that TF (Ptashne, 1988). However, with the advent of genome-wide ChIP-seq and RNA-seq 
technologies the relationship between TF binding and regulated expression of nearby genes has 
proven to be complex. Genome-wide analyses of transcription factor binding have suggested that 
only 10-25% of transcription factor occupancy relates to the expression of neighboring genes 
(Spitz and Furlong, 2012). Several sources of this discrepancy have been proposed, ranging from 
widespread non-functional binding of TFs to the inability to identify bona fide target genes that 
have only small changes in expression upon loss of the TF. However, an explanation for this 
discrepancy remains to be provided. Addressing the relationship between TF binding and gene 
regulation in mammalian cells should provide new insight into how regulatory elements are 
activated and what role any single TF plays in their activation.  
  The MEF2 family of TFs plays a critical role in regulating gene expression across many 
cell types and has been associated with cardiac, neurological and vascular disease (Bhagavatula et 
al., 2004; Bienvenu et al., 2013; Chasman et al., 2014; Freilinger et al., 2012; Novara et al., 2010; Wang et 
al., 2003). Their function at regulatory elements has been looked at on a gene-by-gene basis, 
particularly in myocytes (Black and Cripps, 2010). MEF2s have been suggested to bind to DNA 
and interact with multiple co-factors to function as repressors as well as activators (McKinsey et 
al., 2002). Several studies have examined MEF2 binding throughout the genome (He et al., 2011; 	 ﾠ
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Schlesinger  et  al.,  2011;  Sebastian  et  al.,  2013),  though  none  have  evaluated  the  functional 
relationship between MEF2 binding and the regulation of gene expression at a genome-wide 
level. Understanding how MEF2 TFs contribute to enhancer activation genome-wide should give 
insight into both how MEF2 TFs execute their critical functions as well as provide information 
regarding how TF function is determined beyond DNA binding.  
We previously discovered that MEF2D regulates photoreceptor differentiation by directly 
activating a cohort of enhancers and promoters associated with photoreceptor-specific genes, 
including genes that are mutated in human forms of blindness (Chapter 2). Furthermore, MEF2D 
regulates these genes by being recruited to retina-specific regions of the genome partly by its co-
factor CRX. However, additional regulatory mechanisms beyond retina-specific binding must 
modulate the action of MEF2 function because only a small subset of MEF2D binding sites are 
required for expression of nearby genes. MEF2D-bound enhancers that were co-bound by CRX 
and proximal to target genes were preferentially active. However, this alone did not account for 
the  discrepancy  between  MEF2D  binding  and  gene  regulation.  Other  possible  contributing 
factors include redundancy between enhancers regulating any given gene or the presence of sites 
where  MEF2D  binding  is  irrelevant.  Alternatively,  there  may  be  many  target  genes  subtly 
affected by loss of MEF2D that are difficult to appreciate due to the noise inherent in these 
analyses. To better understand how the MEF2 family of transcription factors regulates programs 
of gene expression we performed a comprehensive analysis of the activity of MEF2D-bound 
enhancers  in  our  model  system  of  retinal  photoreceptor  development  and  examined  how 
MEF2D-bound enhancer activity relates to regulation of gene expression.  
  We found that approximately 1/3 of MEF2D-bound enhancers are active at postnatal day 	 ﾠ
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11  (P11)  as  determined  by  histone  acetylation  and  eRNA  production.  Active  and  inactive 
enhancers display differential motif enrichment, and inactive enhancers have lower levels of 
MEF2D binding. Furthermore, only ~1/3 of active, MEF2D-bound enhancers are dependent on 
MEF2D for their activity, and as might be expected, these enhancers are generally closer to 
genes misregulated in MEF2D KO retinae. Enhancers dependent on MEF2D were more likely to 
have an MRE. Overall, we have narrowed the critical functions of MEF2D, a widely expressed 
and broadly bound transcription factor, to the activation of a relatively small cohort of enhancers 
regulating  MEF2D  target  genes.  Furthermore,  we  have  examined  determinants  of  regulatory 
element activation at multiple levels, and found that DNA accessibility and co-factor binding in 
particular correlate with functional TF binding, however MRE affinity or conservation does not. 
These results suggest that the mismatch between number of MEF2 binding sites and the number 
of misregulated genes is largely due to a significant amount of binding where MEF2D is not 
necessary for enhancer activation.  
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3.2 Results  
MEF2D binds enhancers broadly throughout the retinal genome  
Our previous study characterized 2403 high-confidence sites of MEF2D binding in P11 
retinae (Chapter 2). By examining the proximity of each peak to the nearest gene transcriptional 
start site, we find that the majority of these MEF2D bound regions in the retina are greater than 
1kb away from the nearest TSS, suggesting that MEF2D is predominantly bound to genetic 
enhancers  (83%;  2003/2403)  (Figure  3.1A).  In  order  to  begin  to  analyze  enhancer  activity 
genome-wide,  we  first  confirmed  this  bias  by  performing  ChIP-Seq  for  epigenetic  marks  of 
enhancers and promoters and determining the relative enrichment of each mark at MEF2D bound 
sites distal or proximal to a TSS (Figure 3.1B) (Heintzman et al., 2007). Enhancer elements can 
be  identified  by  their  enrichment  of  H3K4me1,  as  opposed  to  promoters,  which  have  high 
H3K4me3 and low H3K4me1 (Heintzman et al., 2007). The small subset of MEF2D sites <1kb 
from a TSS is enriched for H3K4me3, a hallmark of promoter elements, while distal MEF2D 
sites are enriched for H3K4me1, a hallmark of enhancers (Figure 3.1C). These enhancer sites 
are also modestly enriched for H3K4me3 reflecting that a significant percentage of MEF2D-
bound enhancers are located within introns of the gene body.  
 
Identification of active, MEF2D-bound enhancers genome-wide 
  We previously observed that while MEF2D binds at >2400 genomic sites in the retina 
(Chapter 2), only 93 of these are proximal to genes that are strongly misregulated in MEF2D 
knockout retinae, including 75 enhancers. This observation is significant because it suggests that    	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Figure 3.1. MEF2D predominantly binds enhancers throughout the retinal genome.  
(A) Distribution of MEF2D binding in the retina.  
(B) MEF2D, H3K4me1 and H3K4me3 ChIP-Seq tracks at the Guca1b genomic locus. MEF2D 
ChIP-Seq  data  are  shown  for  2  WT  and  1  MEF2D  KO  sample.  Arrow  denotes  Guca1b 
transcriptional start site (TSS). A light gray vertical bar highlights the identified MEF2D peak. 
DNAse hypersensitivity (DHS) is also shown from the ENCODE Consortium.  
(C) Aggregate plots of ChIP-Seq signal for 5.6kb region centered on summits of MEF2D-bound 
regions at promoters (left) or enhancers (right). Enhancers were defined as >1kb from any gene’s 
TSS, promoters as <1kb from a gene TSS. Plots are centered on summits of MEF2D peaks and 
show ChIP-Seq for histone marks total H3 (light blue), H3K4ME1 (dark blue) and H3K4me3 
(green) and MEF2D in MEF2D WT retinae (purple) or MEF2D KO retinae (orange). DHS data 
from 8-week WT retinae (ENCODE) is also shown. 
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Figure 3.1. (Continued) MEF2D predominantly binds enhancers throughout the 
retinal genome. 
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while MEF2D binds its targets directly, the majority of MEF2D bound elements are not actively 
required  for  regulating  gene  expression  in  the  retina.  Indeed  we  previously  determined  that 
MEF2D-bound regulatory elements proximal to target genes are far more likely to be active then 
those regulatory elements proximal to genes unchanged in MEF2D KO versus WT retinae. This 
conclusion supports the model that while MEF2D binds broadly, only a subset of MEF2D bound 
enhancers are active in any given tissue. To determine why so few MEF2D-bound sites seem 
relevant  for  gene  expression  we  sought  to  directly  test  if  MEF2D-bound  sites  were  broadly 
differentially active genome-wide and to identify in an unbiased manner characteristics that may 
determine whether or not a MEF2D-bound site is active. 
  Several recent studies suggest that acetylation of histone 3 lysine 27 (H3K27ac) is a 
hallmark of enhancers that are actively engaged in regulating transcription (Creyghton et al., 
2010; Rada-Iglesias et al., 2011). Other studies have identified non-coding transcription of RNA 
at enhancers (eRNAs) as a mark of active enhancers (Kim et al., 2010; Li et al., 2013; Wang et 
al., 2011) We previously performed ChIP-Seq for H3K27Ac and analyzed eRNA production at 
MEF2D-bound sites in p11 WT retinae, and confirmed that these marks of active enhancers 
correlated with enhancer activity in reporter assays in retinal photoreceptors (Chapter 2). To 
assess the levels of these marks at MEF2D-bound enhancers globally we re-examined our data 
sets of ChIP-Seq for H3K27Ac in p11 WT retinae and eRNA expression in our RNA-Seq dataset 
(Figure 3.2A). To maximize specificity, we considered MEF2D-bound enhancers to be active 
only if they had both eRNAs and H3K27Ac ChIP signal and inactive only if they had neither 
eRNAs nor H3K27Ac ChIP signal. These two independent signatures of enhancer activity were 
well  correlated  (Pearson’s  R=0.57).    We  found  that  660  MEF2D-bound  enhancers  had  both 
eRNAs and H3K27Ac and so were considered active enhancers, whereas we identified 584 of   	 ﾠ
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 Figure 3.2. Identification of active MEF2D-bound enhancers genome-wide.  
(A) Example tracks of inactive (left) and active (right) MEF2D-bound enhancers. MEF2D-bound 
enhancer  regions  are  highlighted  in  light  gray.  MEF2D  and  H3K27Ac  ChIP-Seq  tracks  are 
shown, as is an example RNA-seq track from MEF2D WT retinae. For RNA-seq, the numbers of 
reads  aligning  to  forward  (F,  black)  and  reverse  (R,  gray)  genomic  strands  are  separately 
displayed.  
(B)  Aggregate  plots  of  H3K27Ac  ChIP-Seq  signal  (blue).  Plots  are  centered  on  summits  of 
MEF2D-bound  regions  that  either  had  both  eRNAs  and  H3K27Ac  ChIP-seq  signal  (active 
enhancers, right) or had neither (inactive enhancers, left).  
(C)  Aggregate  plots  of  RNA-seq  reads  (coding  reads  removed)  for  forward  (dark  blue)  and 
reverse (red) strands. Plots are centered on summits of MEF2D-bound active enhancers (right) or 
inactive enhancers (left) as in (B).  
(D) Cumulative distribution of WT average exon density (from RNA-Seq data, n=2) for genes 
nearest active enhancers (red) or inactive enhancers (black).  
   Figure 3.2. (Continued) Identification of active MEF2D-bound enhancers 
genome-wide
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inactive MEF2D-bound sites lacking both eRNAs and H3K27Ac (Figure 3.2B, 3.2C). Taken 
together  these  data  strongly  suggest  that  MEF2D-bound  sites  are  differentially  activated 
throughout the genome.  
  To  confirm  globally  that  the  activity  of  MEF2D-bound  enhancers  is  relevant  to 
endogenous gene expression, we looked at the correlation between the activity of MEF2D-bound 
enhancers and the expression level of the nearest gene. Active, MEF2D-bound enhancers were 
more likely to be near highly expressed genes than inactive MEF2D-bound enhancers (KS test, p 
= 9.728e-17) (Figure 3.2D), and in fact almost all active peaks (>80%) were near an active gene. 
This  suggests  that  active  MEF2D-bound  enhancers  globally  contribute  to  regulating  gene 
expression, even if they are not near a MEF2D target gene.  
  To find determinants of MEF2D-binding site activity, we looked for the presence of 
additional  transcription  factor  binding  motifs  that  were  enriched  in  either  active  or  inactive 
MEF2D-bound  sites.  We  found  that  the  top  motifs  enriched  in  active  sites  as  compared  to 
inactive  sites  were  GCAACTAGGTCA  (p=1e-14)  and  CTAAGCCK  (p=1e-13),  which 
correspond to RORA (p=0.00003) and CRX (p=1e-13) transcription factor consensus binding 
motifs respectively (Figure 3.3A). The enrichment of the CRX binding motif is consistent with 
our previous results where we identified a correlation between co-binding of CRX and increased 
activity at MEF2D-bound enhancers. The enrichment of a motif for Rora is intriguing as Rorb (a 
close homolog of Rora) is also an important transcription factor in photoreceptor development 
whose  loss-of-function  phenotype  phenocopies  the  Mef2d  KO  and  Crx  KO  outer  segment 
development phenotype (Freund et al., 1997; Furukawa et al., 1999; Jia et al., 2009; Swain et al., 
1997). This finding implies that MEF2D may activate enhancers in cooperation with a core set of    	 ﾠ
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Figure 3.3. Motif enrichment in active versus inactive MEF2D-bound enhancers.  
(A) Position weighted matrices (PWM) of top two enriched motifs under active MEF2D-bound 
enhancers  as  compared  to  inactive  MEF2D-bound  enhancers.  Below  each,  high-ranking 
JASPAR matrix corresponding to most enriched PWM.  
(B) PWM and corresponding JASPAR matrix for top motif in inactive MEF2D-bound enhancers 
as compared to active MEF2D-bound enhancers.  
(C) Cumulative distribution of MRE strength (p-value describing similarity to canonical MRE) 
for all MREs with p<1e-4 found in 400bp regions centered on MEF2D peak summits.   
   Figure 3.3. (Continued) Motif enrichment in active versus inactive MEF2D-bound 
enhancers
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key photoreceptor transcription factors, beyond CRX.  Additionally, the top de novo motif found 
in inactive as compared to active MEF2D-bound sites was CTATTTTKAG (p=1e-24), which is 
consistent with the canonical MEF2 recognition element (MRE) (p=1e-6) (Figure 3.3B). We 
confirmed this observation by quantifying how similar the MREs present in the two peak subsets 
are to the canonical MRE (Figure 3.3C). The inactive peaks indeed had more MREs than active 
peaks  (80%  versus  53%).  Furthermore,  when  just  the  MREs  between  the  two  subsets  were 
compared, the MREs under inactive peaks were significantly closer to the consensus MRE than 
those  under  active  peaks  (KS  test,  p=8.7e-7).  This  suggests  that  inactive,  MEF2D-bound 
elements are bona fide MEF2D binding sites rather than non-specific ChIP-Seq signal which 
would not be expected to be enriched for the MRE motif. These inactive, MEF2D-binding sites 
with high affinity MREs likely have an important function in cells, though the context in which it 
is relevant remains to be determined.    
  We also noted that overall, inactive peaks are smaller than active peaks (Figure 3.4A). 
This  is  consistent  with  previous  studies  that  have  shown  regions  of  low  TF  occupancy  are 
generally  nonfunctional  (Fisher  et  al.,  2012).  To  evaluate  whether  MEF2D  peak  size  might 
explain the difference in regulatory element activity, we generated new subgroups of inactive 
and active peaks that were normalized for MEF2D ChIP peak size (n=396 peaks/group), and 
found that this did not change the differences between active and inactive peaks with respect to 
histone mark presence, eRNA production, enrichment of MREs (Figure 3.4).  
  The finding that a relatively small subset of MEF2D-bound enhancers is active strongly 
suggests  that  selective  activation  is  a  key  aspect  of  MEF2D  bound  regulatory  regions.  
Additionally, these results underscore that MEF2D binding to a regulatory element does not 
equate to activation of that element. A major reason therefore for the overrepresentation of   	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Figure 3.4. Properties of active and inactive enhancers normalized by size of MEF2D peak.  
(A)  Aggregate  plots  of  MEF2D  ChIP-Seq  signal  for  5.6kb  region  centered  on  summits  of 
MEF2D-bound regions at all inactive (left) or active (right) enhancers. Plots are centered on 
summits of MEF2D peaks.  
(B) Aggregate plots as described in (A) for subsets of inactive and active enhancers normalized 
by MEF2D peak size.  
(C) Aggregate plots of H3K27Ac ChIP-Seq signal (blue, top) or RNA-seq reads (bottom) at 
same peak sets as in (B).  
(D) Aggregate plots of DNA binding motif occurrence for the MEF2 motif (purple) or CRX 
motif (blue) in a 2kb window centered on summits of the same MEF2D-bound regions as in (B) 
and (C).  
 
   Figure 3.4. (Continued) Properties of active and inactive enhancers normalized 
by size of MEF2D peak
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 transcription  factor  bound  sites  compared  to  misregulated  genes  is  because  a  significant 
percentage of transcription factor binding sites are inactive in the context of our experiments and 
not directly engaged in regulating gene expression. The refinement of 2003 total MEF2D-bound 
enhancers to 660 active enhancers represents a four-fold enrichment in fraction of enhancers near 
target  genes.  Nonetheless,  only  75  enhancers  are  proximal  to  MEF2D  target  genes.    This 
discrepancy  suggests  that  while  MEF2D-bound  sites  are  differentially  active,  additional 
mechanisms  must  limit  the  number  of  active  enhancers  that  are  required  to  regulate  gene 
expression.  One  possibility  may  be  that  multiple  enhancers  regulate  each  target  gene 
(approximately 10 enhancers per gene).  Another more likely possibility is that only a subset of 
active, MEF2D-bound enhancers functionally requires MEF2D for their activity.  To test this 
second possibility we compared H3K27Ac and eRNA levels in WT retinae to levels in littermate 
Mef2d KO retinae. 
 
MEF2D is required for enhancer activity at a subset of its bound enhancers 
Just as MEF2D binding does not signify that an enhancer is active, MEF2D binding at 
active enhancers does not mean that those enhancers are dependent on MEF2D for their activity. 
We had previously observed that MEF2D bound regulatory regions near strongly misregulated 
genes  are  more  active  (Chapter  2),  but  there  are  still  more  active  regulatory  elements  than 
strongly misregulated genes. MEF2D may be required at multiple enhancers for the coordinate 
activation of a given target gene. Alternatively (but not mutually exclusively), MEF2D may bind 
in many areas where it is not always necessary for an enhancer’s activity, suggesting that even 
within a single cell type, different enhancers have varying combinations of transcription factors 	 ﾠ
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and not all transcription factors are required at all regulatory elements where they are bound.  
  There are currently few studies that examine the change in enhancer activity upon loss of 
a particular transcription factor on a global level. However, we had previously demonstrated that 
loss of H3K27Ac and eRNAs in Mef2d KO retinae correlated with loss of enhancer reporter 
activity  by  mutating  the  MEF2  binding  site  (MRE)  or  using  a  MEF2D  shRNA.  Thus,  we 
reasoned a global survey of changes in H3K27Ac and eRNAs in MEF2D KO retinae would be 
able to identify the active, MEF2D-bound enhancers that require Mef2d for their activity.  
We  defined  MEF2D-dependent  enhancers  as  distal  sites  that  had  both  a  greater  than  50% 
reduction in eRNA density and a greater than 50% reduction in H3K27Ac ChIP signal at the 
MEF2D-bound region in Mef2d KO retinae compared to WT (Figure 3.5). Using these criteria, 
about 35% of active enhancers (230/660) were highly dependent on MEF2D. In contrast, about 
45%  of  enhancers  (294/660)  had  no  change  in  histone  acetylation  or  eRNAs  in  Mef2d  KO 
retinae. These analyses suggested that only very few active, MEF2D-bound enhancers require 
MEF2D for their activity, which is consistent with our previous results that MEF2D selectively 
controls enhancers at target genes.  
  To  confirm  that  these  newly  identified  MEF2D-dependent  enhancers  are  relevant  for 
endogenous gene expression, we analyzed the change in gene expression in Mef2d KO retinae of 
genes nearest MEF2D-dependent enhancers. We found that genes nearest MEF2D-dependent 
enhancers changed more significantly in Mef2d KO retinae than genes near enhancers that were 
not  MEF2D-dependent  (KS  test,  p  =  9.713e-27)  (Figure  3.5).  These  genes  included  those 
previously identified as putative direct targets of MEF2D (from Chapter 2), suggesting that the 
contribution of MEF2D to enhancers near target genes is non-redundant and critical for their   	 ﾠ
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Figure 3.5. MEF2D is required for enhancer activity at a subset of its bound enhancers.  
(A)  Example  tracks  of  Pcdh15  genomic  locus  in  MEF2D  WT  (left)  or  KO  (right)  retinae. 
MEF2D-bound enhancer regions are highlighted in light gray. MEF2D ChIP-Seq, H3K27Ac 
ChIP-Seq and RNA-seq in either MEF2D WT or MEF2D KO retinae are displayed.  
(B) H3K27Ac ChIP-Seq read density and Average RNA-seq read density of eRNAs at all active 
MEF2D-bound enhancers in WT versus MEF2D KO retinae. Read density was calculated  +/- 1 
kb from the center of the WT MEF2D peak. Data points in red indicate the MEF2D-dependent 
subset of enhancers that lose both eRNAs and H3K27Ac ChIP-Seq signal by >50% in MEF2D 
KO retinae.  
(C) Cumulative distribution of ratio of average exon read density in MEF2D KO retinae as 
compared to WT retinae (n=2 per genotype, RNA-Seq data) for genes nearest active enhancers 
that were MEF2D-dependent (red) or MEF2D-independent (black).  
   Figure 3.5.  (Continued) MEF2D is required for enhancer activity at a subset of 
its bound enhancers 
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expression,  and  that  this  method  of  looking  at  enhancer  activity  effectively  identifies  target 
enhancers relevant to target gene expression.  
  To determine why some active, MEF2D-bound enhancers are MEF2D-dependent while 
others are not, we performed a differential de novo motif analysis on these two categories of 
enhancers.    We  hypothesized  that  other  transcription  factor  motifs  may  be  enriched  near 
MEF2D-independent enhancers and that the presence of additional transcriptional regulators may 
be  able  to  compensate  for  the  loss  of  MEF2D.  Unexpectedly,  we  did  not  observe  strong 
enrichment of any single motif near MEF2D-independent enhancers.  Instead, we found that 
enhancers that were MEF2D-dependent were more enriched for the presence of an MRE (p=1e-
18; 68% of dependent peaks versus 33% of independent peaks) (Figure 3.6). It is unclear why 
this enrichment may exist, however it may suggest evolution has selected for reliable MEF2D 
binding at these sites to prevent loss of enhancer activity. 
 
  By examining the change in histone acetylation and eRNA production in  Mef2d KO 
retinae, we were able to take 2403 MEF2D-bound regions and identify the 10% of peaks (230) 
that are active and MEF2D-dependent. We previously observed that the 75 enhancers near target 
genes were preferentially MEF2D regulated and active as compared to a control 75 enhancer 
group. Here, we see the significance of these numbers in the context of MEF2D genome wide. 
These 75 enhancers near target genes are about 1/3 of the number of MEF2D-regulated enhancer 
elements. This narrowing to 230 MEF2D-dependent enhancers is a three-fold enrichment as 
compared to only looking at active enhancers that are bound by MEF2D, suggesting that the 
presence of active enhancers bound by a TF where that TF is not necessary for that regulatory 
element’s activity is responsible for a great deal of the discrepancy between TF binding and gene    	 ﾠ
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Figure 3.6. MEF2D-dependent regulatory elements are enriched for conserved MREs.  
(A) Position weighted matrix (PWM) of top enriched motif under MEF2D-dependent enhancers 
as  compared  to  MEF2D-independent  enhancers.  Below,  high-ranking  JASPAR  matrix 
corresponding to the PWM.  
(B) Cumulative distribution of MRE strength (p-value describing similarity to canonical MRE) 
for all MREs with p<1e-4 found in 400bp regions centered on MEF2D peak summits.  
   Figure 3.6. (Continued) MEF2D-dependent regulatory elements are enriched for 
conserved MREs 
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regulation. Overall, this is a ten-fold enrichment for functional enhancers as compared to the 
2003 total MEF2D-bound enhancers originally observed. 
  These analyses are significant as they make it possible to identify which MEF2D-bound 
enhancers are relevant for driving photoreceptor-specific gene expression.  At the same time, 
these results provide insight into why transcription factors act specifically upon particular target 
genes rather than other genes near their binding sites.  MEF2D binds many areas in the retinal 
genome, but only a subset of these sites are highly active.  Among all MEF2D sites the highly 
active enhancers are characterized by the enrichment of additional transcription factor motifs, 
especially motifs for RORA/B and CRX, suggesting that these three factors work together as a 
suite of transcriptional regulators to coordinate photoreceptor development.  This hypothesis is 
strengthened  by  the  fact  that  MEF2D,  RORB  and  CRX  KO  mice  all  share  very  similar 
phenotypes,  a  failure  of  retinal  photoreceptor  outer  segment  formation.    Finally,  among  all 
active, MEF2D-bound elements, only a subset of these sites is dependent on MEF2D for activity 
and for the expression of their target genes. Together these results demonstrate that the function 
of a transcription factor is regulated at many levels and is strongly influenced by the transcription 
factor milieu of the cell.  	 ﾠ
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3.4 Discussion  
  The  function  of  the  majority  of  TF  binding  in  the  regulation  of  programs  of  gene 
expression persists as an unsolved problem in the field of Transcription Regulation.  Here we 
demonstrate that at a given time point only a minority of total TF-bound enhancers are active. 
Furthermore, only a fraction of those active regulatory elements require that TF for their activity. 
Not only does this identify which TF-binding sites are ultimately relevant for gene expression, 
but this also points to an in vivo mechanism for transcription factor function.  In the case of 
MEF2D,  we  see  that  this  broadly  expressed  transcription  factor  achieves  its  tissue  specific 
function  by  regulating  the  activity  of  a  relatively  small  number  of  enhancers  in  a  manner 
upstream of histone acetylation and eRNA production. 
Data examining TF binding is subject to experimental noise and artifact, where ChIP-seq 
reads do not reflect true TF occupancy. In the previous chapter we demonstrated that significant 
artifacts exist in assessing MEF2D binding genome-wide that could only be distinguished with 
careful KO studies, where only ~ 20% of our peaks reflected reproducible TF binding. This may 
suggest that ChIP-Seq studies performed without biological replicates or knockout controls are 
subject to a considerable percentage of false positive binding sites which may account for some 
of the discrepancy between number of TF binding sites and misregulated genes.   
  Of the regulatory elements where MEF2D truly binds, we found that still only a subset 
was actively engaged in gene regulation under our experimental conditions (Figure 3.2). It has 
been suggested that many of the smaller binding sites seen in ChIP-Seq do not affect gene 
expression, and instead reflect TF searching patterns, or nonproductive collisions with DNA 	 ﾠ
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(Fisher et al., 2012). However, even when controlling for peak size we still find both active and 
inactive MEF2D-bound enhancers (Figure 3.5).  
  These  inactive  MEF2D-bound  enhancers  may  only  appear  non-functional  because 
MEF2D may be docked at inactive sites in anticipation of a future activation of the enhancer. 
Enhancer elements have recently been found to be highly dynamic over development (Nord et 
al., 2013). Additionally, MEF2 TFs are transcriptionally activated in response to specific stimuli 
in other paradigms (Flavell et al., 2008; Youn and Liu, 2000). TFs may bind to enhancers before 
their engagement in gene regulation, and the developmental snapshot we see with ChIP-seq and 
RNA-seq at p11 may capture this transitional period.  
  Alternatively,  these  inactive  MEF2D-bound  enhancers  may  never  be  active  in  the 
developing  retina.  One  explanation  for  this  would  be  that  the  amount  of  steady-state  TF 
occupancy, as assessed by conventional ChIP, may not be as effective for identifying functional 
sites as competitive ChIP experiments which measure TF binding kinetics (Lickwar et al., 2012). 
A different, intriguing possibility is that sites of MEF2D binding that are not functional may be 
examples  of  evolving  DNA  regulatory  elements,  where  MEF2D  binding  is  insufficient  for 
regulatory element activation but new DNA mutations at this site that promote the binding of 
other TF co-factors may license the enhancer to engage in regulating gene expression.    
A significant number of MEF2D-bound enhancers are however active. We examined the 
function of MEF2D at these enhancers by evaluating changes in enhancer activity in Mef2d KO 
retinae. We found that many MEF2D-bound enhancers that are active do not lose activity in 
MEF2D  KO  retinae,  suggesting  that  MEF2D  may  play  a  role  at  these  enhancers  but  is  not 
necessary for their activation (Figure 3.6). This may be due to redundancies for TF function 	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within a given enhancer, where the loss of a single TF may not be sufficient to disrupt the 
activity  of  that  enhancer.  Alternatively,  it  may  be  that  MEF2D  is  important  at  all  active 
enhancers where it has a function that is not read out by changes in H3K27 acetylation or eRNA 
production,  for  example  facilitating  long-range  DNA  interactions.  Enhancers  proximal  to 
MEF2D target genes but not bound to MEF2D often lose marks of activity in Mef2d KO retinae, 
suggesting that multiple enhancers, not all directly bound by MEF2D, may be interacting to 
promote the expression of a target gene.  
Redundancies between enhancers to ensure robust gene expression may account for why 
loss of activity at some MEF2D-bound enhancers may not correlate with changes in proximal 
gene  expression,  as  230  MEF2D-dependent  enhancers  is  still  greater  than  the  75  enhancers 
proximal to highly misregulated genes. Some enhancers may lose activity in the MEF2D KO, but 
fail to change target gene expression because of compensation by neighboring enhancers, or the 
emergence of normally inactive shadow enhancers (Spitz and Furlong, 2012). This remains an 
open question and will require more computational analyses as well as techniques to identify 
long-range interactions (e.g. Hi-C) to identify the cohort of enhancers regulating any given gene, 
and how this changes in MEF2D KO retinae. Identification of long-range interactions will also 
be important for identifying the cases where MEF2D dependent enhancers are critical for the 
expression of genes that are not their nearest neighbor.  
  An alternate explanation for why all 230 MEF2D-dependent enhancers are not proximal 
to  MEF2D  target  genes  is  that  loss  of  function  in  some  MEF2D-dependent  enhancers  may 
produce only subtle changes in gene expression. Approximately 40% of the genes near MEF2D-
dependent enhancers were changed by only 10-50%, and thus would not have met our two-fold 	 ﾠ
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cutoff  for  potential  MEF2D  target  genes.  Evaluating  small  changes  in  gene  expression  is 
challenging in the face of biological and technical noise in any series of experiments, and likely 
leads to an underestimate of genes regulated by any given TF. In general, restricting future 
analyses  to  genes  proximal  to  TF-dependent  enhancers  and  promoters  may  facilitate  the 
identification of direct target genes that only have small changes in expression upon TF loss-of-
function.  These genes can then be examined more closely and assessed for biological relevance.   	 ﾠ
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3.5 Experimental Procedures 
Histone mark Chromatin Immunoprecipitation, Sequencing and Data processing  
H3K27Ac ChIP-Seq data was described previously (Chapter 2). ChIP was performed for other histone 
marks in the same manner as described in Chapter 2. Antibodies used were anti-H3 (Abcam ab1791), 
anti-H3K4me1 (Abcam ab8895) and anti-H3K4me3 (Abcam ab8580).   
 
Previously published ChIP-Seq data sets 
In addition to ChIP-Sequencing data we generated, DNAse-Seq data from 8 week old C5JBL/6 
mice was used from the ENCODE consortium (GSM1014175) (Landt et al., 2012). 
 
ChIP- and RNA-Seq analyses 
In general, analyses were performed as previously described (Chapter 2) with the specifications described 
below. 
Differential motif enrichment (Homer 4.1; (Heinz et al., 2010)) as well as analysis of similarity of MRE 
motifs to canonical MRE (FIMO; (Bailey et al., 2009)) were performed for 400bp regions centered around 
the summits of MEF2D peaks for each group being compared. For FIMO, the MRE closest to the peak 
summit was used in the analysis. 
Size normalization of peak subsets was performed by ranking all active and inactive peaks by average size 
of MEF2D ChIP-Seq peak size, and selecting adjacent pairs of active and inactive peaks.   	 ﾠ
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. Chapter 4 
Conclusion 
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  The results presented within this dissertation demonstrate a novel biological role for the 
MEF2  family  member  MEF2D  in  retinal  photoreceptor  development  and  present  a 
comprehensive, in-depth approach to investigating the function of this TF. In this dissertation, 
we were able to take advantage of retinal photoreceptors as a model for understanding the role of 
MEF2 in neural development as well as a model in which to study the mechanisms by which 
MEF2D regulates target genes in the nervous system.   
  In Chapter 2, we identified a cell-autonomous role for MEF2D in the development of 
retinal  photoreceptors,  and  elucidated  a  detailed  mechanism  for  how  MEF2D  functions  in 
photoreceptors.  Using  genome-wide  loss-of-function  experiments,  we  found  that  MEF2D 
regulates critical genes for photoreceptor development together with a novel co-factor, CRX. 
CRX both facilitates MEF2D binding to retina-specific enhancers and serves as a co-activator at 
a subset of MEF2D-bound regulatory elements proximal to target genes. Furthermore, together 
MEF2D and CRX regulate many critical genes and their loss-of-function leads to similar defects 
in photoreceptor differentiation. How MEF2D and CRX cooperate remains an open question. 
They may interact directly, or through a third co-factor such as p300, as discussed in Chapter 2. 
Alternatively,  they  may  each  make  distinct  contributions  to  the  activation  of  their  co-bound 
enhancers by performing separate but complementary functions, such as nucleosome remodeling, 
recruitment  of  histone  acetyltransferases  (HATs),  or  DNA  looping.  Future  experiments  to 
investigate these possibilities will provide greater insight into how photoreceptor-specific gene 
expression is established, as well as what the key role of these TFs is at their bound regulatory 
elements. There are several components to enhancer activation such as nucleosome remodeling, 
histone  methylation,  RNA  polymerase  II  binding,  recruitment  of  histone  acetyltransferases 
(HATs) and histone acetylation, eRNA production and DNA looping to a promoter (Lam et al., 	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2014).  The  precise  order  of  these  molecular  events  is  unknown,  and  how  TFs  differentially 
contribute to these steps remains to be determined. Here, we have demonstrated that a subset of 
enhancers that lose MEF2D lose H3K27 acetylation and eRNA production. This provides an 
opportunity to evaluate how these activation components reflect the stage of enhancer activation. 
For  example,  some  models  have  proposed  that  eRNAs  facilitate  DNA  looping  between 
enhancers and promoters (Li et al., 2013), and so one hypothesis would be that enhancers that 
have lost eRNAs no longer interact with the promoters of their target genes or other enhancers, 
which could be evaluated by chromosome conformation capture (Miele and Dekker, 2009). On 
the  other  hand,  RNA  polymerase  II  binding  is  thought  to  occur  at  poised  enhancers  and  to 
precede eRNA production (Lam et al., 2014), so RNA polymerase II levels at these enhancers 
would not be expected to be affected. This could be evaluated by ChIP.  
  These latter analyses to dissect the mechanics of enhancer activation may benefit most 
from the complementary approach taken in Chapter 3 to studying the function of MEF2D in 
photoreceptors. While in Chapter 2 we focused on how MEF2D regulates the expression of 
critical target genes, in Chapter 3 we approach the function of MEF2D from the perspective of 
how it might be functioning at its numerous binding sites at regulatory elements genome-wide.  
We  find  that  MEF2D  binds  many  regulatory  elements  lacking  marks  of  activity,  and  that 
MEF2D is not critical for enhancer activity at most of the elements where it is active. Exploring 
what differentiates these classes of MEF2D-bound enhancers suggested that even though some 
enhancers are inactive, they are still likely important sites of binding as they are highly enriched 
for MREs. Active enhancers in particular are enriched for motifs for photoreceptor network TFs, 
reinforcing the critical role MEF2D may play in this network. However, there is still a great deal 
to be explored regarding the differences between these classes of enhancers. For example, there 	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is likely to be heterogeneity among the state of enhancers within the subset of those that are 
inactive. Some may be poised for activity, with open chromatin and bound to RNA polymerase 
II. On the other hand it may be that MEF2D can also bind to closed chromatin and some of these 
may be inaccessible with repressive histone marks, with an unclear role in direct regulation of 
gene expression.  
  Ultimately,  both  approaches  in  Chapters  2  and  3  demonstrate  that  a  small  subset  of 
MEF2D-bound enhancers are activated by MEF2D, and that these are enriched for regulatory 
elements  proximal  to  significantly  misregulated  target  genes.  In  considering  the  discrepancy 
between  numerous  TF  binding  sites  and  limited  gene  regulation,  for  MEF2D  it  seems  that 
selective enhancer regulation will be a significant mechanism of specifying this function.  
It will be interesting to examine whether the correlation between MEF2D binding and 
function  at  regulatory  elements  is  similar  to  the  relationship  between  CRX  binding  and 
regulatory element activation. CRX has been suggested to help remodel and open up chromatin 
to allow the binding of several other TFs such as NRL and NR2E3 (Peng and Chen, 2007), 
which suggests that it may play an early critical role in activating enhancers, and that sites of 
CRX binding may be more dependent on CRX for activation than what is seen for MEF2D. 
Preliminary  data  suggests  that  this  is  indeed  the  case,  as  more  CRX-bound  enhancers  lose 
eRNAs in Crx KO retinae than MEF2D-bound enhancers in Mef2d KO retinae, consistent with 
the observation that more genes are misregulated in Crx KO retinae as well (M.M.A and T.J.C, 
unpublished  observations).  Loss  of  CRX  also  leads  to  an  upregulation  of  eRNAs  at  some 
enhancers, which is consistent with loss of CRX also producing an increase in expression of 	 ﾠ
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some genes (M.M.A and T.J.C, unpublished observations). Thus, enhancer activation levels and 
gene expression levels are likely the most consistent correlation in determining a TF’s function.  
  These results provide a roadmap for determining the in vivo function of a TF in a relevant 
biological context. They also reflect the complexity of transcriptional regulation and the caution 
with which the study of transcriptional regulation should be approached. The specific function of 
a TF is regulated at many levels. Not all MREs bind MEF2, and MEF2 binding does not equal 
function, and even correlation between enhancer activity (H3K27Ac, eRNAs) and MEF2 binding 
does  not  imply  that  that  transcription  factor  is  required  for  functional  activity  of  a  given 
enhancer. Adding an assessment of how a TF affects enhancer activity by levels of H3K27Ac 
and  eRNAs  in  future  genome-wide  studies  of  mechanisms  of  gene  regulation  will  greatly 
facilitate our understanding of the role TFs play in complex gene regulatory networks.   
  Finally, an important aspect of this and similar studies is its relevance to genetic diseases 
arising from mutations in non-coding regions. Examples of non-coding mutations that affect TF 
binding sites are increasingly being documented (Cichocki et al., 2014; Gurnett et al., 2007; 
Smith and Shilatifard, 2014). For example, a recent study isolated a non-coding mutation in the 
first intron of Munc13-4, a gene previously shown to be mutated in familial hemophagocytic 
lymphohisticytosis (FHL) (Cichocki et al., 2014). This point mutation disrupts the binding site 
for the transcription factor ELF1 and affects ELF1 binding and thus the activation of a stimulus-
dependent, lymphocyte-specific alternate promoter for a different isoform of Munc13-4. While 
coding mutations in Munc13-4 are known to exist in FHL (Sieni et al., 2014), this and other 
studies reflect the isolation of an emerging class of genetic diseases termed enhanceropathies 
(Smith and Shilatifard, 2014).  	 ﾠ
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  One advantage that facilitated the identification of this regulatory element mutation in 
Munc13-4 was that the mutation was present within the gene locus itself, albeit in an intron. 
Disease mutations at extragenic regulatory regions may be quite far away from the genes they 
regulate (Gurnett et al., 2007). Identifying relevant regulatory elements will significantly aid in 
the discovery and characterization of such enhanceropathies. To this end, the analysis presented 
here cataloged a set of active enhancers in the developing retina and evaluated the contributions 
of the highly conserved TFs MEF2D and CRX in the activity of these enhancers as linked to 
changes in gene expression. As MEF2D and CRX have known DNA binding motifs, their motifs 
in these enhancers represent specific sequences of DNA that, if mutated, would be predicted to 
affect MEF2D or CRX binding, enhancer function and nearby gene expression. This may cause 
or increase relative risk for retinal disease.  
Similar future studies that identify functional regulatory elements in neurons will provide 
two  distinct  advantages  in  the  search  for  noncoding  mutations  in  patients  with  neurological 
diseases. First, they narrow the regions of interest within the genome significantly, possibly 
allowing targeted sequencing in patients without the need of costly whole genome sequencing. 
Secondly, knowing how these enhancers are normally regulated facilitates distinguishing neutral 
mutations  from  possibly  important  point  mutations  that  could  damage  TF  binding  and 
subsequent enhancer activation. Thus isolating regions of possible disease-associated mutations 
may  have  important  implications  for  finding  new  mechanisms  of  retinal  and  more  broadly 
neurological development and disease.  
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